



HU000033149T2



(19) **HU**

(11) Lajstromszám: **E 033 149**

(13) **T2**

**MAGYARORSZÁG**  
Szellemi Tulajdon Nemzeti Hivatala

## EURÓPAI SZABADALOM SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 12 820596**

(22) A bejelentés napja: **2012. 08. 03.**

(96) Az európai bejelentés bejelentési száma:  
**EP 20120820596**

(97) Az európai bejelentés közzétételi adatai:  
**EP 2740796 A1 2013. 02. 07.**

(97) Az európai szabadalom megadásának meghirdetési adatai:  
**EP 2740796 B1 2017. 05. 17.**

(51) Int. Cl.: **C12N 15/09**

**A61K 45/06**

**A61P 35/00**

**C12P 21/08**

**C07K 16/28**

**C07K 16/30**

**A61K 39/395**

**C07K 16/18**

(2006.01)

(2006.01)

(2006.01)

(2006.01)

(2006.01)

(2006.01)

(2006.01)

(2006.01)

(86) A nemzetközi (PCT) bejelentési szám:

**PCT/JP 12/069862**

(87) A nemzetközi közzétételi szám:

**WO 13018894**

(30) Elsőbbségi adatai: <b>2011171300</b>	2011. 08. 04.	JP	(73) Jogosult(ak): <b>Toray Industries, Inc., Tokyo, 103-8666 (JP)</b>
(72) Feltaláló(k): <b>OKANO, Fumiyo, Kamakura-shi Kanagawa 248-8555 (JP)</b> <b>KOBAYASHI, Shinichi, Kamakura-shi Kanagawa 248-8555 (JP)</b> <b>MINAMIDA, Yoshitaka, Kamakura-shi Kanagawa 248-8555 (JP)</b> <b>SAITO, Takanori, Kamakura-shi Kanagawa 248-8555 (JP)</b>			(74) Képviselő: <b>Gödölle, Kékes, Mészáros &amp; Szabó Szabadalmi és Védjegy Iroda, Budapest</b>

(54) **Gyógyászati készítmény rák kezelésére és/vagy megelőzésére**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



EP 2 740 796 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:

17.05.2017 Bulletin 2017/20

(21) Application number: 12820596.0

(22) Date of filing: 03.08.2012

(51) Int Cl.:

C12N 15/09 (2006.01) A61K 39/395 (2006.01)  
A61P 35/00 (2006.01) C07K 16/30 (2006.01)  
C12P 21/08 (2006.01) C07K 16/28 (2006.01)  
A61K 45/06 (2006.01) C07K 16/18 (2006.01)

(86) International application number:  
PCT/JP2012/069862

(87) International publication number:  
WO 2013/018894 (07.02.2013 Gazette 2013/06)

### (54) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PROPHYLAXIS OF CANCER

PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG UND/ODER PRÄVENTION VON  
KREBS

COMPOSITION PHARMACEUTIQUE DESTINÉE À TRAITER OU À PRÉVENIR LE CANCER

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO RS SE SI SK SM TR

(30) Priority: 04.08.2011 JP 2011171300

(43) Date of publication of application:  
11.06.2014 Bulletin 2014/24

(60) Divisional application:  
17163690.5

(73) Proprietor: **Toray Industries, Inc.**  
Tokyo, 103-8666 (JP)

(72) Inventors:

- **OKANO, Fumiyo**  
Kamakura-shi  
Kanagawa 248-8555 (JP)
- **KOBAYASHI, Shinichi**  
Kamakura-shi  
Kanagawa 248-8555 (JP)

• **MINAMIDA, Yoshitaka**

Kamakura-shi  
Kanagawa 248-8555 (JP)

• **SAITO, Takanori**

Kamakura-shi  
Kanagawa 248-8555 (JP)

(74) Representative: **Denison, Christopher Marcus et al**  
**Mewburn Ellis LLP**

City Tower  
40 Basinghall Street  
London EC2V 5DE (GB)

(56) References cited:

WO-A1-2010/016525 WO-A1-2010/016526  
WO-A1-2010/016526 WO-A1-2010/016527  
WO-A1-2013/147169 WO-A1-2013/147176

- **ELLIS J.A. ET AL.: 'Identification and Characterization of a Novel Protein (p137) Which Transcytoses Bidirectionally in Caco-2 Cells.'**  
**J.BIOL.CHEM. vol. 270, no. 35, 1995, pages 20717 - 20723, XP008143762**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 740 796 B1

**Description**

## Technical Field

5 [0001] The present invention relates to novel use of an antibody against CAPRIN-1 or a fragment thereof in a drug such as a therapeutic and/or preventive agent for cancer.

## Background Art

10 [0002] Cancer is the leading cause of death. This disease is currently treated principally by surgical therapy, in combination with radiation therapy and/or chemotherapy. In spite of recent development of novel surgical techniques or discovery of novel anticancer agents, the existing treatment of cancer has an insufficiently improved outcome, except for some cancer types. With recent advances of molecular biology or cancer immunology, antibodies that specifically react with cancer, cancer antigens that are recognized by cytotoxic T cells, genes encoding such cancer antigens, and 15 the like have been identified, raising expectations on specific cancer therapy targeting the cancer antigens (Non Patent Literature 1).

20 [0003] For reducing the adverse reaction of cancer therapy, it is desired that peptides, polypeptides, or proteins recognized as antigens of the cancer should rarely exist in normal cells and specifically exist in cancer cells. In 1991, Boon et al. (Ludwig Institute for Cancer Research, Belgium) isolated a human melanoma antigen MAGE1 recognized by CD8-positive T cells by a cDNA expression cloning method using autologous cancer cell lines and cancer-reactive T cells (Non Patent Literature 2). Then, a SEREX (serological identification of antigens by recombinant expression cloning) method has been reported, which adopts a gene expression cloning approach to identify tumor antigens recognized by antibodies produced in response to autologous cancer *in vivo* in a cancer patient (Non Patent Literature 3 and Patent Literature 1). According to this method, some cancer antigens that are rarely expressed in normal cells and 25 are specifically expressed in cancer have been isolated (Non Patent Literatures 4 to 9). In addition, cell therapy using immunocytes that specifically react with cancer antigens or cancer-specific immunotherapy using vaccines or the like comprising cancer antigens is under clinical trial targeting some of the isolated cancer antigens.

30 [0004] In recent years, various antibody drugs for cancer treatment targeting antigenic proteins on cancer cells have emerged in the world. These drugs have received attention because of their certain efficacy as cancer-specific therapeutic agents. A large majority of antigenic proteins targeted by the drugs, however, are also expressed in normal cells. As a result of administering the antibodies, cancer cells as well as normal cells expressing the antigens are damaged, disadvantageously resulting in adverse reaction. Thus, if cancer antigens specifically expressed on the surface of cancer cells can be identified and antibodies targeting the antigens can be used as drugs, these antibody drugs can be expected 35 to achieve treatment with less adverse reaction.

40 [0005] Cytoplasmic- and proliferation-associated protein 1 (CAPRIN-1) has been known as an intracellular protein that is expressed upon activation or cell division of resting normal cells and forms cytoplasmic stress granules with RNAs in cells to participate in the regulation of transport and translation of mRNAs. This protein has been found to be specifically expressed on the surface of cancer cells and is therefore under study as a target of antibody drugs for cancer treatment (Patent Literature 2).

## Citation List

## Patent Literature

45 [0006]

Patent Literature 1: U.S. Patent No. 5698396

Patent Literature 2: WO2010/016526

50 Non Patent Literature

[0007]

55 Non Patent Literature 1: Tsuyoshi Akiyoshi, "Japanese Journal of Cancer and Chemotherapy", 1997, Vol. 24, p. 55-519 (Japanese Journal of Cancer and Chemotherapy Publishers Inc., Japan)  
 Non Patent Literature 2: Brugge P. et al., Science, 254: 1643-1647 (1991)  
 Non Patent Literature 3: Proc. Natl. Acad. Sci. USA, 92: 11810-11813 (1995)  
 Non Patent Literature 4: Int. J. Cancer, 72: 965-971 (1997)

Non Patent Literature 5: Cancer Res., 58: 1034-1041 (1998)  
 Non Patent Literature 6: Int. J. Cancer, 29: 652-658 (1998)  
 Non Patent Literature 7: Int. J. Oncol., 14: 703-708 (1999)  
 Non Patent Literature 8: Cancer Res., 56: 4766-4772 (1996)  
 5 Non Patent Literature 9: Hum. Mol. Genet. 6:33-39 (1997)

## Summary of Invention

## Technical Problem

10 [0008] An object of the present invention is to produce an antibody which targets CAPRIN-1 specifically expressed on the surface of cancer cells and has better antitumor activity than conventional antibodies, and provide the antibody for use as a therapeutic and/or preventive agent for cancer.

## 15 Solution to Problem

[0009] The present invention has the following aspects:

20 [0010] The present invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide having the amino acid sequence shown by SEQ ID NO: 5. The present invention also provides a pharmaceutical composition comprising the antibody or the fragment thereof as an active ingredient, and a pharmaceutical combination as defined in the claims. The invention also provides said pharmaceutical composition and said pharmaceutical combination, each for use in a method of treating and/or preventing cancer.

25 [0011] In one embodiment of the present invention, the cancer is breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.

[0012] In another embodiment, the antibody is a monoclonal antibody or a polyclonal antibody.

25 [0013] In an alternative embodiment, the antibody is a human antibody, a humanized antibody, a chimeric antibody, a single-chain antibody, or a multispecific antibody (e.g. bispecific antibody).

## 30 Advantageous Effects of Invention

[0014] The antibody against CAPRIN-1 according to the present invention damages cancer cells. Thus, the antibody against CAPRIN-1 is useful in the treatment and/or prevention of cancer.

## 35 Description of Embodiments

40 [0015] The antibody according to the present invention is an antibody that recognizes and binds to a predetermined partial polypeptide of CAPRIN-1 and has antitumor activity. The antibody according to the present invention is more specifically an antibody that recognizes (i.e., has immunological reactivity with) a partial polypeptide of a CAPRIN-1 protein (partial CAPRIN-1 polypeptide) consisting of the amino acid sequence shown by SEQ ID NO: 5. The present invention has revealed that this antibody exhibits antitumor activity. The present invention relates to all antibodies that bind to the fragments of CAPRIN-1 proteins as described above and exhibit antitumor activity.

45 [0016] The antibody against CAPRIN-1 according to the present invention may be any type of antibody that can exert antitumor activity and includes, for example, recombinant antibodies, for example, synthetic antibodies, multispecific antibodies (e.g., bispecific antibodies), humanized antibodies, chimeric antibodies, and single-chain antibodies (scFv), human antibodies, and their antibody fragments, for example, Fab, F(ab')<sub>2</sub>, and Fv. These antibodies and fragments thereof can be prepared by methods known to those skilled in the art. Desirably, the antibody according to the present invention has immunological reactivity with a CAPRIN-1 protein or a partial polypeptide thereof, i.e., binds to the CAPRIN-1 protein through antigen-antibody reaction, preferably, specifically binds to the CAPRIN-1 protein. In this context, the phrase "specifically binding to the CAPRIN-1 protein" means that the antibody specifically binds to the CAPRIN-1 protein without substantially binding to other proteins. The antibody according to the present invention is preferably a monoclonal antibody. Alternatively, the antibody according to the present invention may be a polyclonal antibody as long as homogeneous antibodies can be stably produced. In the case of a human subject, a human antibody or a humanized antibody is desirable for avoiding or suppressing rejection.

55 [0017] The antibody against CAPRIN-1 polypeptide according to the present invention can be examined for its antitumor activity, as described later, by examining *in vivo* the inhibition of tumor growth in a cancer-bearing animal or by examining *ex vivo* the presence or absence of immunocyte- or complement-mediated cytotoxic activity exhibited by the antibody against tumor cells expressing the polypeptide.

[0018] The subject to receive the treatment and/or prevention of cancer according to the present invention is a mammal such as a human, a pet animal, livestock, or a sport animal, preferably a human.

[0019] Hereinafter, the present invention will be described in more detail.

5 <Preparation of antigen for antibody preparation>

[0020] Proteins or fragments thereof used as sensitizing antigens for obtaining the antibody against CAPRIN-1 according to the present invention are not limited by animal species serving as their origins, including humans, dogs, cattle, horses, mice, rats, and chickens. The proteins or the fragments thereof, however, are preferably selected in view of compatibility with parent cells for use in cell fusion. In general, mammal-derived proteins are preferred. Particularly, human-derived proteins are preferred. For example, when CAPRIN-1 is human CAPRIN-1, human CAPRIN-1 proteins, partial peptides thereof, or cells expressing human CAPRIN-1 can be used.

[0021] The nucleotide sequences and amino acid sequences of human CAPRIN-1 and homologs thereof are available, for example, by accessing GenBank (NCBI, USA) and using BLAST or FASTA algorithm (Karlin and Altschul, Proc. Natl. Acad. Sci. USA, 90: 5873-5877, 1993; and Altschul et al., Nucleic Acids Res. 25: 3389-3402, 1997).

[0022] In the present invention, with reference to the nucleotide sequence (SEQ ID NO: 1 or 3) or amino acid sequence (SEQ ID NO: 2 or 4) of human CAPRIN-1, the target CAPRIN-1 is nucleic acids or proteins consisting of sequences having 70% to 100%, preferably 80% to 100%, more preferably 90% to 100%, further preferably 95% to 100%, for example, 97% to 100%, 98% to 100%, 99% to 100%, or 99.5% to 100% sequence identity to the nucleotide sequence or amino acid sequence of the ORF or mature portion of the reference sequence. In this context, the term "% sequence identity" means a percentage (%) of the number of identical amino acids (or nucleotide bases) to the total number of amino acids (or nucleotide bases) when two sequences are aligned such that the maximum degree of similarity (or identity) can be achieved with or without introduced gaps.

[0023] As the fragments of each CAPRIN-1 protein, those comprising an epitope (or an antigenic determinant), which is the smallest unit recognized by an antibody, and having lengths ranging from the amino acid length of the epitope to less than the full-length of the protein can be used. The epitope refers to a polypeptide fragment having antigenicity or immunogenicity in mammals, preferably humans. Its smallest unit consists of approximately 7 to 12 amino acids, for example, 8 to 11 amino acids. The fragment of CAPRIN-1 protein to be used in the preparation of the antibody according to the present invention consists of the amino acid sequence shown by SEQ ID NO: 5 recognized by the antibody of the present invention.

[0024] Polypeptide fragments comprising the above human CAPRIN-1 proteins and partial peptides thereof can be synthesized according to chemical synthesis methods, for example, Fmoc (fluorenylmethyloxycarbonyl) and tBoc (t-butyloxycarbonyl) methods (Seikagaku Jikken Koza (Biochemical Experimentation Course in English) 1, the Japanese Biochemical Society ed., Protein Chemistry IV, Chemical Modification and Peptide Synthesis, Tokyo Kagaku Dojin Co., Ltd. (Japan), 1981). Also, these polypeptides can be synthesized by conventional methods using various commercially available peptide synthesizers.

[0025] Alternatively, polynucleotides encoding the polypeptides may be prepared using genetic engineering approaches known in the art (Sambrook et al., Molecular Cloning, the 2nd edition, Current Protocols in Molecular Biology (1989), Cold Spring Harbor Laboratory Press; Ausubel et al., Short Protocols in Molecular Biology, the 3rd edition, A compendium of Methods from Current Protocols in Molecular Biology (1995), John Wiley & Sons; etc.) and incorporated into expression vectors, which are then introduced into host cells to produce the polypeptides in the host cells. In this way, the human CAPRIN-1 proteins or polypeptide fragments thereof of interest can be obtained.

[0026] The polynucleotides encoding the polypeptides can be readily prepared by genetic engineering approaches known in the art or conventional methods using commercially available nucleic acid synthesizers. For example, a DNA comprising the nucleotide sequence of human CAPRIN-1 gene can be prepared by PCR using a human chromosomal DNA or cDNA library as a template and a pair of primers designed so as to be capable of amplifying the nucleotide sequence. Reaction conditions for this PCR can be appropriately determined. Examples of the conditions can include, but not limited to, 30 cycles each involving reaction steps consisting of 94°C for 30 seconds (denaturation), 55°C for 30 seconds to 1 minute (annealing), and 72°C for 2 minutes (elongation) using thermostable DNA polymerase (e.g., Taq polymerase, Pfu polymerase or the like) and a Mg<sup>2+</sup>-containing PCR buffer, followed by reaction at 72°C for 7 minutes. The PCR approach, conditions, etc. are described in, for example, Ausubel et al., Short Protocols in Molecular Biology, the 3rd edition, A Compendium of Methods from Current Protocols in Molecular Biology (1995), John Wiley & Sons (particularly, Chapter 15).

[0027] Also, appropriate probes or primers can be prepared on the basis of information about the nucleotide sequences of CAPRIN-1 gene and the amino acid sequences of CAPRIN-1 proteins, and used in the screening of, for example, a human cDNA library, to isolate the desired DNA. Preferably, such a cDNA library is produced from cells, organs, or tissues expressing proteins of CAPRIN-1. Examples of such cells or tissues include cells or tissues derived from the testis or from cancers or tumors such as leukemia, breast cancer, lymphoma, brain tumor, lung cancer, pancreatic

cancer, and colorectal cancer. These operations, including the preparation of probes or primers, the construction of a cDNA library, the screening of the cDNA library, and the cloning of the gene of interest, are known to those skilled in the art and can be performed according to methods described in, for example, Sambrook et al., Molecular Cloning, the 2nd edition, Current Protocols in Molecular Biology (1989), and Ausubel et al. (ibid.). DNAs encoding the human CAPRIN-1 proteins and the partial peptides thereof can be obtained from the DNA thus obtained.

**[0028]** The host cells into which the expression vectors are introduced may be any cell capable of expressing the above polypeptides. Examples of prokaryotic cells include, but not limited to, *E. coli*. Examples of eukaryotic cells include, but not limited to: mammalian cells such as monkey kidney cells COS1 and Chinese hamster ovary cells CHO; a human embryonic kidney cell line HEK293; mouse embryonic skin cell line NIH3T3; yeast cells such as budding yeast and fission yeast cells; silkworm cells; and *Xenopus* egg cells.

**[0029]** In the case of using prokaryotic cells as the host cells, the expression vectors used may have an origin that permits replication in the prokaryotic cells, a promoter, a ribosomal binding site, a multicloning site, a terminator, a drug resistance gene, an auxotrophic complementary gene, etc. Examples of expression vectors for *E. coli* can include pUC series, pBluescript II, pET expression systems, and pGEX expression systems. The DNAs encoding the above polypeptides can be incorporated into such expression vectors, with which prokaryotic host cells are then transformed, followed by culture of the obtained transformants so that the polypeptides encoded by the DNAs are expressed in the prokaryotic host cells. In this respect, the polypeptides may be expressed as fusion proteins with other proteins.

**[0030]** In the case of using eukaryotic cells as the host cells, expression vectors for eukaryotic cells having a promoter, a splicing region, a poly(A) addition site, etc. may be used as the expression vectors. Examples of such expression vectors can include pKA1, pCDM8, pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, EBV, pRS, pcDNA3, and pYES2 vectors. In the same way as above, the DNAs encoding the above polypeptides can be incorporated into such expression vectors, with which eukaryotic host cells are then transformed, followed by culture of the obtained transformants so that the polypeptides encoded by the DNAs are expressed in the eukaryotic host cells. In the case of using expression vectors such as pIND/V5-His, pFLAG-CMV-2, pEGFP-N1, or pEGFP-C1, the polypeptides may be expressed as various fusion proteins tagged with His tag (e.g., (His)<sub>6</sub> to (His)<sub>10</sub>), FLAG tag, myc tag, HA tag, GFP, or the like.

**[0031]** The expression vectors can be introduced into the host cells using well known methods such as electroporation, a calcium phosphate method, a liposome method, a DEAE dextran method, microinjection, viral infection, lipofection, and binding with cell-penetrating peptides.

**[0032]** The polypeptide of interest can be isolated and purified from the host cells by a combination of separation operations known in the art. Examples thereof include, but not limited to, treatment with a denaturant (e.g., urea) or a surfactant, ultrasonication, enzymatic digestion, salting-out, solvent fractionation and precipitation, dialysis, centrifugation, ultrafiltration, gel filtration, SDS-PAGE, isoelectric focusing electrophoresis, ion-exchange chromatography, hydrophobic chromatography, affinity chromatography, and reverse-phase chromatography.

**[0033]** In order to prepare the antibody according to the present invention, antigens thus prepared can be used as sensitizing antigens as described later.

<Structure of antibody>

**[0034]** Antibodies (immunoglobulin) are usually heteromultimeric glycoproteins each comprising at least two heavy chains and two light chains. The immunoglobulins, except for IgM, are heterotetrameric glycoproteins of approximately 150 kDa each composed of two identical light (L) chains and two identical heavy (H) chains. Typically, each light chain is connected to a heavy chain via a single covalent disulfide bond, though the number of disulfide bonds between heavy chains varies among different immunoglobulin isotypes. Each of the heavy and light chains also has an intrachain disulfide bond. Each heavy chain has a variable domain (VH region) at one end, followed by a series of constant regions. Each light chain has a variable domain (VL region) at one end and has a single constant region at the other end. The light chain constant region is aligned with the first heavy chain constant region, while the light chain variable domain is aligned with the heavy chain variable domain. Particular regions called complementarity determining regions (CDRs) in the antibody variable domains exhibit specific variability and impart binding specificity to the antibody. Portions relatively conserved in the variable regions are called framework regions (FRs). The complete heavy and light chain variable domains each comprise four FRs connected via three CDRs. These three CDRs are called CDRH1, CDRH2, and CDRH3 in this order from the N-terminus of the heavy chain. Likewise, the CDRs are called CDRL1, CDRL2, and CDRL3 in the light chain. CDRH3 is most important for the binding specificity of the antibody for its antigen. In addition, CDRs in each chain are kept close to each other by the FR regions and contribute to the formation of an antigen-binding site in the antibody, together with CDRs in the other chain. The constant regions do not directly contribute to antibody-antigen binding, but exhibit various effector functions, for example, involvement in antibody-dependent cellular cytotoxicity (AD-CC), phagocytosis mediated by binding to an Fcγ receptor, half-life/clearance rate mediated by a neonatal Fc receptor (FcRn), and complement-dependent cytotoxicity (CDC) mediated by a C1q component in the complement cascade.

<Preparation of antibody>

**[0035]** The anti-CAPRIN-1 antibody according to the present invention means an antibody having immunological reactivity with a full-length CAPRIN-1 protein or a fragment thereof. Particularly, the anti-CAPRIN-1 antibody of the present invention is an antibody immunologically binding to a partial polypeptide of a CAPRIN-1 protein (partial CAPRIN-1 polypeptide) that is a peptide containing an epitope and consisting of the amino acid sequence shown by SEQ ID NO: 5. The antibody of the present invention preferably recognizes an epitope consisting of approximately 7 to 12 consecutive amino acids, for example, 8 to 11 consecutive amino acids, in the amino acid sequence shown by SEQ ID NO: 5. This anti-CAPRIN-1 antibody of the present invention can specifically bind to the full-length CAPRIN-1 protein. The antibody of the present invention can be obtained by selecting an antibody immunologically binding to a polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5, according to a routine method from among antibodies obtained with CAPRIN-1 proteins or fragments thereof as antigens.

**[0036]** In this context, the "immunological reactivity" means the property of the antibody binding to the CAPRIN-1 antigen (a full-length CAPRIN-1 protein or a partial polypeptide thereof) *in vivo*. Via such binding of the antibody of the present invention to the CAPRIN-1, the antibody exerts the function of damaging (e.g., killing, suppressing, or regressing) tumor cells. The antibody of the present invention can damage tumors such as breast cancer, kidney cancer, pancreatic cancer, colorectal cancer (e.g. colon cancer), lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma as a result of binding to the CAPRIN-1 protein.

**[0037]** The antibody of the present invention may be any type of antibody. Examples of the type of the antibody according to the present invention include monoclonal antibodies, polyclonal antibodies, synthetic antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, single-chain antibodies, and antibody fragments (e.g., Fab, F(ab')<sub>2</sub>, and Fv). Also, the antibody is any class of immunoglobulin molecule, for example, IgG, IgE, IgM, IgA, IgD, or IgY, or any subclass, for example, IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2.

**[0038]** Further the antibody may be modified by acetylation, formylation, amidation, phosphorylation, PEGylation, or the like, as well as glycosylation.

**[0039]** Hereinafter, preparation examples of various antibodies will be shown.

**[0040]** When the antibody of the present invention is a monoclonal antibody, for example, breast cancer cell lines SK-BR-3 expressing CAPRIN-1 is administered to each mouse for immunization. The spleen is extracted from this mouse. After separation of spleen cells, the cells are fused with mouse myeloma cells. Clones producing antibodies having a cancer cell growth inhibitory effect are selected from among the obtained fusion cells (hybridomas). Alternatively, clones producing antibodies binding to a polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5 may be selected. The hybridomas producing monoclonal antibodies having a cancer cell growth inhibitory effect or the hybridomas producing monoclonal antibodies against the polypeptides of SEQ ID NO: 5, etc. are isolated and cultured. The antibody of the present invention can be prepared by purification from the culture supernatant according to a general affinity purification method.

**[0041]** The monoclonal antibody-producing hybridomas may be prepared, for example, as follows. First, animals are immunized with sensitizing antigens according to a method known in the art. This immunization method generally involves intraperitoneally or subcutaneously injecting the sensitizing antigens to mammals. Specifically, the sensitizing antigens are diluted with or suspended in PBS (phosphate-buffered saline), physiological saline, or the like into an appropriate amount and then mixed, if desired, with an appropriate amount of a conventional adjuvant, for example, a complete Freund's adjuvant. After emulsification, it is administered to each mammal several times every 4 to 21 days. Alternatively, an appropriate carrier may be used for the immunization with sensitizing antigens.

**[0042]** After confirmation of a rise in the level of the desired antibody in the serum of the animal (typically, mammal) thus immunized, immunocytes are collected from the animal and subjected to cell fusion. Preferred examples of the immunocytes particularly include spleen cells.

**[0043]** Mammalian myeloma cells, for example, can be used as partner parent cells to be fused with the immunocytes. Various cell lines known in the art, for example, P3U1 (P3-X63Ag8U1), P3 (P3x63Ag8.653) (J. Immunol. (1979) 123, 1548-1550), P3x63Ag8U.1 (Current Topics in Microbiology and Immunology (1978) 81, 1-7), NS-1 (Kohler, G. and Milstein, C. Eur. J. Immunol. (1976) 6, 511-519), MPC-11 (Margulies, D.H. et al., Cell (1976) 8, 405-415), SP2/0 (Shulman, M. et al., Nature (1978) 276, 269-270), FO (deSt. Groth, S.F. et al., J. Immunol. Methods (1980) 35, 1-21), S194 (Trowbridge, I.S. J. Exp. Med. (1978) 148, 313-323), and R210 (Galfre, G. et al., Nature (1979) 277, 131-133), are preferably used as the myeloma cells.

**[0044]** The cell fusion between the immunocytes and the myeloma cells can be performed basically according to a method known in the art, for example, the method of Kohler and Milstein (Kohler, G. and Milstein, C. Methods Enzymol. (1981) 73, 3-46).

**[0045]** More specifically, the cell fusion is carried out, for example, in the presence of a cell fusion promoter in a conventional nutrient medium. For example, polyethylene glycol (PEG) or hemagglutinating virus of Japan (HVJ) is used

as the fusion promoter. If desired, an auxiliary such as dimethyl sulfoxide may be further added in order to enhance fusion efficiency.

**[0046]** The ratio between the immunocytes and the myeloma cells used can be arbitrarily set. For example, the amount of the immunocytes is preferably set to 1 to 10 times the amount of the myeloma cells. Examples of the medium that can be used in the cell fusion include RPMI1640 and MEM media suitable for the growth of the myeloma cell lines as well as conventional media for use in this type of cell culture. In addition, a serum supplement such as fetal calf serum (FCS) may be used in combination with these media.

**[0047]** For the cell fusion, the immunocytes and the myeloma cells are well mixed in a predetermined amount of the medium. A PEG solution (average molecular weight: for example, approximately 1000 to 6000) preheated to approximately 37°C is usually added to the mixture at a concentration of 30 to 60% (w/v) and mixed therewith to form the hybridomas of interest. Subsequently, procedures of sequentially adding an appropriate medium and removing the supernatant by centrifugation are preferably repeated to remove cell fusion agents or the like unfavorable for the growth of the hybridomas.

**[0048]** The hybridomas thus obtained are cultured in a conventional selective medium, for example, a HAT medium (medium containing hypoxanthine, aminopterin, and thymidine) for selection. Culture in the HAT medium is continued for a period (usually, several days to several weeks) sufficient for the death of cells (non-fused cells) other than the hybridomas of interest. Subsequently, hybridomas producing the antibody of interest are screened for and cloned as single clones by a conventional limiting dilution method.

**[0049]** In addition to such obtainment of the hybridomas by the immunization of non-human animals with antigens, hybridomas producing human antibodies having the desired activity (e.g., cell growth inhibitory activity) may be obtained by sensitizing human lymphocytes, for example, EB virus-infected human lymphocytes, with proteins, protein-expressing cells, or lysates thereof *in vitro* and fusing the sensitized lymphocytes with human-derived myeloma cells capable of dividing permanently, for example, U266 (Accession No. TIB196).

**[0050]** The monoclonal antibody-producing hybridomas thus prepared can be subcultured in a conventional medium and can also be stored for a long period in liquid nitrogen.

**[0051]** Specifically, the desired antigens or cells expressing the desired antigens are used as sensitizing antigens in immunization according to a conventional immunization method. The obtained immunocytes are fused with parent cells known in the art according to a conventional cell fusion method. Monoclonal antibody-producing cells (hybridomas) can be screened for by a conventional screening method to prepare the hybridomas producing monoclonal antibodies of interest.

**[0052]** Another example of the antibody that may be used in the present invention is a polyclonal antibody. The polyclonal antibody can be obtained, for example, as follows:

**[0053]** Serum is obtained from small animals such as mice, human antibody-producing mice, or rabbits immunized with natural CAPRIN-1 proteins or recombinant CAPRIN-1 proteins expressed as fusion proteins with GST or the like in microorganisms such as *E. coli*, or partial peptides thereof. Alternatively, serum may be obtained from mammals immunized with CAPRIN-1 fragment polypeptides each comprising the amino acid sequence shown by SEQ ID NO: 5 or an amino acid sequence having 80% or higher, preferably 85% or higher, more preferably 90% or higher, further preferably 95% or higher sequence identity to the amino acid sequence (preferably, a polypeptide consisting of the amino acid sequence of SEQ ID NO: 5), or polypeptides each comprising (preferably, consisting of) an epitope consisting of approximately 7 to 12 consecutive amino acids, for example, 8 to 11 consecutive amino acids, in the amino acid sequence shown by SEQ ID NO: 5 or an amino acid sequence having 80% or higher, preferably 85% or higher, more preferably 90% or higher, further preferably 95% or higher sequence identity to the amino acid sequence, as sensitizing antigens. These serums are purified using, for example, ammonium sulfate precipitation, protein A or protein G columns, DEAE ion-exchange chromatography, or affinity columns coupled with CAPRIN-1 proteins or synthetic peptides to prepare the anti-CAPRIN-1 polyclonal antibody. The polyclonal antibody of the present invention includes antibodies obtained from human antibody-producing animals (e.g., mice) immunized with CAPRIN-1 proteins.

**[0054]** In this context, for example, KM mice (Kirin Pharma Co., Ltd./Medarex) and Xeno mice (Amgen Inc.) are known as the human antibody-producing mice (e.g., International Publication Nos. WO02/43478 and WO02/092812). Complete human polyclonal antibodies can be obtained from the blood of such mice immunized with CAPRIN-1 proteins or fragments thereof. Alternatively, spleen cells may be isolated from the mice thus immunized and fused with myeloma cells. In this way, human monoclonal antibodies can be obtained.

**[0055]** The antigens can be prepared according to, for example, a method using animal cells (JP Patent Publication (Kohyo) No. 2007-530068 A (2007)) or a method using baculovirus (e.g., International Publication No. WO98/46777). Antigens having low immunogenicity can be bound to immunogenic macromolecules such as albumin for immunization. Antigens may be administered with adjuvants for immunization.

**[0056]** Alternatively, the antibody of the present invention may be obtained as recombinant antibodies, which are produced using a genetic engineering technique which involves: cloning the antibody genes from hybridomas; incorporating the antibody genes into appropriate vectors; and introducing the vectors into hosts (see, e.g., Carl, A.K. Borrebaeck,

James, W. Lerrick, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). Specifically, antibody variable region (V region) cDNAs are synthesized from the mRNAs of hybridomas using reverse transcriptase. After obtainment of DNAs encoding the antibody V regions of interest, the DNAs are ligated with DNAs encoding the desired antibody constant regions (C regions). The resulting ligation products are incorporated into expression vectors. Alternatively, the antibody V region-encoding DNAs may be incorporated into expression vectors containing antibody C region DNAs. These DNAs are incorporated into the expression vectors so as to be expressed under the control of expression control regions, for example, an enhancer and a promoter. Next, host cells can be transformed with the resulting expression vectors and allowed to express antibodies.

**[0057]** The anti-CAPRIN-1 antibody of the present invention is preferably a monoclonal antibody. Alternatively, the anti-CAPRIN-1 antibody of the present invention may be a polyclonal antibody, a genetically engineered antibody (chimeric antibody, humanized antibody, etc.), or the like.

**[0058]** The monoclonal antibody includes human monoclonal antibodies, non-human animal monoclonal antibodies (e.g., mouse, rat, rabbit, and chicken monoclonal antibodies), chimeric monoclonal antibodies, and the like. The monoclonal antibody may be prepared by the culture of hybridomas obtained by the fusion between spleen cells from non-human animals (e.g., mice or human antibody-producing mice, chickens, and rabbits) immunized with CAPRIN-1 proteins or fragments thereof and myeloma cells. Alternatively, genes of heavy and light chain variable regions from the spleen cells of non-human animals (e.g., mice, human antibody-producing mice, chickens, and rabbits) immunized with CAPRIN-1 proteins or fragments thereof may be incorporated via linkers into phagemid vectors, which are then introduced into *E. coli* so that single-chain antibodies are expressed via helper phages to prepare the antibodies of interest. The chimeric antibody is an antibody prepared from a combination of sequences derived from different animals and is, for example, an antibody composed of mouse antibody heavy and light chain variable regions and human antibody heavy and light chain constant regions. The chimeric antibody can be prepared using a method known in the art which involves, for example: ligating DNAs encoding the antibody V regions with DNAs encoding human antibody C regions; incorporating the resulting ligation products into expression vectors; and introducing the vectors into hosts so that antibodies are produced.

**[0059]** Monoclonal antibodies that have immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5 and have an antitumor effect are prepared by methods described later in Examples. These monoclonal antibodies each comprise, for example, a heavy chain variable (VH) region having the amino acid sequence of SEQ ID NO: 9, 19, 58, 63, 69, or 77 and a light chain variable (VL) region having the amino acid sequence of SEQ ID NO: 13, 23, 53, 62, 65, 73, or 81. In these monoclonal antibodies, the VH region can comprise CDR1 shown by the amino acid sequence of SEQ ID NO: 6, 16, 55, 66, or 74, CDR2 shown by the amino acid sequence of SEQ ID NO: 7, 17, 56, 67, or 75, and CDR3 shown by the amino acid sequence of SEQ ID NO: 8, 18, 57, 68, or 76, and the VL region can comprise CDR1 shown by the amino acid sequence of SEQ ID NO: 10, 20, 50, 59, 70, or 78, CDR2 shown by the amino acid sequence of SEQ ID NO: 11, 21, 51, 60, 64, 71, or 79, and CDR3 shown by the amino acid sequence of SEQ ID NO: 12, 22, 52, 61, 72, or 80.

**[0060]** The humanized antibody, also called reshaped human antibody, is an engineered antibody. The humanized antibody is constructed by grafting antibody CDRs derived from an immunized animal into the complementarity determining regions of a human antibody. A general gene recombination approach therefor is also known.

**[0061]** Specifically, for example, DNA sequences designed so as to link mouse, rabbit, and chicken antibodies CDRs and human antibody framework regions (FRs) are synthesized by PCR using several prepared oligonucleotides having terminal portions overlapping with each other. The obtained DNAs are ligated with DNAs encoding human antibody constant regions. Subsequently, the resulting ligation products are incorporated into expression vectors, which are then introduced into hosts for antibody production to obtain the antibody of interest (see European Patent Application Publication No. EP239400 and International Publication No. WO96/02576). The human antibody FRs connected via CDRs are selected such that the complementarity determining regions form a favorable antigen-binding site. If necessary, amino acids in the framework regions of antibody variable regions may be substituted such that the complementarity determining regions of the resulting reshaped human antibody form an appropriate antigen-binding site (Sato K. et al., Cancer Research 1993, 53: 851-856). In addition, these framework regions may be replaced with framework regions derived from various human antibodies (see International Publication No. WO99/51743).

**[0062]** The human antibody framework regions connected via CDRs are selected such that the complementarity determining regions form a favorable antigen-binding site. If necessary, amino acids in the framework regions of antibody variable regions may be substituted such that the complementarity determining regions of the resulting reshaped human antibody form an appropriate antigen-binding site (Sato K. et al., Cancer Research 1993, 53: 851-856).

**[0063]** Amino acids in variable regions (e.g., FRs) or constant regions of the chimeric antibody or the humanized antibody thus prepared may be substituted, for example, by other amino acids.

**[0064]** The amino acid substitution is the substitution of, for example, less than 15, less than 10, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less amino acids, preferably 1 to 5 amino acids, more preferably 1 or 2 amino acids. The substituted antibody should be functionally equivalent to an unsubstituted antibody. The substitution

is desirably conservative amino acid substitution, which is the substitution between amino acids similar in properties such as charge, side chains, polarity, and aromaticity. The amino acids can be classified in terms of similar properties into, for example: basic amino acids (arginine, lysine, and histidine); acidic amino acids (aspartic acid and glutamic acid); uncharged polar amino acids (glycine, asparagine, glutamine, serine, threonine, cysteine, and tyrosine); nonpolar amino acids (leucine, isoleucine, alanine, valine, proline, phenylalanine, tryptophan, and methionine); branched amino acids (leucine, valine, and isoleucine); and aromatic amino acids (phenylalanine, tyrosine, tryptophan, and histidine).

**[0065]** Examples of modified antibodies can include antibodies bound with various molecules such as polyethylene glycol (PEG). In the modified antibody of the present invention, the substance to be bound is not limited. In order to obtain such a modified antibody, the obtained antibody can be chemically modified. A method therefor has already been established in the art.

**[0066]** In this context, the phrase "functionally equivalent" means that an antibody concerned has biological or biochemical activity similar to that of the antibody of the present invention, specifically, the antibody concerned has the function of damaging tumor and essentially causes no rejection when applied to humans, for example. Examples of such activity can include cell growth inhibitory activity and binding activity.

**[0067]** A method for preparing a polypeptide functionally equivalent to a certain polypeptide, which involves introducing a mutation into a polypeptide, is well known to those skilled in the art. For example, those skilled in the art can introduce a mutation as appropriate into the antibody of the present invention using site-directed mutagenesis (Hashimoto-Gotoh, T. et al., (1995) Gene 152, 271-275; Zoller, MJ., and Smith, M. (1983) Methods Enzymol. 100, 468-500; Kramer, W. et al., (1984) Nucleic Acids Res. 12, 9441-9456; Kramer, W. and Fritz, HJ., (1987) Methods Enzymol. 154, 350-367; Kunkel, TA., (1985) Proc. Natl. Acad. Sci. USA. 82, 488-492; and Kunkel (1988) Methods Enzymol. 85, 2763-2766) or the like, thereby prepare an antibody functionally equivalent to the antibody of the present invention.

**[0068]** An antibody that recognizes an epitope of a CAPRIN-1 protein described above or a CAPRIN-1 polypeptide fragment including thereof can be obtained by a method generally known to those skilled in the art. For example, the antibody can be obtained by a method which involves determining the epitope of the CAPRIN-1 protein recognized by the anti-CAPRIN-1 antibody having a cancer cell growth inhibitory effect obtained by the above by a conventional method (e.g., epitope mapping or a method for identifying an epitope as described later) and preparing an antibody using a polypeptide having an amino acid sequence contained in the epitope as an immunogen, or a method which involves determining an epitope for an antibody prepared by a conventional method and selecting an antibody that recognizes the same epitope as that for the anti-CAPRIN-1 antibody. In this context, the "epitope" refers to a polypeptide fragment having antigenicity or immunogenicity in mammals, preferably humans. Its smallest unit consists of approximately 7 to 12 amino acids, preferably 8 to 11 amino acids.

**[0069]** The antibody of the present invention is an antibody having immunological reactivity with CAPRIN-1, an antibody specifically recognizing CAPRIN-1, or an antibody specifically binding to CAPRIN-1 and exhibits cytotoxic activity or tumor growth inhibitory effect on cancer. The antibody preferably has a structure that causes little or no rejection in recipient animals. Examples of such antibodies include human antibodies, humanized antibodies, chimeric antibodies (e.g., human-mouse chimeric antibodies), single-chain antibodies, and bispecific antibodies when the recipient animals are humans. These antibodies have heavy and light chain variable regions derived from a human antibody or have heavy and light chain variable regions consisting of complementarity determining regions (CDR1, CDR2, and CDR3) derived from a non-human animal antibody and framework regions derived from a human antibody. Alternatively, these antibodies are recombinant antibodies having heavy and light chain variable regions derived from a non-human animal antibody and heavy and light chain constant regions derived from a human antibody. The antibody of the present invention is preferably the former two antibodies.

**[0070]** Such recombinant antibodies can be prepared as follows: DNAs encoding monoclonal antibodies (e.g., human, mouse, rat, rabbit, and chicken monoclonal antibodies) against human CAPRIN-1 are cloned from the antibody-producing cells such as hybridomas and used as templates to prepare DNAs encoding the light and heavy chain variable regions of the antibodies by RT-PCR or the like. The respective sequences of the light and heavy chain variable regions and the respective sequences of CDR1, CDR2, and CDR3 in each region are determined on the basis of the Kabat EU numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institute of Health, Bethesda, Md. (1991)).

**[0071]** A DNA encoding each variable region or a DNA encoding each CDR is prepared using a genetic engineering technique (Sambrook et al., Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989)) or a DNA synthesizer. The above-mentioned human monoclonal antibody-producing hybridomas can be prepared by immunizing human antibody-producing animals (e.g., mice) with human CAPRIN-1 and then fusing spleen cells excised from the immunized animals with myeloma cells. Separately, DNAs encoding light or heavy chain variable and constant regions derived from a human antibody are prepared, if necessary, using a genetic engineering technique or a DNA synthesizer.

**[0072]** For the humanized antibody, a DNA encoding the humanized antibody can be prepared by producing DNAs in which the CDR coding sequences in DNAs encoding a human antibody-derived light or heavy chain variable regions

are substituted by corresponding CDR coding sequences of a non-human animal (e.g., mouse, rat, rabbit, or chicken)-derived antibody, ligating the resulting DNAs with the DNAs encoding human antibody-derived light or heavy chain constant regions, respectively.

**[0073]** For the chimeric antibody, a DNA encoding the chimeric antibody can be prepared by ligating DNAs encoding light or heavy chain variable regions of a non-human animal (e.g., mouse, rat, rabbit, or chicken)-derived antibody with DNAs encoding human antibody-derived light or heavy chain constant regions.

**[0074]** The single-chain antibody means an antibody in which heavy and light chain variable regions are linearly linked to each other via a linker. A DNA encoding the single-chain antibody can be prepared by ligating a DNA encoding the heavy chain variable region, a DNA encoding the linker, and a DNA encoding the light chain variable region. In this context, the heavy and light chain variable regions are both derived from a human antibody or derived from a human antibody in which CDRs alone are substituted by CDRs of a non-human animal (e.g., mouse, rat, rabbit, or chicken)-derived antibody. The linker consists of 12 to 19 amino acids. Examples thereof include (G<sub>4</sub>S)<sub>3</sub> consisting of 15 amino acids (G.B. Kim et al., Protein Engineering Design and Selection 2007, 20 (9): 425-432).

**[0075]** The bispecific antibody (diabody) means an antibody capable of specifically binding to two different epitopes. A DNA encoding the bispecific antibody can be prepared by, for example, ligating a DNA encoding a heavy chain variable region A, a DNA encoding a light chain variable region B, a DNA encoding a heavy chain variable region B, and a DNA encoding a light chain variable region A in this order, wherein the DNA encoding the light chain variable region B and the DNA encoding the heavy chain variable region B are ligated via a DNA encoding a linker as described above. In this context, the heavy and light chain variable regions are all derived from a human antibody or derived from a human antibody in which CDRs alone are substituted by CDRs of a non-human animal (e.g., mouse, rat, rabbit, or chicken)-derived antibody.

**[0076]** The recombinant DNAs thus prepared can be incorporated into one or more appropriate vectors, which are then introduced into host cells (e.g., mammalian cells, yeast cells, and insect cells), and the DNAs are (co)expressed to produce recombinant antibodies (see, P.J. Delves., ANTIBODY PRODUCTION ESSENTIAL TECHNIQUES., 1997 WILEY, P. Shepherd and C. Dean., Monoclonal Antibodies., 2000 OXFORD UNIVERSITY PRESS; and J.W. Goding., Monoclonal Antibodies: principles and practice., 1993 ACADEMIC PRESS).

**[0077]** Examples of the antibody of the present invention prepared by any of the methods described above include the following antibodies (a) to (g) obtained in Examples described later:

- 30 (a) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 10, 11, and 12 (e.g., an antibody having a heavy chain variable region of SEQ ID NO: 9 and a light chain variable region of SEQ ID NO: 13);
- 35 (b) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 16, 17, and 18 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 20, 21, and 22 (e.g., an antibody constructed using a heavy chain variable region of SEQ ID NO: 19 and a light chain variable region of SEQ ID NO: 23);
- 40 (c) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 50, 51, and 52 (e.g., an antibody constructed using a heavy chain variable region of SEQ ID NO: 9 and a light chain variable region of SEQ ID NO: 53);
- 45 (d) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 55, 56, and 57 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 59, 60, and 61 (e.g., an antibody constructed using a heavy chain variable region of SEQ ID NO: 58 and a light chain variable region of SEQ ID NO: 62);
- 50 (e) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 55, 56, and 57 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 59, 64, and 61 (e.g., an antibody constructed using a heavy chain variable region of SEQ ID NO: 63 and a light chain variable region of SEQ ID NO: 65);
- 55 (f) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 66, 67, and 68 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 70, 71, and 72 (e.g., an antibody constructed using a heavy chain variable region of SEQ ID NO: 69 and a light chain variable region of SEQ ID NO: 73);
- (g) an antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 74, 75, and 76 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 78, 79, and 80 (e.g., an antibody constructed using a heavy chain variable region of SEQ ID NO: 77 and a light chain variable region of SEQ ID NO: 81);

[0078] In this context, the amino acid sequences shown by SEQ ID NOs: 6, 7, and 8, and SEQ ID NOs: 16, 17, and 18 correspond to CDR1, CDR2, and CDR3, respectively, of a mouse antibody-derived heavy chain variable region. The amino acid sequences shown by SEQ ID NOs: 10, 11, and 12, SEQ ID NOs: 20, 21, and 22, and SEQ ID NOs: 50, 51, and 52 correspond to CDR1, CDR2, and CDR3, respectively, of a mouse antibody-derived light chain variable region.

5 The amino acid sequences shown by SEQ ID NOs: 55, 56, and 57, SEQ ID NOs: 66, 67, and 68, and SEQ ID NOs: 74, 75, and 76 correspond to CDR1, CDR2, and CDR3, respectively, of a chicken antibody-derived heavy chain variable region. The amino acid sequences shown by SEQ ID NOs: 59, 60, and 61, SEQ ID NOs: 59, 64, and 61, SEQ ID NOs: 70, 71, and 72, and SEQ ID NOs: 78, 79, and 80 correspond to CDR1, CDR2, and CDR3, respectively, of a chicken antibody-derived light chain variable region.

10 [0079] Examples of the humanized antibody, the chimeric antibody, the single-chain antibody, or the bispecific antibody of the present invention include antibodies described below. The following antibodies are illustrative embodiments of the antibody (a), but there may be also similar embodiments of the other antibodies (b) to (g).

[0080]

15 (i) an antibody comprising a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 6, 7, and 8 and the amino acid sequences of human antibody-derived framework regions and a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12 and the amino acid sequences of human antibody-derived framework regions.

20 (ii) an antibody comprising a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 6, 7, and 8 and the amino acid sequences of human antibody-derived framework regions, a heavy chain constant region comprising a human antibody-derived amino acid sequence, a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12 and the amino acid sequences of human antibody-derived framework regions, and a light chain constant region comprising a human antibody-derived amino acid sequence.

25 (iii) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 9, a heavy chain constant region comprising a human antibody-derived amino acid sequence, a light chain variable region comprising the amino acid sequence of SEQ ID NO: 13, and a light chain constant region comprising a human antibody-derived amino acid sequence.

30 [0081] The sequences of the constant and variable regions of human antibody heavy and light chains are available from, for example, NCBI (USA; GenBank, UniGene, etc.). For example, the following sequences can be referred to: Accession No. J00228 for a human IgG1 heavy chain constant region; Accession No. J00230 for a human IgG2 heavy chain constant region; Accession No. X03604 for a human IgG3 heavy chain constant region; Accession No. K01316 for a human IgG4 heavy chain constant region; Accession Nos. V00557, X64135, and X64133 for a human light chain  $\kappa$  constant region; and Accession Nos. X64132 and X64134 for a human light chain  $\lambda$  constant region.

35 [0082] Preferably, these antibodies have cytotoxic activity and can thereby exert an antitumor effect.

40 [0083] The above particular sequences of the heavy and light chain variable regions and CDRs in the above-mentioned antibodies are provided merely for illustrative purposes, and it is clear that the antibody of the present invention is not limited by the particular sequences. Hybridomas capable of producing anti-human CAPRIN-1 human antibodies or non-human animal antibodies (e.g., mouse antibodies) different from those specifically described above are prepared, and monoclonal antibodies produced by the hybridomas are recovered and it is determined whether or not the recovered antibodies are the antibodies of interest using the immunological binding activity against human CAPRIN-1 and cytotoxic activity as indicators. The monoclonal antibody-producing hybridomas of interest are thereby identified. Then, DNAs encoding heavy and light chain variable regions of the antibodies of interest are prepared from the hybridomas and sequenced, as described above. The DNAs are used for the preparation of different antibodies.

45 [0084] The antibody described above may be any of the antibodies (a) to (g), etc. having the substitution, deletion, or addition of one or several amino acids, in particular, in a region other than CDRs, for example, in a framework region sequence and/or a constant region sequence, as long as the antibody has such specificity that it can specifically recognize CAPRIN-1. Herein, the term "several" preferably means 2 to 5, more preferably 2 or 3.

50 [0085] The antibody of the present invention has an affinity constant  $K_a$  ( $K_{on}/K_{off}$ ) of preferably at least  $10^7$  M<sup>-1</sup>, at least  $10^8$  M<sup>-1</sup>, at least  $5 \times 10^8$  M<sup>-1</sup>, at least  $10^9$  M<sup>-1</sup>, at least  $5 \times 10^9$  M<sup>-1</sup>, at least  $10^{10}$  M<sup>-1</sup> at least  $5 \times 10^{10}$  M<sup>-1</sup> at least  $10^{11}$  M<sup>-1</sup> at least  $5 \times 10^{11}$  M<sup>-1</sup>, at least  $10^{12}$  M<sup>-1</sup>, or at least  $10^{13}$  M<sup>-1</sup> for the CAPRIN-1 protein or the fragment thereof.

55 [0086] The antibody of the present invention can be conjugated with an antitumor agent. The conjugation of the antibody with the antitumor agent can be performed via a spacer having a group reactive with an amino group, a carboxyl group, a hydroxy group, a thiol group, or the like (e.g., a succinimidyl group, a formyl group, a 2-pyridyldithio group, a maleimidyl group, an alkoxycarbonyl group, or a hydroxy group).

[0087] Examples of the antitumor agent include the following antitumor agents known by literatures, etc.: paclitaxel, doxorubicin, daunorubicin, cyclophosphamide, methotrexate, 5-fluorouracil, thiotapec, busulfan, imrosulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, altretamine, triethylenemelamine, triethylenephosphoramide, triethyl-

enethiophosphoramide, trimethylololomelamine, bullatacin, bullatacinone, camptotheycin, bryostatin, callystatin, cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, eletherobin, pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, chlophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, calicheamicin, dynemicin, clodronate, esperamicin, aclacinomycin, actinomycin, authramycin, azaserine, bleomycin, cactinomycin, carabacin, carminomycin, carzinophilin, chromomycin, dactinomycin, detorbicin, 6-diazo-5-oxo-L-norleucine, Adriamycin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, pterofterin, trimetrexate, fludarabine, 6-mercaptopurine, thiampirine, thioguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, androgens (e.g., calusterone, dromostanolone propionate, epitiostanol, mepitiostane, and testolactone), aminoglutethimide, mitotane, trilostane, frolinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, el fornithine, elliptinium acetate, epothilone, etoglucid, lentinan, lonidamine, maytansine, ansamitocin, mitoguazone, mitoxantrone, mopidanmol, nitraerine, pentostatin, phenamet, pirarubicin, losoxantrone, podophyllinic acid, 2-ethylhydrazide, procarbazine, razoxane, rhizoxin, schizophyllan, spirogermanium, tenuazonic acid, triaziquone, roridin A, anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, docetaxel, chlorambucil, gemcitabine, 6-thioguanine, mercaptoperine, cisplatin, oxaliplatin, carboplatin, vinblastine, etoposide, ifosfamide, mitoxantrone, vincristine, vinorelbine, novantrone, teniposide, edatrexate, daunomycin, aminopterin, Xeloda, ibandronate, irinotecan, topoisomerase inhibitors, difluoromethylornithine (DMFO), retinoic acid, capecitabine, and pharmaceutically acceptable salts and derivatives thereof.

[0088] Alternatively, the antibody of the present invention can be administered in combination with an antitumor agent to produce a higher therapeutic effect. This approach is adaptable to a patient with a cancer expressing CAPRIN-1 either before or after surgical operation. This approach can be applied, particularly after surgery, to CAPRIN-1-expressing cancer, which has been treated conventionally with an antitumor agent alone, to produce higher prevention of cancer recurrence or prolongation of survival time.

[0089] Examples of the antitumor agent used in the combined administration with the antibody of the present invention include the following antitumor agents known by literatures, etc.: paclitaxel, doxorubicin, daunorubicin, cyclophosphamide, methotrexate, 5-fluorouracil, thiotepe, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylololomelamine, bullatacin, bullatacinone, camptotheycin, bryostatin, callystatin, cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, eletherobin, pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, chlophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, calicheamicin, dynemicin, clodronate, esperamicin, aclacinomycin, actinomycin, authramycin, azaserine, bleomycin, cactinomycin, carabacin, carminomycin, carzinophilin, chromomycin, dactinomycin, detorbicin, 6-diazo-5-oxo-L-norleucine, Adriamycin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, pterofterin, trimetrexate, fludarabine, 6-mercaptopurine, thiampirine, thioguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, frolinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, el fornithine, elliptinium acetate, epothilone, etoglucid, lentinan, lonidamine, maytansine, ansamitocin, mitoguazone, mitoxantrone, mopidanmol, nitraerine, pentostatin, phenamet, pirarubicin, losoxantrone, podophyllinic acid, 2-ethylhydrazide, procarbazine, razoxane, rhizoxin, schizophyllan, spirogermanium, tenuazonic acid, triaziquone, roridin A, anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, docetaxel, chlorambucil, gemcitabine, 6-thioguanine, mercaptoperine, cisplatin, oxaliplatin, carboplatin, vinblastine, etoposide, ifosfamide, mitoxantrone, vincristine, vinorelbine, novantrone, teniposide, edatrexate, daunomycin, aminopterin, Xeloda, ibandronate, irinotecan, topoisomerase inhibitors, difluoromethylornithine (DMFO), retinoic acid, capecitabine, and pharmaceutically acceptable salts (known in the art) and derivatives (known in the art) thereof. Of these antitumor agents, cyclophosphamide, paclitaxel, docetaxel, or vinorelbine is particularly preferably used.

[0090] The antibody of the present invention may be bound to a radioisotope known by literatures, etc., such as  $^{211}\text{At}$ ,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{90}\text{Y}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{153}\text{Sm}$ ,  $^{212}\text{Bi}$ ,  $^{32}\text{P}$ ,  $^{175}\text{Lu}$ , or  $^{176}\text{Lu}$ . Preferably, a radioisotope effective for the treatment or diagnosis of tumor is used. Such a radioisotope is also included in the scope of the antitumor agent according to the present invention.

## &lt;Identification of epitope&gt;

**[0091]** The antibody of the present invention recognizes the amino acid sequence shown by SEQ ID NO: 5 as an epitope, as shown below in Examples. One example of a method for confirming the epitope for the antibody of the present invention comprises immobilizing the polypeptide of SEQ ID NO: 5 (epitope) onto a plate and evaluating the antibody for its reactivity against this epitope. Specifically, the polypeptide of SEQ ID NO: 5 is immobilized onto a plate through reaction with an electrophilic functional group attached via a spacer of e.g., oligoethylene glycol to the plate, and then reacted with the antibody of the present invention. For example, a HRP (horseradish peroxidase)-labeled secondary antibody capable of binding to the antibody of the present invention can be reacted therewith to evaluate the reactivity of the antibody (to confirm the epitope for the antibody of the present invention). The polypeptide of SEQ ID NO: 5 to be immobilized on a plate may be used as a form consisting of the sequence of SEQ ID NO: 5 or a partially modified form (e.g., a modified form of the polypeptide at the N- or C-terminal residue with any several amino acids or a protein such as KLH or a modified form of the polypeptide with a MAP protein), as long as the antibody of the present invention binds to these polypeptide forms.

**[0092]** Some antibodies of the present invention may not react with the polypeptide of SEQ ID NO: 5 (i.e., the epitope not being confirmed) in the above method. In such a case, the epitope for the antibody of the present invention can be confirmed by reacting the antibody with the antigen under solution conditions that facilitate antigen-antibody binding as described in Example 2, obtaining the resulting antigen-antibody complex by an immunoprecipitation method, and then separating a polypeptide moiety bound to the antibody, and determining its amino acid sequence. The antigen may be a polypeptide consisting of the sequence of SEQ ID NO: 5, its partially modified one, or a CAPRIN-1 protein as long as an epitope reactive with the antibody of the present invention can be confirmed therefor by the above-mentioned methods.

## &lt;Antitumor effect&gt;

**[0093]** It is considered that the antitumor effect of the anti-CAPRIN-1 antibody to be used in the present invention on CAPRIN-1-expressing cancer cells is brought about by the following mechanism: Antibody-dependent effector cell-mediated cytotoxicity (ADCC) against the CAPRIN-1-expressing cells and complement-dependent cytotoxicity (CDC) against the CAPRIN-1-expressing cells. However, the scope of the present invention is not intended to be limited by the mechanism.

**[0094]** The antitumor effect based on the mechanism is known to correlate with the number of antibody-binding target molecules expressed on the surface of cancer cells (Niwa R., Clinical Cancer Research (2005) Mar 15; 11 (6): 2327-2336). The number of target molecules expressed on the surface of cancer cells can be examined using an existing assay kit capable of measuring the number of molecules on cell surface. Specifically, the number of antibody-binding target molecules can be determined by: reacting cancer cells with, for example, antibodies against the target molecules as primary antibodies; reacting therewith fluorescently labeled antibodies against the primary antibodies, together with calibration curve beads with the preliminarily known number of molecules; measuring the mean fluorescence intensity of the samples; and determining the number of the target molecules on the basis of the obtained calibration curve.

**[0095]** Thus, the anti-CAPRIN-1 antibody to be used in the present invention can be assayed for its activity by determining *ex vivo* the ADCC activity or the CDC activity against CAPRIN-1-expressing cancer cells or by examining the number of CAPRIN-1 molecules expressed on the surface of cancer cells in the case of using the anti-CAPRIN-1 antibody according to the present invention as a primary antibody as specifically shown below in Examples.

**[0096]** The anti-CAPRIN-1 antibody to be used in the present invention binds to CAPRIN-1 proteins on cancer cells and exhibits an antitumor effect through the activity. Thus, the anti-CAPRIN-1 antibody of the present invention is considered to be useful in the treatment or prevention of cancer. Specifically, the present invention provides a pharmaceutical composition for treatment and/or prevention of cancer, comprising the anti-CAPRIN-1 antibody as an active ingredient. The anti-CAPRIN-1 antibody to be used for the purpose of administration to human bodies (antibody therapy) is preferably a human antibody or a humanized antibody for reducing immunogenicity.

**[0097]** The anti-CAPRIN-1 antibody with higher binding affinity for a CAPRIN-1 protein on the surface of cancer cells exerts stronger antitumor activity. Thus, the antibody according to the present invention can be expected to have a stronger antitumor effect due to the high binding affinity for the CAPRIN-1 protein, and therefore it can be used as a pharmaceutical composition for use in the treatment and/or prevention of cancer. Preferably, the antibody according to the present invention has high binding affinity with association constant (affinity constant)  $K_a$  ( $K_{on}/k_{off}$ ) of preferably at least  $10^7$  M<sup>-1</sup>, at least  $10^8$  M<sup>-1</sup>, at least  $5 \times 10^8$  M<sup>-1</sup>, at least  $10^9$  M<sup>-1</sup>, at least  $5 \times 10^9$  M<sup>-1</sup>, at least  $10^{10}$  M<sup>-1</sup>, at least  $5 \times 10^{10}$  M<sup>-1</sup>, at least  $10^{11}$  M<sup>-1</sup>, at least  $5 \times 10^{11}$  M<sup>-1</sup>, at least  $10^{12}$  M<sup>-1</sup>, or at least  $10^{13}$  M<sup>-1</sup>, as described above.

**[0098]** A larger number of CAPRIN-1 molecules that can bind to anti-CAPRIN-1 antibodies on the surface of cancer cells produces stronger antitumor activity. Desirably, in order to produce the expected antitumor effect, the number of CAPRIN-1 molecules to which the antibodies bind is  $10^4$  or more, preferably  $10^5$  or more CAPRIN-1 molecules per cancer cell, as measured using the anti-CAPRIN-1 antibody of the present invention. Tumor (cancer cells) having a

large number of CAPRIN-1 molecules on its cell surface is particularly preferred as cancer subject to the administration of the antibody of the present invention.

5 <Binding to antigen-expressing cells>

[0099] The ability of the antibody to bind to CAPRIN-1 can be determined by use of binding assay using, for example, ELISA, Western blot, immunofluorescence, and flow cytometry analysis, as described in Examples.

10 <Immunohistochemical staining>

15 [0100] The antibody that recognizes CAPRIN-1 can be tested for its reactivity with CAPRIN-1 by an immunohistochemical method well known to those skilled in the art using a paraformaldehyde- or acetone-fixed frozen section or paraformaldehyde-fixed paraffin-embedded tissue section of a tissue obtained from a patient during surgical operation or from a xenograft tissue-carrying animal inoculated with a cell line expressing CAPRIN-1 either spontaneously or after transfection.

[0101] For immunohistochemical staining, the antibody reactive with CAPRIN-1 can be stained by various methods. For example, the antibody can be visualized through reaction with a horseradish peroxidase-conjugated goat anti-mouse antibody, goat anti-rabbit antibody, or goat anti-chicken antibody.

20 <Pharmaceutical composition, and means for treating and/or preventing cancer>

[0102] A target of the pharmaceutical composition for treatment and/or prevention of cancer of the present invention is not particularly limited as long as the target is cancer (cells) expressing a CAPRIN-1 gene.

25 [0103] The terms "tumor" and "cancer" used herein mean malignant neoplasm and are used interchangeably with each other.

[0104] The cancer targeted in the present invention is cancer expressing a CAPRIN-1 protein-encoding gene and is preferably breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.

30 [0105] Specific examples of these cancers include, but not limited to, breast adenocarcinoma, complex-type breast adenocarcinoma, malignant mixed tumor of mammary gland, intraductal papillary adenocarcinoma, lung adenocarcinoma, squamous cell cancer, small-cell cancer, large-cell cancer, glioma which is tumor of neuroepithelial tissue, ventricular ependymoma, neuronal tumor, embryonal neuroectodermal tumor, neurilemmoma, neurofibroma, meningioma, chronic lymphocytic leukemia, lymphoma, gastrointestinal lymphoma, alimentary lymphoma, small to medium cell-type lymphoma, cecal cancer, ascending colon cancer, descending colon cancer, transverse colon cancer, sigmoid colon cancer, rectal cancer, epithelial ovarian cancer, germ cell tumor, stromal cell tumor, pancreatic ductal carcinoma, invasive pancreatic ductal carcinoma, pancreatic adenocarcinoma, acinar cell carcinoma, adenosquamous carcinoma, giant cell tumor, intraductal papillary-mucinous neoplasm, mucinous cystic neoplasm, pancreaticoblastoma, serous cystadenocarcinoma, solid papillary tumor, gastrinoma, glucagonoma, insulinoma, multiple endocrine neoplasia type-1 (Wermer's syndrome), nonfunctional islet cell tumor, somatostatinoma, and VIPoma.

40 [0106] The subject (patient) as the recipient is preferably mammals, for example, mammals including primates, pet animals, livestock, and sport animals, and particularly preferably humans, dogs, and cats.

45 [0107] When using the antibody of the present invention in a pharmaceutical composition, the pharmaceutical composition can be formulated by a method known to those skilled in the art. For example, the pharmaceutical composition can be used in the form of a parenteral injection of an aseptic solution or suspension with water or any other pharmaceutically acceptable liquid. For example, the pharmaceutical composition may be formulated with the antibody mixed in a unit dosage form required for generally accepted pharmaceutical practice, in combination with pharmacologically acceptable carriers or media, specifically, sterilized water, physiological saline, plant oil, an emulsifier, a suspending agent, a surfactant, a stabilizer, a flavoring agent, an excipient, a vehicle, a preservative, a binder, etc, as appropriate.

50 The amount of the active ingredient in such a preparation is determined such that an appropriate dose within the indicated range can be achieved.

[0108] An aseptic composition for injection can be formulated according to conventional pharmaceutical practice using a vehicle such as injectable distilled water.

55 [0109] Examples of aqueous solutions for injection include physiological saline, isotonic solutions containing glucose and other adjuvants, for example, D-sorbitol, D-mannose, D-mannitol, and sodium chloride. These solutions may be used in combination with an appropriate solubilizer, for example, an alcohol (particularly, ethanol) or a polyalcohol (e.g., propylene glycol and polyethylene glycol), or a nonionic surfactant, for example, polysorbate 80 (TM) or HCO-60.

[0110] Examples of oily solutions include those using sesame oil or soybean oil. The solutions may be used in com-

bination with a solubilizer such as benzyl benzoate or benzyl alcohol. A buffer (e.g., a phosphate buffer solution or a sodium acetate buffer solution), a soothing agent (e.g., procaine hydrochloride), a stabilizer (e.g., benzyl alcohol or phenol), or an antioxidant may be added to the solutions. The injection solutions thus prepared are generally charged into appropriate ampules.

**[0111]** The pharmaceutical composition of the present invention is administered orally or parenterally, preferably parenterally. Specific examples of its dosage forms include injections, intranasal administration agents, transpulmonary administration agents, and percutaneous administration agents. Examples of the injections include intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection, through which the pharmaceutical composition can be administered systemically or locally.

**[0112]** Also, the administration method can be appropriately selected depending on the age, weight, sex, symptoms, etc. of a patient. The dose of a pharmaceutical composition containing the antibody or a polynucleotide encoding the antibody can be selected within a range of, for example, 0.0001 to 1000 mg/kg of body weight per dose. Alternatively, the dose can be selected within a range of, for example, 0.001 to 100000 mg/body of a patient, though the dose is not necessarily limited to these numeric values. Although the dose and the administration method vary depending on the weight, age, sex, symptoms, etc. of a patient, those skilled in the art can appropriately select the dose and the method.

**[0113]** The pharmaceutical composition including the antibody of the present invention or fragments thereof can be administered to a subject to treat and/or prevent cancer, preferably breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.

**[0114]** The present invention further encompasses means for treating and/or preventing cancer, by administering the pharmaceutical composition of the present invention in combination with the antitumor agent as exemplified above or a pharmaceutical composition comprising the antitumor agent to a subject. The antibody of the present invention or the fragment thereof may be administered simultaneously with or separately from the antitumor agent to the subject. In the case of separately administering these pharmaceutical compositions, either one may be administered first or later. Their dosing intervals, doses, administration routes, and the number of doses can be appropriately selected by a specialist. The other pharmaceutical dosage forms to be administered simultaneously also include, for example, pharmaceutical compositions formulated by mixing the antibody of the present invention or the fragment thereof or the antitumor agent into a pharmacologically acceptable carrier (or medium). The above descriptions about composition, formulation, administration routes, doses, cancer, etc. as to the pharmaceutical compositions and dosage forms containing the antibody of the present invention are also applicable to any of the above-mentioned pharmaceutical compositions and dosage forms containing the antitumor agent.

**[0115]** Thus, the present invention also provides a pharmaceutical combination as defined in the claims, comprising the pharmaceutical composition of the present invention and a pharmaceutical composition comprising the antitumor agent as exemplified above, and a method for treating and/or preventing cancer, comprising administering thereof. The present invention also provides a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or the fragment thereof of the present invention and the antitumor agent together with a pharmacologically acceptable carrier.

<Polypeptide and DNA>

**[0116]** The present invention further provides a DNA encoding the antibody of the present invention or the fragment (antibody-binding fragment) thereof. The DNA may be a DNA encoding the heavy and/or light chains of the antibody or may be a DNA encoding the heavy and/or light chain variable regions of the antibody. The DNA may also be a DNA encoding each or a combination of the complementarity determining regions of antibody. Such a DNA includes, for example, a heavy chain variable region-encoding DNA comprising nucleotide sequences encoding the amino acid sequences of SEQ ID NOs: 6, 7, and 8, and a light chain variable region-encoding DNA comprising nucleotide sequences encoding the amino acid sequences of SEQ ID NOs: 10, 11, and 12, in the case of the above-mentioned antibody (a).

**[0117]** The complementarity determining regions (CDRs) encoded by the DNA having these sequences serve as regions that determine the specificity of the antibody. Sequences encoding the other regions (i.e., constant regions and framework regions) of the antibody may therefore be sequences derived from other antibodies. In this context, "other antibodies" also include antibodies derived from non-human organisms, but are preferably those derived from humans from the viewpoint of reducing adverse reactions. Specifically, in the DNA of the present invention, regions encoding each framework region and each constant region in the heavy and light chains preferably comprise nucleotide sequences encoding corresponding human antibody-derived amino acid sequences.

**[0118]** Further examples of the DNA encoding the antibody of the present invention include a DNA encoding a heavy chain variable region comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 9, and a DNA encoding a light chain variable region comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 13, in the case of the above-mentioned antibody (a). In this context, an example of nucleotide sequences

encoding the amino acid sequence of SEQ ID NO: 9 is the nucleotide sequence of SEQ ID NO: 14. An example of nucleotide sequences encoding the amino acid sequence of SEQ ID NO: 13 is the nucleotide sequence of SEQ ID NO: 15. When such a DNA comprises regions encoding constant regions of the heavy and light chains, each of the regions preferably comprises a nucleotide sequence encoding a corresponding human antibody-derived amino acid sequence (amino acid sequence of each constant region of the heavy and light chains).

**[0119]** These antibody DNAs can be obtained, for example, by the methods described above, or the following method. First, total RNAs are prepared from hybridomas producing the antibody of the present invention using a commercially available RNA extraction kit, and cDNAs are synthesized therefrom using reverse transcriptase and random primers or the like. Subsequently, the antibody-encoding cDNAs are amplified by PCR using oligonucleotide primers for conserved sequences of variable regions in known mouse antibody heavy or light chain genes. Sequences encoding the constant regions can be obtained by PCR amplification of the known sequences. The nucleotide sequence of the DNA can be incorporated into a plasmid or a phage for sequencing, for example, and determined according to a conventional method.

**[0120]** The present invention further provides the following polypeptides and DNAs related to the above-mentioned antibodies (a) to (g):

- (i) a polypeptide comprising any of amino acid sequences of SEQ ID NOs: 9, 19, 58, 63, 69, and 77, and a DNA encoding the polypeptide (e.g., a DNA comprising any of the nucleotide sequences of SEQ ID NOs: 14 and 24);
- (ii) a polypeptide comprising any of amino acid sequences of SEQ ID NOs: 13, 23, 53, 62, 65, 73, and 81, and a DNA encoding the polypeptide (e.g., a DNA comprising any of the nucleotide sequences of SEQ ID NOs: 15, 25, and 54);
- (iii) heavy chain CDR polypeptides selected from the group consisting of amino acid sequences shown by SEQ ID NOs: 6, 7, and 8, SEQ ID NOs: 16, 17, and 18, SEQ ID NOs: 55, 56, and 57, SEQ ID NOs: 66, 67, and 68, and SEQ ID NOs: 74, 75, and 76, and a DNA encoding the polypeptides; and
- (iv) light chain CDR polypeptides selected from amino acid sequences shown by SEQ ID NOs: 10, 11, and 12, SEQ ID NOs: 20, 21, and 22, SEQ ID NOs: 50, 51, and 52, SEQ ID NOs: 59, 60, and 61, SEQ ID NOs: 59, 64, and 61, SEQ ID NOs: 70, 71, and 72, and SEQ ID NOs: 78, 79, and 80, and a DNA encoding the polypeptides.

**[0121]** These polypeptides and DNAs can be prepared using genetic engineering techniques as described above.

### 30 Examples

**[0122]** Hereinafter, the present invention will be described specifically with reference to Examples. However, the scope of the present invention is not intended to be limited by these specific examples.

### 35 Example 1 Analysis of CAPRIN-1 expression in each tissue

**[0123]** CAPRIN-1 gene expression in canine and human normal tissues and various cell lines was examined by RT-PCR according to Example 1(4) of WO2010/016526. As a result, strong expression was observed in the testis among the healthy canine tissues, whereas expression was observed in canine breast cancer and adenocarcinoma tissues. Further, as a result of examining the expression in human tissues, the expression was observed only in the testis among normal tissues, as with the canine CAPRIN-1 gene. By contrast, the expression was detected in many types of cancer cell lines, including 8 human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-157, BT-20, MDA-MB-231V, and MRK-nu-1) and 4 pancreatic cancer cell lines (Capan-2, MIAPaCa-2, Panc-1, and BxPc-3), among cancer cells. These results demonstrated that CAPRIN-1 expression is not found in normal tissues other than the testis, whereas CAPRIN-1 is expressed in the breast cancer cell lines and the pancreatic cancer cell lines.

### Example 2 Preparation of mouse monoclonal antibody against CAPRIN-1

#### (1) Preparation of mouse monoclonal antibody #1

**[0124]** 100 µg of human CAPRIN-1 proteins (having the amino acid sequence of SEQ ID NO: 2) prepared in Example 3 of WO2010/016526 was mixed with an equal amount of MPL+TDM adjuvant (Sigma-Aldrich Corp.). This mixture was used as an antigen solution per mouse. The antigen solution was intraperitoneally administered to each 6-week-old Balb/c mouse (prepared by Japan SLC, Inc.). Then, 7 administrations were performed every 1 week to complete immunization. Three days after the final immunization, the spleen of each mouse was excised and ground between two sterilized glass slides. Procedures of washing with PBS(-) (manufactured by Nissui Pharmaceutical Co., Ltd.) and centrifuging at 1500 rpm for 10 minutes to remove the supernatant were repeated three times to obtain spleen cells. The obtained spleen cells were mixed with mouse myeloma cells SP2/0 (purchased from ATCC) at a ratio of 10:1. A PEG

solution prepared by mixing 200  $\mu$ l of an RPMI1640 medium containing 10% FBS, which was heated to 37°C, with 800  $\mu$ l of PEG1500 (manufactured by Boehringer Ingelheim GmbH) was added to the cell mixture, and then it was left to stand for 5 minutes for cell fusion. After removal of the supernatant via centrifugation at 1700 rpm for 5 minutes, the cells were suspended in 150 ml of an RPMI1640 medium containing 15% FBS supplemented with 2% equivalent of a

5 HAT solution (Gibco) (HAT selective medium). This suspension was seeded onto fifteen 96-well plates (Nunc) at 100  $\mu$ l/well. The spleen cells and the myeloma cells were fused by culturing for 7 days at 37°C, 5% CO<sub>2</sub> to obtain hybridomas.

10 [0125] The prepared hybridomas were screened for the binding affinity of antibodies produced by the hybridomas against CAPRIN-1 proteins as an indicator. A 1  $\mu$ g/ml solution of the CAPRIN-1 protein prepared in Example 3 of WO2010/016526 was added to a 96-well plate at 100  $\mu$ l/well and left to stand at 4°C for 18 hours. Each well was washed three times with PBS-T. Then, a 0.5% bovine serum albumin (BSA) solution (manufactured by Sigma-Aldrich Corp.) was added thereto at 400  $\mu$ l/well and left to stand at room temperature for 3 hours. The solution in each well was removed, and each well was washed three times with 400  $\mu$ l of PBS-T. Then, the culture supernatant of each hybridoma obtained above was added thereto at 100  $\mu$ l/well and left to stand at room temperature for 2 hours. Each well was washed three times with PBS-T. Then, HRP-labeled anti-mouse IgG (H+L) antibodies (manufactured by Invitrogen Corp.) diluted 5000-fold with PBS were added thereto at 100  $\mu$ l/well and left to stand at room temperature for 1 hour. Each well was washed three times with PBS-T. Then, a TMB substrate solution (manufactured by Thermo Fisher Scientific Inc.) was added thereto at 100  $\mu$ l/well and left to stand for 15 to 30 minutes to cause color reaction. After the color development, the reaction was terminated by the addition of 1N sulfuric acid at 100  $\mu$ l/well. The absorbance was measured at 450 nm and 595 nm using an absorption spectrometer. As a result, several hybridomas producing antibodies having high absorbance were selected.

15 [0126] The selected hybridomas were added to a 96-well plate at 0.5 cells/well and cultured in the plate. One week later, hybridomas forming single colonies in the wells were observed. The cells in these wells were further cultured, and the cloned hybridomas were screened for the binding affinity of antibodies produced by the hybridomas to the CAPRIN-1 protein as an indicator. A 1  $\mu$ g/ml solution of the CAPRIN-1 protein prepared in Example 3 of WO2010/016526 was added to a 96-well plate at 100  $\mu$ l/well and left to stand at 4°C for 18 hours. Each well was washed three times with PBS-T. Then, a 0.5% BSA solution was added thereto at 400  $\mu$ l/well and left to stand at room temperature for 3 hours. The solution in each well was removed, and each well was washed three times with 400  $\mu$ l of PBS-T. Then, the culture supernatant of each hybridoma obtained above was added thereto at 100  $\mu$ l/well and left to stand at room temperature for 2 hours. Each well was washed three times with PBS-T. Then, HRP-labeled anti-mouse IgG (H+L) antibodies (manufactured by Invitrogen Corp.) diluted 5000-fold with PBS were added thereto at 100  $\mu$ l/well and left to stand at room temperature for 1 hour. Each well was washed three times with PBS-T. Then, a TMB substrate solution (manufactured by Thermo Fisher Scientific Inc.) was added thereto at 100  $\mu$ l/well and left to stand for 15 to 30 minutes to cause color reaction. After the color development, the reaction was terminated by the addition of 1N sulfuric acid at 100  $\mu$ l/well. The absorbance was measured at 450 nm and 595 nm using an absorption spectrometer. As a result, 88 hybridoma lines producing monoclonal antibodies reactive with the CAPRIN-1 protein were obtained.

20 [0127] Next, these monoclonal antibodies were screened for antibodies reactive with the surface of breast cancer cells expressing CAPRIN-1. Specifically, 10<sup>6</sup> cells of a human breast cancer cell line MDA-MB-231V were centrifuged in a 1.5-ml microcentrifuge tube. 100  $\mu$ l of the culture supernatant of the hybridoma obtained above was added thereto and left to stand for 1 hour on ice. After washing with PBS, FITC-labeled goat anti-mouse IgG antibodies (manufactured by Invitrogen Corp.) diluted 500-fold with PBS containing 0.1% FBS were added thereto and left to stand for 1 hour on ice. After washing with PBS, the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and Company). On the other hand, the same operation as above was performed using the serum of each untreated 6-week-old Balb/c mouse diluted 500-fold with a medium for hybridoma culture, instead of the antibodies, to prepare a control. As a result, one monoclonal antibody (#1) having stronger fluorescence intensity than that of the control, i.e., reactive with the surface of the breast cancer cells, was selected.

45 (2) Identification of CAPRIN-1 epitope recognized by anti-CAPRIN-1 monoclonal antibody #1

50 [0128] The cancer cell surface-reactive anti-CAPRIN-1 monoclonal antibody #1 obtained in the section (1) was used to identify a CAPRIN-1 epitope region recognized thereby. 100  $\mu$ g of recombinant CAPRIN-1 proteins was dissolved in a protein inhibitor-free dissolution buffer and reacted with the mouse monoclonal antibody #1. A digestive enzyme trypsin or chymotrypsin was added to the solution to perform digestion reaction at an adequate temperature. After the reaction, a protein G Sepharose carrier was added to the reaction mixture, reacted therewith, and precipitated by centrifugation. After removal of the supernatant, the carrier was washed with a dissolution buffer and PBS and dissolved in 0.1% formic acid, and the supernatant was recovered. The recovered supernatant sample was applied to a reverse-phase column (HLB Extraction Cartridge (Oasis)) for antibody removal to obtain a sample solution. The obtained sample was subjected to reverse-phase liquid chromatography (Chromatography Nanosystem (KYA Tech Corp.)) to recover a solution containing only peptides, which was then introduced to a tandem mass spectrometer quadrupole-TOF mass spectrometer

(Waters-MicroMass) for MS/MS analysis to detect the peptides contained in the sample. As a result, a polypeptide consisting of the amino acid sequence of SEQ ID NO: 5 was identified as a partial CAPRIN-1 sequence recognized by the anti-CAPRIN-1 monoclonal antibody #1.

5 (3) Preparation of mouse monoclonal antibodies #2 and #3

[0129] In a similar way to that described in the section (1), a fusion protein of the amino acid sequence of SEQ ID NO: 5 identified in the section (2) and a carrier protein KLH (keyhole limpet haemocyanin) was mixed as an immunogen with an equal amount of an adjuvant TiterMax Gold<sup>(R)</sup> (CytRx Corp.), and this mixture was subcutaneously administered at 10 a dose of 20  $\mu$ g/shot to each mouse at 7-day intervals. After administration with four shots in total, spleen cells were obtained from the mouse 3 days after the final immunization and fused with mouse myeloma cells in the same way as in the section (1) to produce hybridomas. Then, antibodies were screened for, as an indicator, the reactivity of the 15 antibodies contained in the culture supernatants of the produced hybridomas with a 1  $\mu$ g/ml solution of CAPRIN-1 proteins prepared in Example 3 of WO2010/016526 or a fusion protein (used as an immunogen) of the amino acid sequence of SEQ ID NO: 5 and a carrier protein KLH. The 1  $\mu$ g/ml solution of CAPRIN-1 proteins prepared in Example 20 3 of WO2010/016526 and the fusion protein (30  $\mu$ g/ml) of the amino acid sequence of SEQ ID NO: 5 and a carrier protein KLH were each added at 100  $\mu$ l/well to 96-well plates and left to stand at 4°C for 18 hours. Each well was washed with PBS-T. Then, a Blockace (DS Pharma Biomedical Co., Ltd.) solution was added thereto at 400  $\mu$ l/well and left to stand at room 25 temperature for 3 hours. The solution in each well was removed, and each well was washed with PBS-T. Then, the culture supernatant of each hybridoma obtained above was added thereto at 100  $\mu$ l/well and left to stand at room temperature for 2 hours. Each well was washed with PBS-T. Then, HRP-labeled anti-mouse IgG (H+L) antibodies (manufactured by Invitrogen Corp.) diluted 5000-fold with PBS were added thereto at 100  $\mu$ l/well and left to stand at room 30 temperature for 1 hour. Each well was washed with PBS-T. Then, a TMB substrate solution (manufactured by Thermo Fisher Scientific Inc.) was added thereto at 100  $\mu$ l/well and left to stand for 5 to 30 minutes to cause color reaction. After the color development, the reaction was terminated by the addition of 1N sulfuric acid at 100  $\mu$ l/well. The absorbance was measured at 450 nm and 595 nm using an absorption spectrometer. As a result, hybridomas producing 35 antibodies having high absorbance were selected.

[0130] The selected hybridomas were added to a 96-well plate at 0.3 cells/well and cultured in the plate. One week later, hybridomas forming single colonies in the wells were observed. The cells in these wells were further cultured, and 40 the cloned hybridomas were screened in the same way as above for the binding affinity of antibodies produced by the hybridomas to the amino acid sequence of SEQ ID NO: 5 as a partial CAPRIN-1 sequence as an indicator to obtain hybridomas producing antibodies against the amino acid of SEQ ID NO: 5.

[0131] Monoclonal antibodies produced by the obtained hybridomas were screened for antibodies reactive with the 45 surface of breast cancer cells expressing CAPRIN-1. Specifically, 10<sup>6</sup> cells of a human breast cancer cell line MDA-MB-231 V were centrifuged in a 1.5-ml microcentrifuge tube. 100  $\mu$ l of the culture supernatant of the hybridoma obtained above was added thereto and left to stand for 1 hour on ice. After washing with PBS, FITC-labeled goat anti-mouse IgG antibodies (manufactured by Invitrogen Corp.) diluted 500-fold with PBS containing 0.1% FBS were added thereto and left to stand for 1 hour on ice. After washing with PBS, the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and Company). On the other hand, the same operation as above was performed to prepare a sample 50 using the serum of each untreated 6-week-old Balb/c mouse diluted 500-fold with a medium for hybridoma culture or prepare a negative control sample by the reaction only with secondary antibodies, instead of the antibodies. As a result, 2 monoclonal antibodies (#2 and #3) having stronger fluorescence intensity than that of the negative control, i.e., reactive with the surface of the breast cancer cells, were obtained.

[0132] The obtained mouse monoclonal antibodies #2 and #3 were examined for their specific reaction with the 55 amino acid sequence of SEQ ID NO: 5 as a partial CAPRIN-1 sequence used as an immunogen. A 30  $\mu$ g/ml solution of the amino acid sequence of SEQ ID NO: 5 prepared with a 0.1 M aqueous sodium carbonate solution and a partial CAPRIN-1 sequence free from the amino acid sequence of SEQ ID NO: 5 were each added to a 96-well plate Immobilizer Amino for ELISA (Nunc) at 100  $\mu$ g/ml and reacted for one whole day and night at 4°C to bind the peptides to the wells. A 0.1 M aqueous sodium carbonate solution containing 10 mM ethanalamine was added to the peptide-bound wells and left to stand at room temperature for 1 hour. The solution in each well was removed, and each well was then washed with PBS-T. Then, a Blockace solution was added thereto at 400  $\mu$ l/well and left to stand at room temperature for 3 hours. The solution in each well was removed, and each well was washed with PBS-T. Then, the culture supernatant containing the mouse monoclonal antibody #2 was added thereto at 50  $\mu$ l/well and reacted at room temperature for 1 hour. Then, each well was washed with PBS-T, and HRP-labeled anti-mouse IgG (H+L) antibodies (manufactured by Invitrogen) diluted 5000-fold with a Blockace solution were added thereto at 50  $\mu$ l/well and left to stand at room temperature for 1 hour. Each well was fully washed with PBS-T. Then, a TMB substrate solution (manufactured by Thermo Fisher Scientific Inc.) was added thereto at 100  $\mu$ l/well and left to stand for 5 to 30 minutes to cause color reaction. After the color development, the reaction was terminated by the addition of 1N sulfuric acid at 100  $\mu$ l/well. The absorbance was measured

at 450 nm and 595 nm using an absorption spectrometer. As a result, the mouse monoclonal antibodies #2 and #3 did not react with the partial CAPRIN-1 sequence free from the amino acid sequence of SEQ ID NO: 5, but specifically reacted only with the amino acid sequence of SEQ ID NO: 5. The results demonstrated that the polypeptide of SEQ ID NO: 5 contains an epitope region for the anti-CAPRIN-1 antibodies #2 and #3.

5

Example 3 Preparation of chicken monoclonal antibody against CAPRIN-1

**[0133]** Chicken-derived monoclonal antibodies were prepared using as an immunogen a fusion protein of the amino acid sequence of SEQ ID NO: 5 identified in Example 2(2) and a carrier protein KLH (keyhole limpet haemocyanin). 300 µg of the immunogen was mixed with an equal amount of a complete Freund's adjuvant. This mixture was used as an antigen solution per chicken. The antigen solution was intraperitoneally administered to each 7-week-old chicken. Then, 7 administrations were performed every 4 weeks to complete immunization. Four days after the final immunization, the spleen of each chicken was excised and ground between two sterilized glass slides. Procedures of washing with PBS(-) (manufactured by Nissui Pharmaceutical Co., Ltd.) and centrifuging at 1500 rpm for 10 minutes to remove the supernatant were repeated three times to obtain spleen cells. The obtained spleen cells were mixed with light chain-deficient chicken myeloma cells established from chickens by transformation using avian reticuloendotheliosis virus, at a ratio of 5:1. A PEG solution prepared by mixing 200 µl of an IMDM medium containing 10% FBS, which was heated to 37°C, with 800 µl of PEG1500 (manufactured by Boehringer Ingelheim GmbH) was added to the cell mixture, and then it was left to stand for 5 minutes for cell fusion. After removal of the supernatant via centrifugation at 1700 rpm for 5 minutes, the cells were suspended in 300 ml of an IMDM medium containing 10% FBS supplemented with 2% equivalent of a HAT solution (Gibco) (HAT selective medium). This suspension was seeded onto thirty 96-well plates (Nunc) at 100 µl/well. The spleen cells and the chicken myeloma cells were fused by culturing for 7 days at 37°C, 5% CO<sub>2</sub> to obtain hybridomas. Then, the antibodies were screened for, as an indicator, the reactivity of the antibody contained in the culture supernatants of the prepared hybridomas with a solution of CAPRIN-1 proteins prepared as described in Example 3 of WO2010/016526 or a fusion protein (used as an immunogen) of the amino acid sequence of SEQ ID NO: 5 and a carrier protein BSA. Specifically, the 1 µg/ml solution of CAPRIN-1 proteins prepared in Example 3 of WO2010/016526 and the fusion protein (1 µg/ml) of the amino acid sequence of SEQ ID NO: 5 and the carrier protein BSA were each added at 50 µl/well to 96-well plates and left to stand at 4°C for 18 hours. Each well was washed with PBS-T. Then, a Blockace (DS Pharma Biomedical Co., Ltd.) solution was added thereto at 300 µl/well and left to stand at room temperature for 3 hours. The solution in each well was removed, and each well was washed with PBS-T. Then, the culture supernatant of each hybridoma obtained above was added thereto at 50 µl/well and left to stand at room temperature for 1 hour. Each well was washed with PBS-T. Then, HRP-labeled anti-chicken IgY antibodies (manufactured by KPL, Kirkegaard & Perry Laboratories, Inc.) diluted 1000-fold with PBS were added thereto at 100 µl/well and left to stand at room temperature for 1 hour. Each well was washed three times with PBS-T. Then, an OPD substrate solution was added thereto at 50 µl/well and left to stand for 5 to 15 minutes to cause color reaction. After the color development, the reaction was terminated by the addition of 2N sulfuric acid at 50 µl/well. The absorbance was measured at 490 nm and 630 nm using an absorption spectrometer. As a result, several hybridomas producing antibodies having high absorbance were selected.

**[0134]** The selected hybridomas were added to a 96-well plate at 0.5 cells/well and cultured in the plate. One week later, hybridomas forming single colonies in the wells were observed. The cells in these wells were further cultured, and the cloned hybridomas were screened for, as an indicator, the binding affinity of antibodies produced by the hybridomas to the CAPRIN-1 proteins or the reactivity of the antibodies against the fusion protein (used as an immunogen) of the amino acid sequence of SEQ ID NO: 5 and the carrier protein BSA, to obtain chicken monoclonal antibodies.

**[0135]** Next, these monoclonal antibodies were screened for antibodies reactive with the surface of breast cancer cells expressing CAPRIN-1. Specifically, 2 × 10<sup>5</sup> cells of a human breast cancer cell line MDA-MB-231V were centrifuged in a 1.5-ml microcentrifuge tube. 50 µl of the culture supernatant of each hybridoma obtained above was added thereto and left to stand for 1 hour on ice. After washing with PBS, FITC-labeled goat anti-chicken IgG (H+L) antibodies (manufactured by SouthernBiotech) diluted 100-fold with PBS containing 0.5% FBS were added thereto and left to stand for 1 hour on ice. After washing with PBS, the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and Company). On the other hand, the same operation as above was performed using a medium for hybridoma culture to prepare a negative control sample. As a result, 4 chicken monoclonal antibodies (chicken monoclonal antibodies #1, #2, #3, and #4) having stronger fluorescence intensity than that of the control, i.e., reactive with the surface of breast cancer cells expressing CAPRIN-1, were selected. These antibodies can bind to CAPRIN-1 expressed on the surface of breast cancer cells.

55

## Example 4 Characterization of selected monoclonal antibody

## (1) Characterization of mouse monoclonal antibody

5 [0136] Amplification fragments of genes encoding the variable regions of the mouse monoclonal antibodies obtained in Example 2 were obtained according to a method described in Example 5 of WO2010/016526 and analyzed for their gene sequences and amino acid sequences encoded thereby. The resulting gene sequence encoding the heavy chain variable region of the mouse-derived monoclonal antibody #1 is shown in SEQ ID NO: 24, and the amino acid sequence is shown in SEQ ID NO: 19; and the gene sequence encoding the light chain variable region thereof is shown in SEQ  
 10 ID NO: 25, and the amino acid sequence is shown in SEQ ID NO: 23. The resulting gene sequence encoding the heavy chain variable region of the mouse-derived monoclonal antibody #2 is shown in SEQ ID NO: 14, and the amino acid sequence is shown in SEQ ID NO: 9; and the gene sequence encoding the light chain variable region thereof is shown in SEQ ID NO: 15, and the amino acid sequence is shown in SEQ ID NO: 13. The resulting gene sequence encoding the heavy chain variable region of the mouse-derived monoclonal antibody #3 is shown in SEQ ID NO: 14, and the  
 15 amino acid sequence is shown in SEQ ID NO: 9; and the gene sequence encoding the light chain variable region thereof is shown in SEQ ID NO: 54, and the amino acid sequence is shown in SEQ ID NO: 53.

20 [0137] In other words, the mouse monoclonal antibody #1 was found to comprise the heavy chain variable region of SEQ ID NO: 19 and the light chain variable region of SEQ ID NO: 23, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 16, 17, and 18, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 20, 21, and 22, respectively. The mouse monoclonal antibody #2 was found to comprise the heavy chain variable region of SEQ ID NO: 9 and the light chain variable region of SEQ ID NO: 13, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively. The mouse monoclonal antibody #3 was found to comprise the heavy chain variable region of SEQ ID NO: 9 and the light chain variable region of SEQ ID NO: 53, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 50, 51, and 52, respectively.

## 30 (2) Characterization of chicken monoclonal antibody

35 [0138] Amplification fragments of genes encoding the variable regions of the chicken monoclonal antibodies (chicken monoclonal antibodies #1, #2, #3, and #4) obtained in Example 3 were obtained according to the method described in Example 4 of WO2011/096519 and analyzed for their gene sequences and amino acid sequences encoded thereby. The resulting amino acid sequence of the heavy chain variable region of the chicken monoclonal antibody #1 is shown in SEQ ID NO: 58, and the amino acid sequence of the light chain variable region thereof is shown in SEQ ID NO: 62. The amino acid sequence of the heavy chain variable region of the chicken monoclonal antibody #2 is shown in SEQ ID NO: 63, and the amino acid sequence of the light chain variable region thereof is shown in SEQ ID NO: 65. The amino acid sequence of the heavy chain variable region of the chicken monoclonal antibody #3 is shown in SEQ ID NO: 69, and the amino acid sequence of the light chain variable region thereof is shown in SEQ ID NO: 73. The amino acid sequence of the heavy chain variable region of the chicken monoclonal antibody #4 is shown in SEQ ID NO: 77, and the amino acid sequence of the light chain variable region thereof is shown in SEQ ID NO: 81.

40 [0139] In other words, the chicken monoclonal antibody #1 was found to comprise the heavy chain variable region of SEQ ID NO: 58 and the light chain variable region of SEQ ID NO: 62, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 55, 56, and 57, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 59, 60, and 61, respectively. The chicken monoclonal antibody #2 was found to comprise the heavy chain variable region of SEQ ID NO: 63 and the light chain variable region of SEQ ID NO: 65, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 55, 56, and 57, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 59, 64, and 61, respectively. The chicken monoclonal antibody #3 was found to comprise the heavy chain variable region of SEQ ID NO: 69 and the light chain variable region of SEQ ID NO: 73, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 66, 67, and 68, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 70, 71, and 72, respectively. The chicken monoclonal antibody #4 was found to comprise the heavy chain variable region of SEQ ID NO: 77 and the light chain variable region of SEQ ID NO: 81, wherein the heavy chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 74, 75, and 76, respectively, and the light chain variable region had CDR1, CDR2, and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 78,

79, and 80, respectively.

#### Example 5 Preparation of polyclonal antibody against partial CAPRIN-1 polypeptide present on cancer cell surface

5 [0140] For the purpose of obtaining polyclonal antibodies against partial CAPRIN-1 polypeptides present on cancer cell surface, a polypeptide (CAPRIN-1-derived peptide shown in SEQ ID NO: 5) comprising the epitope regions for the anti-CAPRIN-1 monoclonal antibodies #1, #2, and #3, a polypeptide having a region of amino acid residues 50 to 98 in the human CAPRIN-1 amino acid sequence of SEQ ID NO: 2, and a polypeptide having a region of amino acid residues 10 233 to 305 of SEQ ID NO: 2 were synthesized. 1 mg of these peptides were each mixed as an antigen with an equal volume of an incomplete Freund's adjuvant (IFA) solution. This mixture was subcutaneously administered to rabbit four times every two weeks. Then, blood was collected therefrom to obtain antiserum containing polyclonal antibody against each antigen. The antiserum was further purified using a protein G carrier (manufactured by GE Healthcare Bio-Sciences Ltd.), followed by replacement with PBS, to obtain polyclonal antibodies against partial CAPRIN-1 polypeptides present 15 on cancer cell surface. In addition, the serum of a rabbit that received no antigen was prepared by purification using a protein G carrier in the same way as above and used as a control antibody.

### Example 6 Analysis of CAPRIN-1 protein expression on cancer cell

[0141] Next, 8 human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-157, BT-20, MDA-MB-231V, and MRK-nu-1) observed to have a high level of CAPRIN-1 gene expression were examined for their expression of CAPRIN-1 proteins on the cell surface. 5 x 10<sup>5</sup> cells of the human breast cancer cell lines that were observed above to have the gene expression were each centrifuged in a 1.5-ml microcentrifuge tube. After adding 2  $\mu$ g (5  $\mu$ l) of the polyclonal antibodies against CAPRIN-1-derived peptides prepared as described above in Example 5 thereto, the cells were further mixed with 95  $\mu$ l of PBS containing 0.1% fetal bovine serum, and left to stand for 1 hour on ice. After washing with PBS, the resulting solution was mixed with 2  $\mu$ l of Alexa 488-labeled goat anti-rabbit IgG antibodies (manufactured by Invitrogen Corp.) and 98  $\mu$ l of PBS containing 0.1% fetal bovine serum (FBS) and left to stand for 30 hours on ice. After washing with PBS, the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and Company). On the other hand, the same operation as above was performed using the control antibodies prepared as described above in Example 5 instead of the polyclonal antibodies against CAPRIN-1-derived peptides to prepare a control. As a result, the cancer cells treated with the anti-CAPRIN-1 antibodies all exhibited fluorescence intensity at least 35% stronger than that of the control. This demonstrated that CAPRIN-1 proteins are expressed on the cell membrane surface of the human cancer cell lines. The rates of enhancement in the fluorescence intensity are expressed as the rates of increase in mean fluorescence intensity (MFI) in respective cell lines, which are calculated according to the following formula.

Rate of increase in mean fluorescence intensity (Rate of enhancement in fluorescence)

intensity) (%) = ((MFI of cells reacted with the anti-CAPRIN-1 antibodies) - (Control MFI)) / (Control MFI) × 100

[0142] Also, the fluorescence intensity was measured in 3 kidney cancer cell lines (Caki-1, Caki-2, and A498), a urinary bladder cancer cell line (T24), an ovary cancer cell line (SKOV3), a lung cancer cell line (QG56), a prostate cancer cell line (PC3), a uterine cervix cancer cell line (HeLa), a fibrosarcoma cell line (HT1080), 2 brain tumor cell lines (T98G and U87MG), a gastric cancer cell line (MNK28), a colorectal cancer cell line (Lovo), and pancreatic cancer cell lines (CapAn-2, MIAPaCa-2, Panc-1, and BxPC-3) using the same approach as above. As a result, all the cancer cells had fluorescence intensity at least 35% stronger than that of the control.

[0143] As with the results obtained above, CAPRIN-1 expression was also confirmed using the anti-CAPRIN-1 monoclonal antibody (mouse monoclonal antibody #1) having the heavy chain variable region of SEQ ID NO: 19 and the light chain variable region of SEQ ID NO: 23, the anti-CAPRIN-1 monoclonal antibody (mouse monoclonal antibody #2) having the heavy chain variable region of SEQ ID NO: 9 and the light chain variable region of SEQ ID NO: 13, and the anti-CAPRIN-1 monoclonal antibody (mouse monoclonal antibody #3) having the heavy chain variable region of SEQ ID NO: 9 and the light chain variable region of SEQ ID NO: 53, which were obtained in Example 2, and the anti-CAPRIN-1 chicken monoclonal antibody #1 having the heavy chain variable region of SEQ ID NO: 58 and the light chain variable region of SEQ ID NO: 62, the anti-CAPRIN-1 chicken monoclonal antibody #2 having the heavy chain variable region of SEQ ID NO: 63 and the light chain variable region of SEQ ID NO: 65, the anti-CAPRIN-1 chicken monoclonal antibody #3 having the heavy chain variable region of SEQ ID NO: 69 and the light chain variable region of SEQ ID NO: 73, and the anti-CAPRIN-1 chicken monoclonal antibody #4 having the heavy chain variable region of SEQ ID NO: 77 and the

light chain variable region of SEQ ID NO: 81 (chicken monoclonal antibodies #1 to #4), which were obtained in Example 3.

Example 7 Immunohistochemical staining

5 (1) CAPRIN-1 expression in mouse and canine normal tissues

[0144] A mouse (Balb/c, female) and a dog (beagle, female) were exsanguinated under ether anesthesia and under ketamine/isoflurane anesthesia and subjected to abdominal section. Then, each organ (stomach, liver, eyeball, thymus, muscle, bone marrow, uterus, small intestine, esophagus, heart, kidney, salivary gland, large intestine, mammary gland, 10 brain, lung, skin, adrenal gland, ovary, pancreas, spleen, and urinary bladder) was transferred to a 10-cm dish containing PBS. Each organ was cut open in PBS and perfusion-fixed overnight in a 0.1 M phosphate buffer solution (pH 7.4) containing 4% paraformaldehyde (PFA). The perfusate was discarded, and the tissue surface of each organ was rinsed with PBS. Each tissue was placed in a PBS solution containing 10% sucrose in a 50-ml centrifuge tube and shaken at 15 4°C for 2 hours using a rotor. The solution was replaced with a PBS solution containing 20% sucrose, and the resulting solution was left to stand at 4°C until the tissue was precipitated. Then, the solution was replaced with a PBS solution containing 30% sucrose, and the resulting solution was left to stand at 4°C until the tissue was precipitated. The tissue was taken out, and necessary portions were cut off with a surgical knife. Next, OCT compound (Tissue Tek) was poured onto the tissue surface and spread over the surface. Then, the tissue was mounted on Cryomold. The Cryomold was placed on dry ice to quickly freeze the tissue, and then the tissue was sliced into 10 to 20  $\mu$ m thick using Cryostat (manufactured by Leica Biosystems), and dried in air, together with the glass slide, for 30 minutes using a hair dryer to 20 prepare a glass slide with a tissue slice placed thereon. Next, the glass slide was placed in a staining bottle filled with PBS-T (physiological saline containing 0.05% Tween 20), and procedures of replacing PBS-T with a fresh one every 5 minutes were performed three times. Redundant water around each section was wiped off with Kimwipe. The section on the glass slide was encircled with a Dako pen (manufactured by Dako Japan Inc.). Then, MOM mouse Ig blocking 25 reagent (Vectastain) for the mouse tissues and a PBS-T solution containing 10% FBS for the canine tissues were applied thereto as blocking solutions, and the glass slide was left to stand at room temperature for 1 hour in a moist chamber.

[0145] Next, a cancer cell surface-reactive polyclonal antibody against the CAPRIN-1-derived peptide (SEQ ID NO: 5) prepared in Example 5 was prepared into a 10  $\mu$ g/ml solution with a blocking solution, and this solution was applied thereto. The glass slide was left to stand overnight at 4°C in a moist chamber. After washing with PBS-T for 10 minutes 30 three times, MOM biotin-labeled anti-IgG antibodies (Vectastain) diluted 250-fold with a blocking solution were applied thereto, and the glass slide was left to stand at room temperature for 1 hour in a moist chamber. After washing with PBS-T for 10 minutes three times, Avidin-Biotin ABC reagent (Vectastain) was applied thereto, and the glass slide was left to stand at room temperature for 5 minutes in a moist chamber. After washing with PBS-T for 10 minutes three times, a DAB staining solution (10 mg of DAB + 10  $\mu$ l of 30%  $H_2O_2$  / 50 ml of 0.05 M tris-HCl (pH 7.6)) was applied thereto, 35 and the glass slide was left to stand at room temperature for 30 minutes in a moist chamber. After rinsing with distilled water, a hematoxylin reagent (manufactured by Dako Japan Inc.) was applied thereto, and the glass slide was left to stand at room temperature for 1 minute and then rinsed with distilled water. The glass slide was placed in 70%, 80%, 90%, 95%, and 100% ethanol solutions in this order for 1 minute per solution and then left to stand overnight in xylene. The glass slide was taken out and mounted in Glycergel Mounting Medium (manufactured by Dako Japan Inc.), followed 40 by observation. As a result, the intracellular expression of CAPRIN-1 was slightly observed in respective tissues of the salivary gland, kidney, colon, and stomach. Its expression, however, was not observed on the cell surface of these tissues. In addition, no expression was observed in tissues derived from the other organs.

(2) Expression of CAPRIN-1 in canine breast cancer tissue

[0146] Frozen breast cancer tissues of dogs pathologically diagnosed as malignant breast cancer were used in the preparation of frozen section slides and immunohistochemical staining using the polyclonal antibodies against the CAPRIN-1-derived peptide (SEQ ID NO: 5) prepared in Example 5, in the same way as above. As a result, the expression of CAPRIN-1 was observed in the canine breast cancer tissues.

45 (3) Expression of CAPRIN-1 in various human cancer tissues

[0147] Paraffin-embedded human various cancer tissue array samples (manufactured by US Biomax, Inc.) were used in immunohistochemical staining using the polyclonal antibodies (prepared in Example 5) against the CAPRIN-1-derived peptide (SEQ ID NO: 5) in the same way as above. As a result, the expression of CAPRIN-1 was observed in esophageal cancer, colon cancer, rectal cancer, lung cancer, pancreatic cancer, kidney cancer, urinary bladder cancer, and uterine cervix cancer.

## Example 8 Preparation of human-mouse chimeric monoclonal antibody

[0148] The gene amplification fragment prepared in Example 4 comprising the sequence (SEQ ID NO: 14) of the heavy chain variable region of the mouse monoclonal antibody #2 was treated at both ends with a restriction enzyme, then purified, and inserted according to a conventional method into a vector pcDNA4/myc-His (manufactured by Invitrogen Corp.) already having gene inserts of a mouse antibody-derived leader sequence and a human IgG<sub>1</sub> H chain constant region comprising the amino acid sequence of SEQ ID NO: 48. Also, the gene amplification fragment comprising the sequence (SEQ ID NO: 15) of the light chain variable region of the mouse monoclonal antibody #2 was treated at both ends with a restriction enzyme, then purified, and inserted according to a conventional method into a vector pcDNA3.1/myc-His (manufactured by Invitrogen Corp.) already having gene inserts of a mouse antibody-derived leader sequence and a human IgG<sub>1</sub> L chain constant region comprising the amino acid sequence of SEQ ID NO: 49.

[0149] Next, the recombinant vector having the insert of the nucleotide sequence encoding the heavy chain variable region (SEQ ID NO: 14) of the mouse monoclonal antibody #2 and the recombinant vector having the insert of the nucleotide sequence encoding the light chain variable region (SEQ ID NO: 15) of the mouse monoclonal antibody #2 were introduced into CHO-K1 cells (obtained from Riken Cell Bank). Specifically,  $2 \times 10^5$  CHO-K1 cells were cultured in a Ham's F12 medium (manufactured by Invitrogen Corp.) containing 1 ml of 10% FBS per well in a 12-well culture plate, and washed with PBS(-). Then, a fresh Ham's F12 medium containing 1 ml of 10% FBS per well was added thereto. 250 ng each of the vectors in 30  $\mu$ l of OptiMEM (manufactured by Invitrogen Corp.) was mixed with 30  $\mu$ l of Polyfect transfection reagent (manufactured by Qiagen N.V.), and this mixture was added to each well. The CHO-K1 cells cotransfected with the recombinant vectors were cultured in a Ham's F12 medium containing 10% FBS supplemented with 200  $\mu$ g/ml Zeocin (manufactured by Invitrogen Corp.) and 200  $\mu$ g/ml Geneticin (manufactured by Roche Diagnostics K.K.) and then seeded in a 96-well plate at 0.5 cells/well to prepare a cell line stably producing a human-mouse chimeric monoclonal antibody #1 (#1) having the variable regions of the mouse monoclonal antibody #1. Cell lines stably producing a human-mouse chimeric monoclonal antibody #2 (#2) or a human-mouse chimeric monoclonal antibody #3 (#3) were also prepared in the same way as above as to the mouse monoclonal antibodies #2 and #3.

[0150] Each prepared cell line was cultured for 5 days in a 150-cm<sup>2</sup> flask at  $5 \times 10^5$  cells/ml in 30 ml of a serum-free OptiCHO medium (manufactured by Invitrogen Corp.) to obtain culture supernatants containing #1, #2, or #3.

[0151] Also, cell lines stably producing human-mouse chimeric comparative antibodies 1 to 11 were prepared in the same way as above respectively, on the basis of the following anti-CAPRIN-1 mouse-derived monoclonal antibodies disclosed in WO2010/016526 as comparative antibodies: a comparative antibody 1 having the heavy chain variable region of SEQ ID NO: 26 and the light chain variable region of SEQ ID NO: 27; a comparative antibody 2 having the heavy chain variable region of SEQ ID NO: 28 and the light chain variable region of SEQ ID NO: 29; a comparative antibody 3 having the heavy chain variable region of SEQ ID NO: 30 and the light chain variable region of SEQ ID NO: 31; a comparative antibody 4 having the heavy chain variable region of SEQ ID NO: 32 and the light chain variable region of SEQ ID NO: 33; a comparative antibody 5 having the heavy chain variable region of SEQ ID NO: 34 and the light chain variable region of SEQ ID NO: 35; a comparative antibody 6 having the heavy chain variable region of SEQ ID NO: 36 and the light chain variable region of SEQ ID NO: 37; a comparative antibody 7 having the heavy chain variable region of SEQ ID NO: 38 and the light chain variable region of SEQ ID NO: 39; a comparative antibody 8 having the heavy chain variable region of SEQ ID NO: 40 and the light chain variable region of SEQ ID NO: 41; a comparative antibody 9 having the heavy chain variable region of SEQ ID NO: 42 and the light chain variable region of SEQ ID NO: 43; a comparative antibody 10 having the heavy chain variable region of SEQ ID NO: 44 and the light chain variable region of SEQ ID NO: 45; and a comparative antibody 11 having the heavy chain variable region of SEQ ID NO: 46 and the light chain variable region of SEQ ID NO: 47. Each prepared cell line was cultured for 5 days in a 150-cm<sup>2</sup> flask at  $5 \times 10^5$  cells/ml in 30 ml of a serum-free OptiCHO medium (manufactured by Invitrogen Corp.) to obtain culture supernatants containing respective human-mouse chimeric comparative monoclonal antibodies 1 to 11.

## Example 9 Preparation of human-chicken chimeric monoclonal antibody

[0152] On the basis of the chicken monoclonal antibody #1 obtained in Example 3, a cell line stably producing a human-chicken chimeric antibody #1 having the variable regions of the chicken monoclonal antibody #1 was prepared according to the method described in Example 4(2) of WO2011/096519 on the basis of. The prepared cell line was cultured for 5 days in a 150-cm<sup>2</sup> flask at  $5 \times 10^5$  cells/ml in 30 ml of a serum-free OptiCHO medium (manufactured by Invitrogen Corp.) to obtain a culture supernatant containing human-chicken chimeric antibody #1.

[0153] Also, on the basis of the chicken monoclonal antibodies #2, #3, and #4, cell lines stably producing a human-chicken chimeric antibody #2, #3, or #4 were also prepared using the same approach as above. Each prepared cell line was used to obtain culture supernatants containing the human-chicken chimeric antibody #1, #2, #3, or #4.

[0154] Example 10 Expression analysis of CAPRIN-1 on surface of various cancer cells using mouse monoclonal antibodies #1, #2, and #3 and chicken monoclonal antibodies #1, #2, #3, and #4

[0155] Next, the human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-157, BT-20, MDA-MB-231V, and MRK-nu-1), the kidney cancer cell lines (Caki-1, Caki-2, A498, and ACHN), the urinary bladder cancer cell line (T24), the ovary cancer cell line (SKOV3), the lung cancer cell lines (QG56 and A549), the pancreatic cancer cell lines (Capan-2 and MIAPaCa-2), the prostate cancer cell line (PC3), the uterine cervix cancer cell line (SW756), the fibrosarcoma cell line (HT1080), the brain tumor cell lines (T98G, U87MG, U251, SNB19, and U373), the gastric cancer cell lines (MNK28 and MNK45), the colorectal cancer cell lines (HT29, Lovo, CaCo2, SW480, and HCT116), the leukemia cell line (AML5), and the lymphoma cell line (Ramos) observed to have CAPRIN-1 gene expression were examined for their expression of CAPRIN-1 proteins on the cell surface using the culture supernatants respectively containing #1, #2, and #3 obtained in Example 2 and the chicken monoclonal antibodies #1, #2, #3, and #4 obtained in Example 3.  $10^6$  cells of each cell line were centrifuged in each 1.5-ml microcentrifuge tube. Each culture supernatant (100  $\mu$ l) containing any of the antibodies #1, #2, and #3 and the chicken monoclonal antibodies #1, #2, #3, and #4 was added to the tube and left to stand for 1 hour on ice. After washing with PBS, FITC-labeled goat anti-mouse IgG (H+L) antibodies (manufactured by Jackson ImmunoResearch Laboratories, Inc.) diluted with PBS containing 0.1% FBS for the mouse-derived antibodies or FITC-labeled goat anti-chicken IgG (H+L) antibodies (manufactured by SouthernBiotech) diluted 100-fold with PBS containing 0.1% FBS for the chicken-derived antibodies were added thereto and left to stand at 4°C for 30 minutes. After washing with PBS, the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and Company). The negative control used was cells reacted only with secondary antibodies. As a result, all the cells each treated with any of the antibodies #1, #2, and #3 and the chicken monoclonal antibodies #1 to #4 had fluorescence intensity at least 35% stronger than that of the negative control. This demonstrated that CAPRIN-1 proteins are expressed on the cell membrane surface of the human cancer cell lines. The rates of enhancement in the fluorescence intensity was expressed as the rates of increase in mean fluorescence intensity (MFI) in respective cell lines, which are calculated according to the following formula.

25 Rate of increase in mean fluorescence intensity (Rate of enhancement in fluorescence intensity) (%) = ((MFI of cells reacted with the anti-CAPRIN-1 antibodies) - (Control MFI)) / (Control MFI)  $\times$  100

30 Example 11 Antitumor activity against cancer cells of antibody against CAPRIN-1-derived peptide (SEQ ID NO: 5)

[0156] In order to evaluate the antibodies against the CAPRIN-1-derived peptide (SEQ ID NO: 5) for the strength of its cytotoxicity against cancer cells expressing CAPRIN-1, ADCC activity was determined. The polyclonal antibodies (prepared in Example 5) against the peptide shown in SEQ ID NO: 5 were used in this evaluation. Similar evaluation was conducted using polyclonal antibodies against other human CAPRIN-1-derived peptides (polyclonal antibodies against amino acid residues 50 to 98 in the amino acid sequence of human CAPRIN-1 and polyclonal antibodies against amino acid residues 233 to 305 in the amino acid sequence of human CAPRIN-1, which were prepared in Example 5) as antibodies for comparison or the rabbit serum-derived control antibodies prepared in Example 5 as a negative control.

[0157]  $10^6$  cells of the human breast cancer cell line MCF7, the human colorectal cancer cell line HCT-116, the human pancreatic cancer cell line MIAPaCa-2, the human kidney cancer cell line Caki-2, and the human lung cancer cell line QG56 observed to have CAPRIN-1 expression were each collected into a 50-ml centrifuge tube, and 100  $\mu$ Ci of chromium 51 was then added thereto, followed by incubation at 37°C for 2 hours. Then, the cells were washed three times with an RPMI1640 medium containing 10% fetal calf serum and added at  $2 \times 10^3$  cells/well to a 96-well V-bottom plate. The polyclonal antibodies against the human CAPRIN-1-derived peptide (SEQ ID NO: 5) and two types of polyclonal antibodies against other human CAPRIN-1-derived peptides (polyclonal antibodies against amino acid residues 50 to 98 of human CAPRIN-1 and polyclonal antibodies against amino acid residues 233 to 305 of human CAPRIN-1) were each added thereto at 1  $\mu$ g/well. Lymphocytes separated from human peripheral blood according to a conventional method were further added thereto at  $4 \times 10^5$  cells/well and cultured for 4 hours at 37°C, 5% CO<sub>2</sub>. After the culture, the amount of chromium (Cr) 51 released from damaged cancer cells was measured in the culture supernatant to calculate the ADCC activity against the cancer cells due to the polyclonal antibodies against the human CAPRIN-1-derived peptides. As a result, all the polyclonal antibodies obtained by immunization with the human partial CAPRIN-1 peptides having the amino acid sequence of amino acid residues 50 to 98 or amino acid residues 233-305 of human CAPRIN-1 had activity less than 10% against the human breast cancer cell line MCF7, the human colorectal cancer cell line HCT-116, the human pancreatic cancer cell line MIAPaCa-2, the human kidney cancer cell line Caki-2, and the human lung cancer cell line QG56. By contrast, the groups of the cells treated with the polyclonal antibodies against the human CAPRIN-1-derived peptide (SEQ ID NO: 5) exhibited 25% or higher cytotoxic activity against all the cancer cell lines. The negative control antibodies had activity less than 4% against all the cancer cells. These results revealed that antibodies against

CAPRIN-1 shown in SEQ ID NO: 5 exerts strong cytotoxic activity against cancer cells expressing CAPRIN-1.

[0158] These results were obtained via determination of cytotoxic activity by, as described above, mixing the anti-CAPRIN-1 antibody used in the present invention, lymphocytes, and  $2 \times 10^3$  cells of each cancer cell line with incorporated chromium 51; culturing the cells for 4 hours; after the culture, measuring the amount of chromium 51 released into the medium; and calculating the cytotoxic activity against each cancer cell line according to the following formula\*.

\*Expression: Cytotoxic activity (%) = [Amount of chromium 51 released from the target cells treated with the antibody against CAPRIN-1 and lymphocytes] / [Amount of chromium 51 released from target cells treated with 1N hydrochloric acid]  $\times 100$

[0159] The human-mouse chimeric monoclonal antibodies #1, #2, and #3 obtained in Example 8 and the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 obtained in Example 9 were evaluated for their cytotoxic activity against human cancer cells. The culture supernatant of each cell line producing any of #1, #2, and #3 and the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 was purified using Hitrap Protein A Sepharose FF (manufactured by GE Healthcare Bio-Sciences Ltd.). After replacement with PBS(-), the solution was filtered through a 0.22- $\mu$ m filter (manufactured by Millipore Corp.). The resulting antibody was used for activity assay.  $10^6$  cells each of the human breast cancer cell line MCF7, the human colorectal cancer cell line HCT-116, the human pancreatic cancer cell line MIAPaCa-2, the human kidney cancer cell line Caki-2, and the human lung cancer cell line QG56 were collected into a 50-ml centrifuge tube, and 100  $\mu$ Ci of chromium 51 was then added thereto, followed by incubation at 37°C for 2 hours. Then, the cells were washed three times with an RPMI1640 medium containing 10% FBS and added at  $2 \times 10^3$  cells/well to a 96-well V-bottom plate to prepare target cells. The purified antibodies (human-mouse chimeric monoclonal antibodies #1, #2, and #3 and human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4) and the human-mouse chimeric comparative monoclonal antibodies 1 to 11 obtained in Example 8 were each added thereto at 1.3  $\mu$ g/well. A cell population containing human NK cells was separated using a conventional method from human peripheral blood lymphocytes prepared according to a conventional method. The cell population containing human NK cells that was used in this evaluation was prepared as follows: human peripheral blood mononuclear cells separated using a specific gravity separation solution Histopaque for peripheral blood mononuclear cell separation (Sigma-Aldrich Corp.) were reacted with FITC fluorescent dye-labeled antibodies (anti-human CD3 antibody, anti-human CD20 antibody, anti-human CD19 antibody, anti-human CD11c antibody, or anti-HLA-DR antibody (Becton, and Dickinson and Company)); and a cell population containing NK cells unstained with the antibodies was separated therefrom using a cell sorter (FACS Vantage SE (Becton, and Dickinson and Company)), or a cell population was separated with human NK cell separation kit (manufactured by Miltenyi Biotec K.K.). The separated cell population containing NK cells was added to the plate at  $2 \times 10^5$  cells/well and cultured for 4 hours at 37°C, 5% CO<sub>2</sub>. After the culture, the amount of chromium 51 released from damaged tumor cells was measured in the culture supernatant to calculate the cytotoxic activity of each anti-CAPRIN-1 antibody against the cancer cells. The negative control used was cells treated with isotype control antibodies. As a result, the isotype control antibodies used and the human-mouse chimeric comparative monoclonal antibodies 1 to 11 had cytotoxic activity of less than 5% against MCF7, less than 3% against HCT-116, 7% against MIAPaCa-2, less than 8% against Caki-2, and less than 5% against QG56. By contrast, the human-mouse chimeric monoclonal antibody #1 and the human-chicken chimeric monoclonal antibodies #1 to #4 had cytotoxic activity of 30% or higher against MCF7, 19% or higher against HCT-116, 28% or higher against MIAPaCa-2, 34% or higher against Caki-2, and 10% or higher against QG56. Also, the human-mouse chimeric monoclonal antibodies #2 and #3 had cytotoxic activity of 32% or higher against MCF7, 18% or higher against HCT-116, 32% or higher against MIAPaCa-2, 18% or higher against Caki-2, and 10% or higher against QG56. Likewise, the isotype control antibodies used and the comparative antibodies 1 to 11 used had cytotoxic activity less than 4% against all other cancer cells: breast cancer cell lines ZR75-1, T47D, Hs578T, BT-20, SK-BR-3, MDA-MB-231V, and MRK-nu-1, glioma cell lines T98G and U373, a lung cancer cell line A549, kidney cancer cell lines Caki-1 and ACHN, a uterine cervix cancer cell line SW756, a urinary bladder cancer cell line T24, gastric cancer cell lines MKN28 and MKN45, a colorectal cancer cell line SW480, a leukemia cell line AML5, and a lymphoma cell line Ramos. By contrast, the human-mouse chimeric monoclonal antibodies #1, #2, and #3 and the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 were observed to have 10% or higher cytotoxic activity against these cell lines. These results showed that the obtained monoclonal antibodies #1, #2, and #3 and human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 against CAPRIN-1 damage CAPRIN-1-expressing cancer cells through their ADCC activity, and it was demonstrated that the human-mouse chimeric monoclonal antibodies #1, #2, and #3 and the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 exhibit stronger cytotoxic activity against human cancer cells than that of the comparative antibodies 1 to 11.

[0160] Also, the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 were evaluated in the same way

as above for their cytotoxic activity against the human breast cancer cell line MDA-MB-436, the human kidney cancer cell line Caki-1, the human lung cancer cell line A549, the human pancreatic cancer cell line Panc-1, and the human colorectal cancer cells DLD-1 observed to have CAPRIN-1 gene expression. Further, human-chicken chimeric antibodies #1 and #2 against CAPRIN-1 described in Example 4 of WO2011/096517 were used as comparative antibodies 12 and 13, respectively; a human-chicken chimeric antibody #1 against CAPRIN-1 described in Example 4 of WO2011/096519 was used as a comparative antibody 13; a human-chicken chimeric antibody #1 and mouse monoclonal antibodies #2, #3, #4, #5, and #6 against CAPRIN-1 described in Example 4 of WO2011/096528 were used as comparative antibodies 14, 15, 16, 17, 18, and 19 respectively; mouse monoclonal antibodies #1, #2, and #3 against CAPRIN-1 described in Example 3 of WO2011/096533 were used as comparative antibodies 20, 21, and 22, respectively; and mouse monoclonal antibodies #1, #2, and #3 against CAPRIN-1 described in Example 3 of WO2011/096534 were used as comparative antibodies 23, 24, and 25, respectively, for evaluation of the cytotoxic activity. Specifically,  $10^6$  cells of the human colorectal cancer cell line DLD-1 were collected into a 50-ml centrifuge tube, and 100  $\mu$ Ci of chromium 51 was then added thereto, followed by incubation at 37°C for 1 hour. Then, the cells were washed three times with an RPMI1640 medium containing 10% FBS and added at  $2 \times 10^3$  cells/well to a 96-well V-bottom plate to prepare target cells. Next, the human-chicken chimeric monoclonal antibodies #1 to #4 and the comparative antibodies 12 to 25 were each added thereto at 1  $\mu$ g/well. A cell population containing human NK cells prepared according to a conventional method was further added thereto at  $10^5$  cells/well and cultured for 4 hours at 37°C, 5% CO<sub>2</sub>. After the culture, the amount of chromium 51 released from damaged tumor cells was measured in the culture supernatant to calculate the cytotoxic activity of each anti-CAPRIN-1 antibody against the cancer cells. Cytotoxicity against MDA-MB-436, Caki-1, A549, and Panc-1 was also evaluated in the same way as above. As a result, all the comparative antibodies 12 to 25 had 5% or lower cytotoxic activity against MDA-MB-436, whereas the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 exhibited 18% or higher cytotoxic activity against this cell line. All the comparative antibodies 12 to 25 had 5% or lower cytotoxic activity against Caki-1, whereas the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 exhibited 14% or higher cytotoxic activity against this cell line. All the comparative antibodies 12 to 25 had 5% or lower cytotoxic activity against A549, whereas the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 exhibited 12% or higher cytotoxic activity against this cell line. All the comparative antibodies 12 to 25 had 5% or lower cytotoxic activity against Panc-1, whereas the human-chicken chimeric monoclonal antibodies #1, #2, #3 and #4 exhibited 18% or higher cytotoxic activity against this cell line. All the comparative antibodies 12 to 25 had 7% or lower cytotoxic activity against DLD-1, whereas the human-chicken chimeric monoclonal antibodies #1, #2, #3, and #4 exhibited 15% or higher cytotoxic activity against this cell line.

[0161] These results were obtained via determination of cytotoxic activity by, as described above, mixing the anti-CAPRIN-1 antibody used in the present invention, lymphocytes (cell population containing NK cells), and  $2 \times 10^3$  cells of each cancer cell line with incorporated chromium 51; culturing the cells for 4 hours; after the culture, measuring the amount of chromium 51 released into the medium; and calculating the cytotoxic activity against each cancer cell line according to the following formula\*.

\*Expression: Cytotoxic activity (%) = [Amount of chromium 51 released from the target cells treated with the antibody against CAPRIN-1 and lymphocytes (cell population containing NK cells)] / [Amount of chromium 51 released from target cells treated with 1N hydrochloric acid] × 100

Example 12 The number of CAPRIN-1 molecules on surface of various cancer cells recognized by anti-CAPRIN-1 monoclonal antibodies #1, #2, and #3

[0162] Human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-157, BT-20, MDA-MB-231V, and MRK-nu-1), kidney cancer cell lines (Caki-1, Caki-2, A498, and ACHN), a urinary bladder cancer cell line (T24), an ovary cancer cell line (SKOV3), lung cancer cell lines (QG56 and A549), pancreatic cancer cell lines (MIAPaCa-2 and Capan-2), a prostate cancer cell line (PC3), a uterine cervix cancer cell line (SW756), a fibrosarcoma cell line (HT1080), brain tumor cell lines (T98G, U87MG, U251, SNB19, and U373), gastric cancer cell lines (MNK28 and MNK45), colorectal cancer cell lines (HT29, Lovo, CaCo2, SW480, and HCT116), a leukemia cell line (AML5), and a lymphoma cell line (Ramos) were examined using an assay kit for the number of molecules "QIFIKIT" (manufactured by Dako Japan Inc.) for the number of CAPRIN-1 molecules on their cell surface recognized by the mouse monoclonal antibodies #1, #2, and #3 obtained in Example 2. Similarly, the number of CAPRIN-1 molecules on the surface of these various cancer cells was also examined using the comparative monoclonal antibodies 1 to 11.

[0163] Specifically, according to the protocol attached to the kit, each antibody (mouse monoclonal antibodies #1, #2, and #3 and comparative antibodies 1 to 11) was diluted into 5 µg/ml at final concentration with PBS, and this dilution was added to each cell line and reacted for 30 minutes. After washing with PBS, fluorescently labeled anti-mouse IgG antibodies attached to the kit were added as secondary antibodies, together with calibration beads attached to the kit, to each cell line and left to stand for 45 minutes on ice. Each cell line and the calibration beads were washed with PBS. Then, the fluorescence intensity was measured using FACSCalibur (Becton, Dickinson and Company) to obtain a mean fluorescence intensity value (mean) for all the antibodies described above. The negative control used was cells reacted with isotype control antibodies, and a mean was also obtained. Each mean fluorescence intensity value (mean) was used to calculate the number of molecules according to the protocol attached to the kit. As a result, the number of CAPRIN-1 molecules on the surface of various cancer cells recognized by the mouse monoclonal antibodies #1, #2, and #3 was 10<sup>5</sup> or more per cell for all the examined human cancer cell lines. On the other hand, the number of molecules recognized by the comparative antibodies 1 to 11 was less than 10<sup>5</sup> per cell.

## 15 Industrial Applicability

[0164] The antibody of the present invention is useful in the treatment and/or prevention of cancer.

## SEQUENCE LISTING

## 20 [0165]

<110> Toray Industries, Inc.

25 <120> Pharmaceutical Composition for Treatment and Prevention of Cancer

<130> PH-5299-PCT

30 <150> JP 2011-171300

<151> 2011-08-04

35 <160> 81

<170> PatentIn version 3.1

40 <210> 1

<211> 5562

<212> DNA

<213> Homo sapiens

45 <220>

<221> CDS

<222> (190)..(2319)

<223>

50 <400> 1

## EP 2 740 796 B1

5	cagagggctg ctggctggct aagtccctcc cgctcccgcc tctcgccctca ctaggagcgg	60
	ctctcggtgc agcgggacag ggcgaagcgg cctgcgcccc cggagcgcgc gacactgccc	120
	ggaagggacc gccacccttg ccccctcagc tgcccactcg tgatttccag cggcctccgc	180
	gcgcgcacg atg ccc tcg gcc acc agc cac agc ggg agc ggc agc aag tcg Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser	231
	1 5 10	
10	tcc gga ccg cca ccg ccg tcg ggt tcc tcc ggg agt gag gcg gcc gcg Ser Gly Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala	279
	15 20 25 30	
15	gga gcc ggg gcc gcc gcg ccg gct tct cag cac ccc gca acc ggc acc Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr	327
	35 40 45	
20	ggc gct gtc cag acc gag gcc atg aag cag att ctc ggg gtg atc gac Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp	375
	50 55 60	
	aag aaa ctt cgg aac ctg gag aag aaa aag ggt aag ctt gat gat tac Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr	423
	65 70 75	
25	cag gaa cga atg aac aaa ggg gaa agg ctt aat caa gat cag ctg gat Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp	471
	80 85 90	
30	gcc gtt tct aag tac cag gaa gtc aca aat aat ttg gag ttt gca aaa Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys	519
	95 100 105 110	
35	gaa tta cag agg agt ttc atg gca cta agt caa gat att cag aaa aca Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr	567
	115 120 125	
40		
45		
50		
55		

## EP 2 740 796 B1

ata aag aag aca gca cgt cgg gag cag ctt atg aga gaa gct gaa Ile Lys Lys Thr Ala Arg Arg Glu Gln Ieu Met Arg Glu Glu Ala Glu 130 135 140	615
5 cag aaa cgt tta aaa act gta ctt gag cta cag tat gtt ttg gac aaa Gln Lys Arg Leu Lys Thr Val Ieu Glu Ieu Gln Tyr Val Ieu Asp Lys 145 150 155	663
10 ttg gga gat gat gaa gta cgg act gac ctg aaa caa ggt ttg aat gga Leu Gly Asp Asp Glu Val Arg Thr Asp Ieu Lys Gln Gly Leu Asn Gly 160 165 170	711
15 gtg cca ata ttg tcc gaa gag gag ttg tca ttg ttg gat gaa ttc tat Val Pro Ile Leu Ser Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr 175 180 185 190	759
20 aag cta gta gac cct gaa cgg gac atg agc ttg agg ttg aat gaa cag Lys Leu Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln 195 200 205	807
25 tat gaa cat gcc tcc att cac ctg tgg gac ctg ctg gaa ggg aag gaa Tyr Glu His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu 210 215 220	855
30 aaa cct gta tgt gga acc acc tat aaa gtt cta aag gaa att gtt gag Lys Pro Val Cys Gly Thr Thr Tyr Lys Val Leu Lys Glu Ile Val Glu 225 230 235	903
35 cgt gtt ttt cag tca aac tac ttt gac agc acc cac aac cac cag aat Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn 240 245 250	951
40 ggg ctg tgt gag gaa gaa gag gca gcc tca gca cct gca gtt gaa gac Gly Leu Cys Glu Glu Ala Ala Ser Ala Pro Ala Val Glu Asp 255 260 265 270	999
45 cag gta cct gaa gct gaa cct gag cca gca gaa gag tac act gag caa Gln Val Pro Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln 275 280 285	1047
50 agt gaa gtt gaa tca aca gag tat gta aat aga cag ttc atg gca gaa Ser Glu Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu 290 295 300	1095
55 aca cag ttc acc agt ggt gaa aag gag cag gta gat gag tgg aca gtt Thr Gln Phe Thr Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val 305 310 315	1143
55 gaa acg gtt gag gtg gta aat tca ctc cag cag caa cct cag gct gca Glu Thr Val Glu Val Val Asn Ser Leu Gln Gln Pro Gln Ala Ala 320 325 330	1191
55 tcc cct tca gta cca gag ccc cac tct ttg act cca gtg gct cag gca Ser Pro Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ala 335 340 345 350	1239
55 gat ccc ctt gtg aga aga cag cga gta caa gac ctt atg gca caa atg Asp Pro Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met 355 360 365	1287
55 cag ggt ccc tat aat ttc ata cag gat tca atg ctg gat ttt gaa aat Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn	1335

## EP 2 740 796 B1

	370	375	380	
5	cag aca ctt gat cct gcc att gta tct gca cag cct atg aat cca aca Gln Thr Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr 385 390 395			1383
	caa aac atg gac atg ccc cag ctg gtt tgc cct cca gtt cat tct gaa Gln Asn Met Asp Met Pro Gln Leu Val Cys Pro Pro Val His Ser Glu 400 405 410			1431
10	tct aga ctt gct cag cct aat caa gtt cct gta caa cca gaa gcg aca Ser Arg Leu Ala Gln Pro Asn Gln Val Pro Val Gln Pro Glu Ala Thr 415 420 425 430			1479
15	cag gtt cct ttg gta tca tcc aca agt gag ggg tac aca gca tct caa Gln Val Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln 435 440 445			1527
	ccc ttg tac cag cct tct cat gct aca gag caa cga cca cag aag gaa Pro Leu Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu 450 455 460			1575
20	cca att gat cag att cag gca aca atc tct tta aat aca gac cag act Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr 465 470 475			1623
25	aca gca tca tca tcc ctt cct gct gcg tct cag cct caa gta ttt cag Thr Ala Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln 480 485 490			1671
	gct ggg aca agc aaa cct tta cat agc agt gga atc aat gta aat gca Ala Gly Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala 495 500 505 510			1719
30	gct cca ttc caa tcc atg caa acg gtg ttc aat atg aat gcc cca gtt Ala Pro Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val 515 520 525			1767
35	cct cct gtt aat gaa cca gaa act tta aaa cag caa aat cag tac cag Pro Pro Val Asn Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln 530 535 540			1815
40	gcc agt tat aac cag agc ttt tct agt cag cct cac caa gta gaa caa Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln 545 550 555			1863
	aca gag ctt cag caa gaa cag ctt caa aca gtg gtt ggc act tac cat Thr Glu Leu Gln Gln Glu Gln Leu Gln Thr Val Val Gly Thr Tyr His 560 565 570			1911
45	ggt tcc cca gac cag tcc cat caa gtg act ggt aac cac cag cag cct Gly Ser Pro Asp Gln Ser His Gln Val Thr Gly Asn His Gln Gln Pro 575 580 585 590			1959
	cct cag cag aac act gga ttt cca cgt agc aat cag ccc tat tac aat Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr Tyr Asn 595 600 605			2007
50	agt cgt ggt gtg tct cgt gga ggc tcc cgt ggt gct aga ggc ttg atg Ser Arg Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met 610 615 620			2055
55	aat gga tac cgg ggc cct gcc aat gga ttc aga gga gga tat gat ggt			2103

	Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly	
	625 630 635	
5	tac cgc cct tca ttc tct aac act cca aac agt ggt tat aca cag tct Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser	2151
	640 645 650	
10	cag ttc agt gct ccc cggtt gat tac tct ggc tat caa cgg gat gga tat Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr	2199
	655 660 665 670	
15	cag cag aat ttc aag cga ggc tct ggg cag agt gga cca cgg gga gcc Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala	2247
	675 680 685	
20	cca cga ggt cgt gga ggg ccc cca aga ccc aac aga ggg atg ccg caa Pro Arg Gly Arg Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln	2295
	690 695 700	
25	atg aac act cag caa gtg aat taa tctgattcac aggattatgt ttaatcgcca Met Asn Thr Gln Gln Val Asn	2349
	705	
30	aaaacacact ggccagtgta ccataatatg ttaccagaag agttattatc tatttgttct cccttcagg aaacttattt gtaaggact gtttcatcc cataaagaca ggactacaat	2409
	tgtcagctt ctattacctg gatatggaag gaaactattt ttactctgca tggtctgtcc	2469
35	taagcgtcat cttgagcctt gcacatgata ctcagattcc tcaccctgc ttaggagtaa aacaatatac ttacaggggt gataataatc tccatagttt tttgaagtgg cttgaaaaag	2529
	gcaagattga cttttatgac attggataaa atctacaaat cagccctcga gttattcaat	2589
40	gataactgac aaactaaatt attcccttag aaaggaagat gaaaggagtg gagtggtt tggcagaaca actgcatttc acagctttc cagttaaatt ggagcactga acgttcagat	2649
	gcataccaaa ttatgcatgg gtcctaatca cacatataag gctggctacc agctttgaca	2709
45	cagcaactgtt catctggcca aacaactgtg gttaaaaaca catgtaaaat gcttttaac agctgatact gtataagaca aagccaagat gcaaaattag gctttgattt gcaacttttg	2769
	tatttagata ctttttgaa cacttaacag tttcttttag acaatgactt ttgttaaggat	3009
50	tggtactatc tatcattcct tatgacatgt acattgtctg tcactaatcc ttggattttg ctgtattgtc acctaaattt gtacaggtac tgatgaaaat ctctagtgaa taatcataac	3069
	actctcggtc acatgtttt cttcagctt gaaagcttt tttaaaagg aaaagatacc	3249
55	aaatgcctgc tgctaccacc ctttcaatt gctatcttt gaaaggcacc agtatgtgtt tttagattgat ttccctgttt cagggaaatc acggacagta gttcagttc tgatggata	3309
	agcaaaaacaa ataaaacgtt tataaaagtt gtatctgaa acactgggt tcaacagcta	3369
	gcagctttag tgattcaccc catgccacgt tagtgcaca aattttatgg tttatctcca	3429
		3489
		3549

	gcaacatttc tctagtaactt gcacttatta tctttgtct aatttaacct taactgaatt	3609
5	ctccgtttct cctggaggca tttatattca gtgataattc cttcccttag atgcataagg	3669
	agagtctcta aatttgcatttgg aaatggacac ttgagtagtg acttagcctt atgtactctg	3729
	tttggaaatttg tgctagcagt ttgagcacta gttctgtgtg cctaggaagt taatgctgct	3789
10	tattgtctca ttctgacttc atggagaatt aatcccacct ttaagcaaag gctactaagt	3849
	taatggtatt ttctgtgcag aaattaaatt ttatttcag catttagccc aggaattctt	3909
	ccagtaggtg ctcagctatt taaaaacaaa actattctca aacattcatc attagacaac	3969
15	tggagttttt gctggtttg taacctacca aaatggatag gctgttgaac attccacatt	4029
	caaaaagttttt gtaggggtggt gggaaatggg ggatcttcaa tgtttatttt aaaataaaaat	4089
	aaaataagtt cttagctttt ctcatgtgtg gttgtggtagt atcatattgg aagggttaac	4149
20	ctgttacttt ggcaaattgag tattttttt ctagcacctc cccttgcgtg cttaaatga	4209
	catctgcctg ggatgtacca caaccatatg ttacctgtat cttagggaa tggataaaaat	4269
	atttgtggtt tactggtaa tccctagatg atgtatgctt gcagtcctat ataaaactaa	4329
25	atttgcatac tttgttagaaa ataatttcat gacattaca atcaggactg aagtaagttc	4389
	ttcacacagt gacctctgaa tcagtttcag agaaggatg ggggagaaaa tgccttctag	4449
	gttttgaact tctatgcatt agtgcagatg ttgtgaatgt gtaaagggtgt tcatagtttg	4509
30	actgtttcta ttttatgtttt ttcaaagaat tgttcctttt tttgaactat aatttttctt	4569
	tttttggta ttttaccatc acagttaaa tgtatatctt ttatgtctct actcagacca	4629
	tattttaaa ggggtgcctc attatggggc agagaacttt tcaataagtc tcattaagat	4689
35	ctgaatcttgc ttcttaagca ttctgtataa tatgtgatttgc cttgtccttag ctgcagaagg	4749
	cctttgtttt ggtcaaattgc atatttttagc agagtttcaa ggaaatgatt gtcacacatg	4809
	tcactgttagc ctcttgggtt agcaagctca cataaaaaat actttgtat atgcataata	4869
40	taaatcatct catgtggata tgaaacttct tttttaaaac taaaaaggt agaatgttat	4929
	tgattacctt gattaggca gttttatcc cagatcctaa taattcctaa aaaatatgga	4989
	aaagttttttt ttcaatcatt gtaccttgcattt attaaaacaa atatccttta agtatttctt	5049
45	atcagtttagc ttctacagtt ctttgtctc cttttatatg cagctttac gtgggagact	5109
	tttccactta aaggagacat agaatgtgtg cttattctca gaaggttcat taactgaggt	5169
	gatgagttaa caactagttg agcagtcagc ttccctaagtg ttttaggaca tttgttcatt	5229
50	atattttccg tcataataact agaggaagtg gaatgcagat aagtgcggaa ttcaaaccct	5289
	tcattttatg tttaagctcc tgaatctgca ttccacttgg gttgtttta agcattctaa	5349
	atttttagttt attataagttt agatttcaca gaatcagtttgc tttgttcattt	5409
55	ttatggagttt aacggggagg aagacccctc aggaaaacga aagtaaatttgc ttaaggctca	5469

EP 2 740 796 B1

tcttcataacc tttttccatt ttgaatccta caaaaatact gcaaaagact agtgaatgtt 5529

taaaaattaca ctagattaaa taatatgaaa gtc 5562

5

<210> 2

<211> 709

<212> PRT

<213> Homo sapiens

10

<400> 2

15

20

25

30

35

40

45

50

55

## EP 2 740 796 B1

Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly  
 1 5 10 15

5 Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala  
 20 25 30

10 Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala  
 35 40 45

15 Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys  
 50 55 60

Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu  
 65 70 75 80

20 Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val  
 85 90 95

25 Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu  
 100 105 110

30 Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys  
 115 120 125

Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys  
 130 135 140

35 Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly  
 145 150 155 160

40 Asp Asp Glu Val Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly Val Pro  
 165 170 175

Ile Leu Ser Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu  
 180 185 190

45 Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu  
 195 200 205

50

55

## EP 2 740 796 B1

His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro  
 210 215 220

5 Val Cys Gly Thr Thr Tyr Lys Val Leu Lys Glu Ile Val Glu Arg Val  
 225 230 235 240

10 Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu  
 245 250 255

15 Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Ala Val Glu Asp Gln Val  
 260 265 270

20 Pro Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu  
 275 280 285

25 Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln  
 290 295 300

30 Phe Thr Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr  
 305 310 315 320

35 Val Glu Val Val Asn Ser Leu Gln Gln Pro Gln Ala Ala Ser Pro  
 325 330 335

40 Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ala Asp Pro  
 340 345 350

45 Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly  
 355 360 365

50 Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr  
 370 375 380

55 Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn  
 385 390 395 400

Met Asp Met Pro Gln Leu Val Cys Pro Pro Val His Ser Glu Ser Arg  
 405 410 415

Leu Ala Gln Pro Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val  
 420 425 430

Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu  
 435 440 445

Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Ile

## EP 2 740 796 B1

450

455

460

5 Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala  
465 470 475 480

10 Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly  
485 490 495

15 Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro  
500 505 510

20 Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro  
515 520 525

25 Val Asn Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln Ala Ser  
530 535 540

30 Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu  
545 550 555 560

35 Leu Gln Gln Glu Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser  
565 570 575

40 Pro Asp Gln Ser His Gln Val Thr Gly Asn His Gln Gln Pro Pro Gln  
580 585 590

45 Gln Asn Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr Tyr Asn Ser Arg  
595 600 605

50 Gly Val Ser Arg Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly  
610 615 620

55 Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg  
625 630 635 640

60 Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser Gln Phe  
645 650 655

65 Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln  
660 665 670

70 Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg  
675 680 685

75 Gly Arg Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln Met Asn  
690 695 700

EP 2 740 796 B1

Thr Gln Gln Val Asn  
705

5        <210> 3  
      <211> 3553  
      <212> DNA  
      <213> Homo sapiens

10      <220>  
      <221> CDS  
      <222> (190)..(2274)  
      <223>

15      <400> 3  
      15

20

25

30

35

40

45

50

55

## EP 2 740 796 B1

5	cagagggtcg ctggctggct aagtccctcc cgctcccgcc tctcgccctca ctaggagcgg	60
	ctctcggtgc agcgggacag ggcgaagcgg cctgcgcccc cggagcgcgc gacactgccc	120
	ggaagggacc gccacccttg cccctcagc tgcccactcg tgatttccag cggcctccgc	180
	gcgcgcacg atg ccc tcg gcc acc agc cac agc ggg agc ggc agc aag tcg Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser	231
	1 5 10	
10	tcc gga ccg cca ccg ccg tcg ggt tcc tcc ggg agt gag gcg gcc gcg Ser Gly Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala	279
	15 20 25 30	
15	gga gcc ggg gcc gcc gcg ccg gct tct cag cac ccc gca acc ggc acc Gly Ala Gly Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr	327
	35 40 45	
20	ggc gct gtc cag acc gag gcc atg aag cag att ctc ggg gtg atc gac Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp	375
	50 55 60	
	aag aaa ctt cgg aac ctg gag aag aaa aag ggt aag ctt gat gat tac Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr	423
	65 70 75	
25	cag gaa cga atg aac aaa ggg gaa agg ctt aat caa gat cag ctg gat Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp	471
	80 85 90	
30	gcc gtt tct aag tac cag gaa gtc aca aat aat ttg gag ttt gca aaa Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys	519
	95 100 105 110	
35	gaa tta cag agg agt ttc atg gca cta agt caa gat att cag aaa aca Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr	567
	115 120 125	
	ata aag aag aca gca cgt cgg gag cag ctt atg aga gaa gaa gct gaa Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu	615
	130 135 140	
40	cag aaa cgt tta aaa act gta ctt gag cta cag tat gtt ttg gac aaa Gln Lys Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys	663
	145 150 155	
45	ttg gga gat gat gaa gtg cgg act gac ctg aaa caa ggt ttg aat gga Leu Gly Asp Asp Glu Val Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly	711

50

55

## EP 2 740 796 B1

	160	165	170	
5	gtg cca ata ttg tcc gaa gag gag ttg tca ttg ttg gat gaa ttc tat Val Pro Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr 175 180 185 190			759
	aag cta gta gac cct gaa cgg gac atg agc ttg agg ttg aat gaa cag Lys Leu Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln 195 200 205			807
10	tat gaa cat gcc tcc att cac ctg tgg gac ctg ctg gaa ggg aag gaa Tyr Glu His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu 210 215 220			855
15	aaa cct gta tgt gga acc acc tat aaa gtt cta aag gaa att gtt gag Lys Pro Val Cys Gly Thr Thr Tyr Lys Val Leu Lys Glu Ile Val Glu 225 230 235			903
	cgt gtt ttt cag tca aac tac ttt gac agc acc cac aac cac cag aat Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn 240 245 250			951
20	ggg ctg tgt gag gaa gaa gag gca gcc tca gca cct gca gtt gaa gac Gly Leu Cys Glu Glu Ala Ala Ser Ala Pro Ala Val Glu Asp 255 260 265 270			999
25	cag gta cct gaa gct gaa gag cca gca gaa gag tac act gag caa Gln Val Pro Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln 275 280 285			1047
	agt gaa gtt gaa tca aca gag tat gta aat aga cag ttc atg gca gaa Ser Glu Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu 290 295 300			1095
30	aca cag ttc acc agt ggt gaa aag gag cag gta gat gag tgg aca gtt Thr Gln Phe Thr Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val 305 310 315			1143
35	gaa acg gtt gag gtg gta aat tca ctc cag cag caa cct cag gct gca Glu Thr Val Glu Val Val Asn Ser Leu Gln Gln Pro Gln Ala Ala 320 325 330			1191
	tcc cct tca gta cca gag ccc cac tct ttg act cca gtg gct cag gca Ser Pro Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ala 335 340 345 350			1239
40	gat ccc ctt gtg aga aga cag cga gta caa gac ctt atg gca caa atg Asp Pro Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met 355 360 365			1287
45	cag ggt ccc tat aat ttc ata cag gat tca atg ctg gat ttt gaa aat Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn 370 375 380			1335
	cag aca ctt gat cct gcc att gta tct gca cag cct atg aat cca aca Gln Thr Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr 385 390 395			1383
50	caa aac atg gac atg ccc cag ctg gtt tgc cct cca gtt cat tct gaa Gln Asn Met Asp Met Pro Gln Leu Val Cys Pro Pro Val His Ser Glu 400 405 410			1431
55	tct aga ctt gct cag cct aat caa gtt cct gta caa cca gaa gcg aca			1479

## EP 2 740 796 B1

	Ser Arg Leu Ala Gln Pro Asn Gln Val Pro Val Gln Pro Glu Ala Thr		
415	420	425	430
5	cag gtt cct ttg gta tca tcc aca agt gag ggg tac aca gca tct caa Gln Val Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln		1527
	435	440	445
10	ccc ttg tac cag cct tct cat gct aca gag caa cga cca cag aag gaa Pro Leu Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu		1575
	450	455	460
15	cca att gat cag att cag gca aca atc tct tta aat aca gac cag act Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr		1623
	465	470	475
20	aca gca tca tca tcc ctt cct gct gcg tct cag cct caa gta ttt cag Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln		1671
	480	485	490
25	gct ggg aca agc aaa cct tta cat agc agt gga atc aat gta aat gca Ala Gly Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala		1719
	495	500	505
30	510		
35	gct cca ttc caa tcc atg caa acg gtg ttc aat atg aat gcc cca gtt Ala Pro Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val		1767
	515	520	525
40	cct cct gtt aat gaa cca gaa act tta aaa cag caa aat cag tac cag Pro Pro Val Asn Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln		1815
	530	535	540
45	gcc agt tat aac cag agc ttt tct agt cag cct cac caa gta gaa caa Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln		1863
	545	550	555
50	aca gag ctt cag caa gaa cag ctt caa aca gtg gtt ggc act tac cat Thr Glu Leu Gln Gln Glu Gln Leu Gln Thr Val Val Gly Thr Tyr His		1911
	560	565	570
55	ggt tcc cca gac cag tcc cat caa gtg act ggt aac cac cag cag cct Gly Ser Pro Asp Gln Ser His Gln Val Thr Gly Asn His Gln Gln Pro		1959
	575	580	585
60	590		
65	cct cag cag aac act gga ttt cca cgt agc aat cag ccc tat tac aat Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr Tyr Asn		2007
	595	600	605
70	agt cgt ggt gtg tct cgt gga ggc tcc cgt ggt gct aga ggc ttg atg Ser Arg Gly Val Ser Arg Gly Ser Arg Gly Ala Arg Gly Leu Met		2055
	610	615	620
75	aat gga tac cgg ggc cct gcc aat gga ttc aga gga gga tat gat ggt Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly		2103
	625	630	635
80	tac cgc cct tca ttc tct aac act cca aac agt ggt tat aca cag tct Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser		2151
	640	645	650
85	cag ttc agt gct ccc cgg gat tac tct ggc tat caa cgg gat gga tat Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr		2199
	655	660	665
90	670		

1	cag cag aat ttc aag cga ggc tct ggg cag agt gga cca cgg gga gcc Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala 675 680 685	2247
5	cca cga ggt aat att ttg tgg tgg tga tcctagctcc taagtggagc Pro Arg Gly Asn Ile Leu Trp Trp 690	2294
10	ttctgttctg gccttggaaag agctgttaat agtctgcattt ttaggaatac atttatcctt tccagacttg ttgcttaggaa ttaaatgaaa tgctctgttt ctaaaactta atcttggacc caaattttaa ttttgaatg atttaatttt ccctgttact atataaactg tcttggaaaac	2354 2414 2474
15	tagaacatat tctcttctca gaaaaagtgt ttttccaact gaaaattatt tttcaggtcc taaaaacctgc taaatgttt taggaagtac ttactgaaac attttgtaa gacattttg gaatgagatt gaacatttat ataaatttat tattcctctt tcatttttt gaaacatgcc	2534 2594 2654
20	tattatattt tagggccaga cacccttaa tggccgata agccatagt aacattaga gaaccattta gaagtgatag aactaatgga atttgcaatg cctttggac ctctattagt gatataaata tcaagttatt tctgactttt aaacaaaact cccaaattcc taacttattg	2714 2774 2834
25	agctataactt aaaaaaaatt acaggtttag agagttttt gttttcttt tactgttggaa aaactacttc ccattttggc aggaagttaa cctatttaac aatttagagct agcatttcatt gtagtctgaa attctaaatg gttctctgat ttgagggagg ttaaacatca aacaggtttc	2894 2954 3014
30	ctctattggc cataacatgt ataaaatgtg tgttaaggag gaattacaac gtactttgat ttgaataacta gtagaaactg gccaggaaaa aggtacattt ttctaaaaat taatggatca cttggaaatt actgacttga ctagaagtat caaaggatgt ttgcatgtga atgtgggta	3074 3134 3194
35	tgttcttcc cacctttagt catattcgat gaaagttgag ttaactgata gctaaaaatc tgtttaaca gcatgtaaaa agttattta tctgttaaaa gtcattatac agtttgaat gttatgttagt ttcttttaa cagtttaggt aataaggctt gtttcattt tggtgcttt	3254 3314 3374
40	attaaatttg atagtagat gttacttact actgaaatgt aagctagagt gtacactaga atgtaagctc catgagagca ggtacattgt ctgtcttctc tgctgtatct attccaaacg	3434 3494
45	cttgatgatg gtgcctggca catagtaggc actcaataaa tatttggatgaa atgaatgaa	3553
50	<210> 4 <211> 694 <212> PRT <213> Homo sapiens	
	<400> 4	

EP 2 740 796 B1

Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly  
1 5 10 15

5 Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala

10

15

20

25

30

35

40

45

50

55

20                    25                    30

5                    35                    40                    45

10

15                    20                    25                    30                    35                    40                    45                    50                    55                    60

65                    70                    75                    80

10                    15                    20                    25                    30                    35                    40                    45                    50                    55                    60                    65                    70                    75                    80

15                    20                    25                    30                    35                    40                    45                    50                    55                    60                    65                    70                    75                    80                    85                    90                    95

20                    25                    30                    35                    40                    45                    50                    55                    60                    65                    70                    75                    80                    85                    90                    95

25                    30                    35                    40                    45                    50                    55                    60                    65                    70                    75                    80                    85                    90                    95

30                    35                    40                    45                    50                    55                    60                    65                    70                    75                    80                    85                    90                    95

35                    40                    45                    50                    55                    60                    65                    70                    75                    80                    85                    90                    95

40                    45                    50                    55                    60                    65                    70                    75                    80                    85                    90                    95

45                    50                    55                    60                    65                    70                    75                    80                    85                    90                    95

50                    55                    60                    65                    70                    75                    80                    85                    90                    95

55                    60                    65                    70                    75                    80                    85                    90                    95

## EP 2 740 796 B1

Pro Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu  
 275 280 285

5 Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln  
 290 295 300

10 Phe Thr Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr  
 305 310 315 320

15 Val Glu Val Val Asn Ser Leu Gln Gln Pro Gln Ala Ala Ser Pro  
 325 330 335

20 Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ala Asp Pro  
 340 345 350

25 Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly  
 355 360 365

30 Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr  
 370 375 380

35 Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn  
 385 390 395 400

40 Met Asp Met Pro Gln Leu Val Cys Pro Pro Val His Ser Glu Ser Arg  
 405 410 415

45 Leu Ala Gln Pro Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val  
 420 425 430

50 Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu  
 435 440 445

55 Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Ile  
 450 455 460

Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala  
 465 470 475 480

Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly  
 485 490 495

50 Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro  
 500 505 510

55 Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro  
 515 520 525

Val Asn Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln Ala Ser  
 530 535 540

5 Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu  
 545 550 555 560

10 Leu Gln Gln Glu Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser  
 565 570 575

15 Pro Asp Gln Ser His Gln Val Thr Gly Asn His Gln Gln Pro Pro Gln  
 580 585 590

20 Gln Asn Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr Tyr Asn Ser Arg  
 595 600 605

25 Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly  
 610 615 620

30 Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg  
 625 630 635 640

35 Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser Gln Phe  
 645 650 655

40 Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln  
 660 665 670

45 Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg  
 675 680 685

40 Gly Asn Ile Leu Trp Trp  
 690

<210> 5  
 <211> 18  
 <212> PRT  
 45 <213> Homo sapiens

<400> 5

50 Val Phe Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr  
 1 5 10 15

Leu Lys

55 <210> 6  
 <211> 5  
 <212> PRT  
 <213> Mus musculus

&lt;400&gt; 6

Ser Tyr Gly Met Ser  
1 5

5

&lt;210&gt; 7

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

10

&lt;400&gt; 7

Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala  
1 5 10

15

&lt;210&gt; 8

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

20

&lt;400&gt; 8

Leu Ala Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln  
1 5 10

25

&lt;210&gt; 9

&lt;211&gt; 110

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

30

&lt;400&gt; 9

Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala  
1 5 10 15

35

Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met Ser Trp Val Arg Gln  
20 25 30

40

Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly  
35 40 45

45

Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser  
50 55 60

50

Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg  
65 70 75 80

55

Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Ser Leu Ala Ser Tyr Tyr  
85 90 95

55

Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser  
100 105 110

5  
 <210> 10  
 <211> 15  
 <212> PRT  
 <213> Mus musculus

10  
 <400> 10

11  
 Thr Met Thr Cys Gln Ala Ser Gln Gly Thr Ser Ile Asn Leu Asn  
 1 5 10 15

15  
 <210> 11  
 <211> 7  
 <212> PRT  
 <213> Mus musculus

20  
 <400> 11

21  
 Gly Ala Ser Ser Leu Glu Asp  
 1 5

25  
 <210> 12  
 <211> 11  
 <212> PRT  
 <213> Mus musculus

30  
 <400> 12

31  
 Leu Gln His Ser Tyr Leu Pro Pro Leu Thr Phe  
 1 5 10

35  
 <210> 13  
 <211> 113  
 <212> PRT  
 <213> Mus musculus

40  
 <400> 13

41  
 Gly Ala Arg Cys Asp Val Gln Met Ile Gln Ser Pro Ser Ser Leu Ser  
 1 5 10 15

42  
 Ala Ser Leu Gly Asp Ile Val Thr Met Thr Cys Gln Ala Ser Gln Gly  
 20 25 30

45  
 Thr Ser Ile Asn Leu Asn Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro  
 35 40 45

50  
 Lys Leu Leu Ile Tyr Gly Ala Ser Ser Leu Glu Asp Gly Val Pro Ser  
 50 55 60

55  
 Arg Phe Ser Gly Ser Cys Phe Gly Thr Asp Phe Thr Leu Thr Ile Ser  
 65 70 75 80

56  
 Ser Leu Glu Asp Glu Asp Met Ala Thr Tyr Phe Cys Leu Gln His Ser

## EP 2 740 796 B1

85 90 95

5           Tyr Leu Pro Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys  
                   100                   105                   110

**Arg**

10       <210> 14  
       <211> 330  
       <212> DNA  
       <213> Mus musculus

15       <400> 14

20       gggggaggct tagtgaagcc tggagggtcc ctgaaactct cctgtgcagc ctctggattc   60  
       actttcagta gctatggcat gtcttgggtt cgccagactc cggagaagag gctggagtgg   120  
       gtcgcaacca ttagtagtgg tggtagttac acctactatc cagacagtgt gaagggtcga   180  
       ttcaccatct ccagagacaa tgccaagaac accctgtacc tgcaaattgag cagtctgagg   240  

25       tctgaggaca cggccatgta ttactgtgca agcctggcct cctactactt tgactactgg   300  
       ggccaaggca ccactctcac agtctcctca                                   330

30       <210> 15  
       <211> 339  
       <212> DNA  
       <213> Mus musculus

35       <400> 15

40       ggtgcagat gtgatgtcca gatgattcag tctccatcct ccctgtctgc atcttggga   60  
       gacatagtca ccatgacttg ccaggcaagt cagggcacta gcattaattt aaactggttt   120  
       cagcaaaaac cagggaaagc tcctaagctc ctgatctatg gtgcaagcag cttggaaagat   180  
       gggtcccat caaggttcag tggcagttgt tttgggacag atttcactct caccatcagc   240  
       agcctggagg atgaagatat ggcaacttat ttctgtctac agcatagttt tctccctccg   300  

45       ctcacgttcg gtgctggac caagctggag ctgaaacgt                           339

50       <210> 16  
       <211> 5  
       <212> PRT  
       <213> Mus musculus

55       <400> 16

56           Thr Tyr Asp Leu His  
                   1                   5

57       <210> 17

<211> 16  
 <212> PRT  
 <213> Mus musculus

5 <400> 17

Val Ile Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe Ile Ser  
 1 5 10 15

10 <210> 18  
 <211> 11  
 <212> PRT  
 <213> Mus musculus

15 <400> 18

Asn Tyr Gly Tyr Ser Ala Trp Phe Ala Tyr Trp  
 1 5 10

20 <210> 19  
 <211> 111  
 <212> PRT  
 <213> Mus musculus

25 <400> 19

Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr  
 1 5 10 15

30 Val Ser Gly Phe Ser Leu Thr Thr Tyr Asp Leu His Trp Val Arg Gln  
 20 25 30

35 Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly  
 35 40 45

40 Ser Thr Asp Tyr Asn Ala Ala Phe Ile Ser Arg Leu Ser Ile Ser Lys  
 50 55 60

Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ala  
 65 70 75 80

45 Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Asn Tyr Gly Tyr Ser Ala  
 85 90 95

50 Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala  
 100 105 110

<210> 20  
 <211> 15  
 <212> PRT  
 <213> Mus musculus

<400> 20

Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser Asn  
1 5 10 15

5 <210> 21  
<211> 7  
<212> PRT  
<213> Mus musculus

10 <400> 21  
10

Lys Val Ser Asn Arg Phe Ser  
1 5

15 <210> 22  
<211> 9  
<212> PRT  
<213> Mus musculus

20 <400> 22  
20

Phe Gln Gly Ser His Val Pro Leu Thr  
1 5

25 <210> 23  
<211> 118  
<212> PRT  
<213> Mus musculus

30 <400> 23  
30

35

40

45

50

55

Pro Ala Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu  
 1 5 10 15

5 Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln  
 20 25 30

10 Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln  
 35 40 45

15 Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg  
 50 55 60

20 Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp  
 65 70 75 80

25 Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr  
 85 90 95

30 Tyr Cys Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr  
 100 105 110

Lys Leu Glu Leu Lys Arg  
 115

35 <210> 24  
 <211> 333  
 <212> DNA  
 <213> Mus musculus

40 <400> 24

45 ggacctggcc tagtgcagcc ctcacagagc ctgtccatca cctgcacagt ctctggttc 60  
 tcattgacta cctatgattt acactgggtt cgccagtctc cagggaaaggg tctggagtgg 120  
 ctgggagtga tatggagtgg tggaagcaca gactataatg cagcttcat atccagactg 180  
 agcatcagca aggacaattc caagagccaa gtttcttta aaatgaacag tctgcaagct 240  
 aatgacacag ccatatatta ctgtgccaga aactacggct actccgcctg gtttgcttac 300  
 tggggccaag ggactctggc cactgtctct gca 333

50 <210> 25  
 <211> 354  
 <212> DNA  
 <213> Mus musculus

55 <400> 25

## EP 2 740 796 B1

cctgcttcca gcagtgtatgt tttgatgacc caaactccac tctccctgcc tgcgttgtt 60  
 ggagatcaag cctccatctc ttgcagatct agtcagagca ttgtacatag taatggaaac 120  
 5 acctatccatgt aatggtacct gcagaaacca ggccagtcgc caaagctcct gatctacaaa 180  
 gtttccaacc gatttctgg ggtcccagac agttcagtg gcagtggatc agggacagat 240  
 10 ttcacactca agatcagcag agtggaggct gaggatctgg gagtttatta ctgcttcaa 300  
 ggttcacatg ttccgctcac gttcggtgct gggaccaagc tggagctgaa acgt 354

&lt;210&gt; 26

&lt;211&gt; 148

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 26

20 Met Glu Trp Ser Gly Val Phe Ile Phe Leu Leu Ser Gly Thr Ala Gly  
 1 5 10 15

25 Val Leu Ser Glu Val Gln Leu His Gln Phe Gly Ala Glu Leu Val Lys  
 20 25 30

30 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe  
 35 40 45

35 Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu  
 50 55 60

40 Glu Trp Ile Gly Asp Ile Asn Pro Asn Tyr Asp Ser Thr Ser Tyr Asn  
 65 70 75 80

Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser  
 85 90 95

45 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val  
 100 105 110

Tyr Tyr Cys Ala Arg Ser Arg Ser Tyr Asp Tyr Glu Gly Phe Ala Tyr  
 115 120 125

50 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro  
 130 135 140

55 Pro Ser Val Tyr  
 145

&lt;210&gt; 27

&lt;211&gt; 139

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 27

5           Met Ser Val Leu Thr Gln Val Leu Gly Leu Leu Leu Leu Trp Leu Thr  
       1                       5                                   10                           15

10           Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser  
       20   25                                   30

15           Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn  
       35   40                                   45

20           Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro  
       50   55                                   60

25           Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser  
       65   70                                   75                                   80

30           Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn  
       85   90                                   95

35           Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp  
       100   105                                   110

40           Ser Thr Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala  
       115   120                                   125

45           Asp Ala Ala Pro Thr Val Ser Asn Pro Tyr Asp  
       130   135

&lt;210&gt; 28

&lt;211&gt; 148

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 28

45

50

55

Met Glu Trp Ser Gly Val Phe Ile Phe Leu Leu Ser Gly Thr Ala Gly  
 1 5 10 15

5 Val Leu Ser Glu Val Gln Leu His Gln Phe Gly Ala Glu Leu Val Lys  
 20 25 30

10 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe  
 35 40 45

15 Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu  
 50 55 60

Glu Trp Ile Gly Asp Ile Asn Pro Asn Tyr Asp Ser Thr Ser Tyr Asn  
 65 70 75 80

20 Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser  
 85 90 95

25 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val  
 100 105 110

30 Tyr Tyr Cys Ala Arg Ser Arg Ser Tyr Asp Tyr Glu Gly Phe Ala Tyr  
 115 120 125

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro  
 130 135 140

35 Pro Ser Val Tyr  
 145

<210> 29

<211> 132

40 <212> PRT

<213> Mus musculus

<400> 29

45 Ala Val Leu Arg Cys Ser Arg Gly Leu Leu Val Ile Trp Ile Ser Asp  
 1 5 10 15

50 Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ala Val Thr Ala Gly Glu  
 20 25 30

Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Trp Ser Val  
 35 40 45

5 Asn Gln Lys Asn Tyr Leu Ser Trp Tyr Gln Gln Lys Gln Arg Gln Pro  
 50 55 60

10 Pro Lys Leu Leu Ile Tyr Gly Ala Ser Ile Arg Glu Ser Trp Val Pro  
 65 70 75 80

15 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile  
 85 90 95

Ser Asn Val His Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln His Asn  
 100 105 110

20 His Gly Ser Phe Leu Pro Ser Arg Ser Glu Gln Val Pro Ser Trp Arg  
 115 120 125

25 Ser Asn Asn Arg  
 130

<210> 30

<211> 148

<212> PRT

30 <213> Mus musculus

<400> 30

35 Met Glu Trp Ser Gly Val Phe Ile Phe Leu Leu Ser Gly Thr Ala Gly  
 1 5 10 15

40 Val Leu Ser Glu Val Gln Leu His Gln Phe Gly Ala Glu Leu Val Lys  
 20 25 30

45 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe  
 35 40 45

50 Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu  
 50 55 60

55 Glu Trp Ile Gly Asp Ile Asn Pro Asn Tyr Asp Ser Thr Ser Tyr Asn  
 65 70 75 80

Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser  
 85 90 95

55 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val  
 100 105 110

Tyr Tyr Cys Ala Arg Ser Arg Ser Tyr Asp Tyr Glu Gly Phe Ala Tyr  
 115 120 125

5 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro  
 130 135 140

10 Pro Ser Val Tyr  
 145

15 <210> 31  
 <211> 117  
 <212> PRT  
 <213> Mus musculus

<400> 31

20 Arg Thr Thr Ser His Met Asp Ser Asp Ile Gln Leu Thr Gln Ser Pro  
 1 5 10 15

25 Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg  
 20 25 30

30 Ala Ser Gly Asn Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln  
 35 40 45

35 Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp  
 50 55 60

40 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser  
 65 70 75 80

45 Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys  
 85 90 95

50 Gln His Phe Trp Ser Thr Leu Thr Phe Gly Gly Thr Lys Leu Glu  
 100 105 110

55 Ile Lys Gln Ser Asp  
 115

50 <210> 32  
 <211> 148  
 <212> PRT  
 <213> Mus musculus

<400> 32

55 Met Glu Trp Ser Gly Val Phe Ile Phe Leu Leu Ser Gly Thr Ala Gly  
 1 5 10 15

Val Leu Ser Glu Val Gln Leu His Gln Phe Gly Ala Glu Leu Val Lys  
 20 25 30

5 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe  
 35 40 45

10 Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu  
 50 55 60

15 Glu Trp Ile Gly Asp Ile Asn Pro Asn Tyr Asp Ser Thr Ser Tyr Asn  
 65 70 75 80

Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser  
 85 90 95

20 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val  
 100 105 110

25 Tyr Tyr Cys Ala Arg Ser Arg Ser Tyr Asp Tyr Glu Gly Phe Ala Tyr  
 115 120 125

30 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro  
 130 135 140

Pro Ser Val Tyr  
 145

35 <210> 33  
 <211> 94  
 <212> PRT  
 <213> Mus musculus

40 <400> 33

Ser Gly Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser  
 1 5 10 15

45 Asn Tyr Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu  
 20 25 30

50 Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe  
 35 40 45

Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val  
 50 55 60

55 Glu Thr Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Ser Trp  
 65 70 75 80

Pro Tyr Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys Gln  
 85 90

5 <210> 34

<211> 148

<212> PRT

<213> Mus musculus

10 <400> 34

Met Glu Trp Ser Gly Val Phe Ile Phe Leu Leu Ser Gly Thr Ala Gly  
 1 5 10 15

15 Val Leu Ser Glu Val Gln Leu His Gln Phe Gly Ala Glu Leu Val Lys  
 20 25 30

20 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe  
 35 40 45

25 Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu  
 50 55 60

25 Glu Trp Ile Gly Asp Ile Asn Pro Asn Tyr Asp Ser Thr Ser Tyr Asn  
 65 70 75 80

30 Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser  
 85 90 95

35 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val  
 100 105 110

40 Tyr Tyr Cys Ala Arg Ser Arg Ser Tyr Asp Tyr Glu Gly Phe Ala Tyr  
 115 120 125

40 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro  
 130 135 140

45 Pro Ser Val Tyr  
 145

50 <210> 35

<211> 105

<212> PRT

<213> Mus musculus

55 <400> 35

EP 2 740 796 B1

Gly Leu Phe Cys Ser Val Glu Arg Cys His Tyr Gln Leu Gln Ser Ser  
1 5 10 15

5 Gln Asn Leu Leu Ser Ile Val Asn Arg Tyr His Tyr Met Ser Gly Asn

20 25 30

10 Pro Pro Lys Leu Leu Val Tyr Pro Ala Leu Leu Ile Tyr Glu Ala Ser  
35 40 45

15 Ile Thr Lys Ser Cys Val Pro Asp Arg Phe Thr Arg Ser Gly Ser Gly  
50 55 60

20 Thr Asn Phe Thr Leu Thr Ile Asn Phe Val His Ala Asp Asp Leu Ile  
65 70 75 80

25 Phe Tyr Tyr Cys Gln His Asn Arg Gly Ser Phe Leu Pro Ser Ser Ser  
85 90 95

30 Val Gln Val Pro Arg Arg Arg Ser Asn  
100 105

<210> 36

<211> 100

30 <212> PRT

<213> Mus musculus

<400> 36

35

40

45

50

55

Asp Ile Leu Gln Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Thr Met Asn  
 1 5 10 15

5 Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Ile Gly Leu Ile  
 20 25 30

10 Asn Pro Tyr Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys  
 35 40 45

15 Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu  
 50 55 60

Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Trp  
 65 70 75 80

20 Gly Val Trp Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr  
 85 90 95

25 Val Ser Ser Lys  
 100

<210> 37

<211> 90

<212> PRT

30 <213> Mus musculus

<400> 37

35 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala  
 1 5 10 15

40 Val Ala Trp Tyr Gln Gln Lys Pro Arg Gln Ser Pro Lys Ala Leu Ile  
 20 25 30

Tyr Leu Ala Ser Asn Arg Asp Thr Gly Leu Pro Asp Arg Phe Pro Gly  
 35 40 45

45 Arg Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile Thr Asn Val Gln Ser  
 50 55 60

50 Glu Asp Leu Glu Asp Tyr Phe Cys Leu Gln His Cys Asn Tyr Pro Asn  
 65 70 75 80

55 Glu Phe Arg Gly Cys Thr Lys Val Pro Ile  
 85 90

<210> 38

<211> 116

<212> PRT

<213> *Mus musculus*

<400> 38

5 Leu Gln Glu Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val Lys  
1 5 10 15

10 Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met Gln  
 20 25 30

Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile  
 35 40 45

15

Tyr Pro Gly Asp Gly Asp Thr Arg Tyr Thr Gln Lys Phe Lys Gly Lys  
 50 55 60

20

Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu

Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly  
85 90 95

30

Glu Tyr Gly Asn Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr  
100 105 110

30

Val Ser Ser Asn  
115

35

<210> 39

<211> 100

<212> PRT

<213> *Mus musculus*

40

58

55

Thr Ser Asp Ala Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala  
 1 5 10 15

5 Ser Gln Asp Ile Asn Ser Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly  
 20 25 30

10 Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly  
 35 40 45

15 Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu  
 50 55 60

Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys Leu  
 65 70 75 80

20 Gln Tyr Asp Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu  
 85 90 95

25 Ile Lys Gln Lys  
 100

<210> 40

<211> 108

<212> PRT

30 <213> Mus musculus

<400> 40

35 Ala Trp Leu Ser Gln Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys  
 1 5 10 15

40 Asp Thr Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu  
 20 25 30

Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro  
 35 40 45

45 Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr  
 50 55 60

50 Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr  
 65 70 75 80

55 Tyr Cys Ala Arg Pro Ile His Tyr Tyr Tyr Gly Ser Ser Leu Ala Tyr  
 85 90 95

55 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Lys  
 100 105

<210> 41  
 <211> 104  
 <212> PRT  
 <213> Mus musculus

5

&lt;400&gt; 41

10

Glu Phe His Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg  
 1 5 10 15

15

Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr  
 20 25 30

20

Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser  
 35 40 45

25

Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg  
 50 55 60

25

Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala  
 65 70 75 80

25

Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Gly Arg Ser Glu Val  
 85 90 95

30

Val Pro Ser Trp Arg Ser Asn Lys  
 100

35

<210> 42  
 <211> 109  
 <212> PRT  
 <213> Mus musculus

40

&lt;400&gt; 42

40

Pro Arg Ala Ser Leu Gly Val Ser Glu Thr Leu Leu Cys Thr Ser Gly  
 1 5 10 15

45

Phe Thr Phe Thr Asp Tyr Tyr Met Ser Trp Val Arg Gln Pro Pro Gly  
 20 25 30

50

Lys Ala Leu Glu Trp Leu Gly Phe Ile Arg Asn Lys Ala Asn Gly Tyr  
 35 40 45

55

Thr Thr Glu Tyr Ser Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg  
 50 55 60

5 Asp Asn Ser Gln Ser Ile Leu Tyr Leu Gln Met Asn Thr Leu Arg Ala  
 65 70 75 80

10 Glu Asp Ser Ala Thr Tyr Tyr Cys Ala Arg Ala Asn Trp Ala Phe Asp  
 85 90 95

Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Lys  
 100 105

15 <210> 43  
 <211> 94  
 <212> PRT  
 <213> Mus musculus  
 20 <400> 43

25 Ser Gly Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser  
 1 5 10 15

Asn Tyr Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu  
 20 25 30

30 Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe  
 35 40 45

35 Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val  
 50 55 60

40 Glu Thr Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Ser Trp  
 65 70 75 80

Pro Tyr Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Gln  
 85 90

45 <210> 44  
 <211> 111  
 <212> PRT  
 <213> Mus musculus  
 50 <400> 44

Pro Ala Cys Leu Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser  
 1 5 10 15

5 Gly Phe Thr Phe Thr Asp Tyr Tyr Met Ser Trp Val Arg Gln Pro Pro  
 20 25 30

10 Gly Lys Ala Leu Glu Trp Leu Gly Phe Ile Arg Asn Lys Ala Asn Gly  
 35 40 45

15 Tyr Thr Thr Glu Tyr Ser Ala Ser Val Lys Gly Arg Phe Thr Ile Ser  
 50 55 60

20 Arg Asp Asn Ser Gln Ser Ile Leu Tyr Leu Gln Met Asn Thr Leu Arg  
 65 70 75 80

25 Ala Glu Asp Ser Ala Thr Tyr Tyr Cys Ala Arg Ala Pro Leu Leu Tyr  
 85 90 95

Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser  
 100 105 110

30 <210> 45  
 <211> 102  
 <212> PRT  
 <213> Mus musculus

35 <400> 45

40

45

50

55

Arg Leu Pro Phe Tyr Ser Leu Glu Gln Arg Ala Thr Ile Ser Tyr Arg  
 1 5 10 15

5 Ala Ser Lys Asn Val Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Asn  
 20 25 30

10 Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Val Ser  
 35 40 45

15 Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly  
 50 55 60

Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala  
 65 70 75 80

20 Thr Tyr Tyr Cys Gln His Ile Arg Glu Leu Thr Arg Ser Glu Leu Val  
 85 90 95

25 Pro Ser Trp Lys Ser Asn  
 100

<210> 46

<211> 101

<212> PRT

30 <213> Mus musculus

<400> 46

35 Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His  
 1 5 10 15

Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile  
 20 25 30

40 Asp Pro Ser Asn Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Lys  
 35 40 45

45 Ala Thr Leu Asn Val Asp Lys Ser Ser Asn Thr Ala Tyr Met Gln Leu  
 50 55 60

50 Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly  
 65 70 75 80

Leu Arg His Tyr Trp Tyr Phe Asp Val Trp Gly Gln Gly Thr Thr Val  
 85 90 95

55 Thr Val Ser Ser Lys  
 100

<210> 47  
 <211> 99  
 <212> PRT  
 <213> Mus musculus

5

&lt;400&gt; 47

10

Thr	Ile	Leu	Trp	Arg	Glu	Gly	Pro	Phe	Ser	Tyr	Arg	Ala	Ser	Lys	Ser
1															15

10

Val	Ser	Thr	Ser	Gly	Tyr	Ser	Tyr	Met	His	Trp	Asn	Gln	Gln	Lys	Pro
															30

15

Gly	Gln	Pro	Pro	Arg	Leu	Leu	Ile	Tyr	Leu	Val	Ser	Asn	Leu	Glu	Ser
															45

20

Gly	Val	Pro	Ala	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr
															60

25

Leu	Asn	Ile	His	Pro	Val	Glu	Glu	Asp	Ala	Ala	Thr	Tyr	Tyr	Cys
65						70					75			80

25

Gln	His	Ile	Arg	Glu	Leu	Thr	Arg	Ser	Glu	Glu	Val	Pro	Ser	Trp	Arg
															95

30

Ser Asn Lys

35

<210> 48  
 <211> 330  
 <212> PRT  
 <213> Homo sapiens

40

&lt;400&gt; 48

45

50

55

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys  
 1 5 10 15

5 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr  
 20 25 30

10 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser  
 35 40 45

15 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser  
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr  
 65 70 75 80

20 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys  
 85 90 95

25 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys  
 100 105 110

30 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro  
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys  
 130 135 140

35 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp  
 145 150 155 160

40 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu  
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu  
 180 185 190

45 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn  
 195 200 205

50 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly  
 210 215 220

55 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu  
 225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr  
 245 250 255

5 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn  
 260 265 270

10 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe  
 275 280 285

15 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn  
 290 295 300

20 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr  
 305 310 315 320

25 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
 325 330

<210> 49

<211> 106

25 <212> PRT

<213> Homo sapiens

<400> 49

30 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln  
 1 5 10 15

35 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr  
 20 25 30

40 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser  
 35 40 45

45 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr  
 50 55 60

50 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys  
 65 70 75 80

55 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro  
 85 90 95

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys  
 100 105

55

<210> 50

<211> 11

<212> PRT

EP 2 740 796 B1

<213> *Mus musculus*

<400> 50

5 Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn  
   1           5                           10

<210> 51

<211> 7

10 <212> PRT

<213> *Mus musculus*

<400> 51

15 Trp Ala Ser Thr Arg Glu Ser  
1 5

<210> 52

<211> 9

20 <212> PRT

<213> *Mus musculus*

<400> 52

25 Gln Gln Tyr Tyr Ser Tyr Pro Phe Thr  
1 5

<210> 53

<211> 115

30 <212> PRT

<213> *Mus musculus*

<400> 53

35 Gly Val Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Leu  
1 5 10 15

Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly  
35 40 45

Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly  
50 55 60

50 Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu  
65 70 75 80

55           Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln  
                          85                   90                   95

Gln Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu

EP 2 740 796 B1

100 105 110

Ile Lys Arg  
115

<210> 54  
<211> 345  
<212> DNA  
<213> *Mus musculus*

<400> 54

15	ggggtcattg tgatgtcaca gtctccatcc tccctagctg tgtcaattgg agagaaggtt	60
	actatgagct gcaagtccag tcagagcctt ttatatagtt gcaatcaaaa gaactacttg	120
	gcctggtacc agcagaaaacc agggcagtct cctaaactgc tgatttactg ggcatccact	180
20	aggaaatctg gggccctga tcgcttcaca ggcagtggat ctgggacaga tttcactctc	240
	accatcagca gtgtgaaggc tgaagacctg gcagtttatt actgtcagca atattatacg	300
	tatccattca cattcgqgctc qqqgacaaaq ttqgaaataa aacgt	345

25                    <210> 55  
                  <211> 4  
                  <212> PRT  
                  <213> *Gallus gallus*

30                    <400> 55

His Ser Met Phe  
1

35 <210> 56  
<211> 17  
<212> PRT  
<213> *Gallus gallus*

40 <400> 56

Gly Ile Tyr Gly Val Gly Arg Ser Ile Arg Tyr Gly Ser Ala Val Lys  
1 5 10 15

G1v

50      <210> 57  
       <211> 20  
       <212> PRT  
       <213> *Gallus gallus*

      <400> 57

Ser Gly Tyr Phe Ser Asn Ser Arg Tyr Trp Asp Ser Gly Ala Tyr Phe  
1 5 10 15

EP 2 740 796 B1

Ile Asp Ala Trp  
20

5 <210> 58  
<211> 127  
<212> PRT  
<213> Gallus gallus

10 <400> 58

Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly  
1 5 10 15

15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Arg Ser His  
20 25 30

20 Ser Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val  
35 40 45

25 Ala Gly Ile Tyr Gly Val Gly Arg Ser Ile Arg Tyr Gly Ser Ala Val  
50 55 60

55 Lys Gly Arg Ala Thr Met Ser Arg Asp Asn Gly Gln Ser Thr Val Arg  
65 70 75 80

30 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Ala Thr Tyr Tyr Cys  
85 90 95

35 Ala Lys Ser Gly Tyr Phe Ser Asn Ser Arg Tyr Trp Asp Ser Gly Ala  
100 105 110

40 Tyr Phe Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile Val Ser  
115 120 125

45 <210> 59  
<211> 8  
<212> PRT  
<213> Gallus gallus

45 <400> 59

50 Ser Gly Gly Tyr Ser Asn Tyr Gly  
1 5

55 <210> 60  
<211> 7  
<212> PRT  
<213> Gallus gallus

55 <400> 60

Tyr Asn Asp Lys Arg Pro Ser  
1 5

5 <210> 61  
<211> 12  
<212> PRT  
<213> Gallus gallus

10 <400> 61  
10

Gly Gly Tyr Asp Ser Ser Thr Asp Ala Gly Ile Phe  
1 5 10

15 <210> 62  
<211> 103  
<212> PRT  
<213> Gallus gallus

20 <400> 62  
20

Ala Leu Thr Gln Pro Ala Ser Val Ser Ala Asn Pro Gly Glu Thr Val  
1 5 10 15

25 Glu Ile Thr Cys Ser Gly Gly Tyr Ser Asn Tyr Gly Trp Tyr Gln Gln  
20 25 30

30 Lys Ser Pro Gly Ser Ala Pro Val Thr Val Ile Tyr Tyr Asn Asp Lys  
35 40 45

35 Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ser Lys Ser Gly Ser  
50 55 60

35 Thr Ala Thr Leu Thr Ile Thr Gly Val Gln Ala Glu Asp Glu Ala Val  
65 70 75 80

40 Tyr Phe Cys Gly Gly Tyr Asp Ser Ser Thr Asp Ala Gly Ile Phe Gly  
85 90 95

45 Ala Gly Thr Thr Leu Thr Val  
100

50 <210> 63  
<211> 127  
<212> PRT  
<213> Gallus gallus

<400> 63

Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly  
 1 5 10 15

5 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Arg Ser His  
 20 25 30

10 Ser Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val  
 35 40 45

Ala Gly Ile Tyr Gly Val Gly Arg Ser Ile Arg Tyr Gly Ser Ala Val  
 50 55 60

15 Lys Gly Arg Ala Thr Met Ser Arg Asp Asn Gly Gln Ser Thr Val Arg  
 65 70 75 80

20 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr Tyr Cys  
 85 90 95

25 Ala Lys Ser Gly Tyr Phe Ser Asn Arg Arg Tyr Trp Asp Ser Gly Ala  
 100 105 110

Tyr Phe Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile Val Ser  
 115 120 125

30 <210> 64  
 <211> 7  
 <212> PRT  
 <213> Gallus gallus

35 <400> 64

Glu Asn Asp Lys Arg Pro Ser  
 1 5

40 <210> 65  
 <211> 103  
 <212> PRT  
 <213> Gallus gallus

45 <400> 65

50

55

EP 2 740 796 B1

Ala Leu Thr Gln Pro Ala Ser Val Ser Ala Asn Leu Gly Gly Thr Val  
1 5 10 15

5 Glu Ile Thr Cys Ser Gly Gly Tyr Ser Asn Tyr Gly Trp Tyr Gln Gln  
20 25 30

10 Lys Ser Pro Gly Ser Ala Pro Val Thr Val Ile Tyr Tyr Asn Asp Lys  
35 40 45

15 Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ser Lys Ser Gly Ser  
50 55 60

Thr Gly Thr Leu Thr Ile Thr Gly Val Arg Ala Glu Asp Glu Ala Val  
65 70 75 80

20 Tyr Tyr Cys Gly Gly Tyr Asp Ser Ser Thr Asp Ala Gly Ile Phe Gly  
85 90 95

25 Ala Gly Thr Thr Leu Thr Val  
100

<210> 66

<211> 4

30 <212> PRT

<213> Gallus gallus

<400> 66

35 Phe Gly Met Phe  
1

<210> 67

<211> 17

40 <212> PRT

<213> Gallus gallus

<400> 67

45 Ser Ile Ser Asp Asn Gly Arg Ser Thr Tyr Tyr Gly Ser Ala Val Lys  
1 5 10 15

50 Gly

<210> 68

<211> 17

<212> PRT

<213> Gallus gallus

55 <400> 68

Asn Ala Tyr Val Gly Arg Gly Cys Cys Phe Ser Tyr Ser Ile Asp Ala  
 1 5 10 15

5 Trp

<210> 69

<211> 124

<212> PRT

10 <213> Gallus gallus

<400> 69

15 Ala Val Thr Leu Asp Glu Ser Gly Gly Leu Gln Thr Pro Gly Gly  
 1 5 10 15

Gly Leu Ser Leu Val Cys Lys Gly Ser Gly Phe Thr Phe Ser Ser Phe  
 20 25 30

20

Gly Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Phe Val  
 35 40 45

25

Ala Ser Ile Ser Asp Asn Gly Arg Ser Thr Tyr Tyr Gly Ser Ala Val  
 50 55 60

30

Lys Gly Arg Ala Thr Ile Ser Arg Asp Asp Gly Gln Ser Thr Val Arg  
 65 70 75 80

35

Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr Tyr Cys  
 85 90 95

35

Ala Lys Asn Ala Tyr Val Gly Arg Gly Cys Cys Phe Ser Tyr Ser Ile  
 100 105 110

40

Asp Ala Trp Gly His Gly Thr Glu Val Ile Val Ser  
 115 120

<210> 70

<211> 11

45 <212> PRT

<213> Gallus gallus

<400> 70

50

Ser Gly Gly Ser Ser Ser Asp Ala Tyr Gly  
 1 5 10

<210> 71

<211> 7

55 <212> PRT

<213> Gallus gallus

<400> 71

Asn Gly Ser Asn Arg Pro Ser  
1 5

5 <210> 72  
<211> 12  
<212> PRT  
<213> Gallus gallus

10 <400> 72  
10

Gly Ser Thr Asp Thr Ser Thr Ser Val Gly Ile Phe  
1 5 10

15 <210> 73  
<211> 106  
<212> PRT  
<213> Gallus gallus

20 <400> 73  
20

Ala Leu Thr Gln Pro Ala Ser Val Ser Val Asn Pro Gly Glu Thr Val  
1 5 10 15

25 Lys Ile Thr Cys Ser Gly Gly Ser Ser Ser Asp Ala Tyr Gly Trp  
20 25 30

30 Tyr Gln Gln Lys Ser Pro Gly Ser Ala Pro Val Thr Leu Ile Tyr Asn  
35 40 45

35 Gly Ser Asn Arg Pro Ser His Ile Pro Ser Arg Phe Ser Gly Ser Thr  
50 55 60

35 Ser Gly Ser Thr Asn Thr Leu Thr Ile Thr Gly Val Gln Val Glu Asp  
65 70 75 80

40 Glu Ala Ile Tyr Phe Cys Gly Ser Thr Asp Thr Ser Thr Ser Val Gly  
85 90 95

45 Ile Phe Gly Ala Gly Thr Thr Leu Thr Val  
100 105

45 <210> 74  
<211> 4  
<212> PRT  
<213> Gallus gallus

<400> 74

55 Tyr Gly Met Gly  
1

<210> 75  
<211> 16

&lt;212&gt; PRT

&lt;213&gt; Gallus gallus

&lt;400&gt; 75

5

Ala	Ile	Arg	Lys	Asp	Gly	Ser	Thr	Asn	Tyr	Gly	Pro	Ala	Val	Lys	Gly
1				5					10					15	

&lt;210&gt; 76

10

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Gallus gallus

&lt;400&gt; 76

15

Arg	Ser	His	Thr	Gly	Val	Asn	Ala	Ala	Lys	Ile	Asp	Ala	Trp
1				5					10				

&lt;210&gt; 77

20

&lt;211&gt; 120

&lt;212&gt; PRT

&lt;213&gt; Gallus gallus

&lt;400&gt; 77

25

Ala	Val	Thr	Leu	Asp	Glu	Ser	Gly	Gly	Gly	Leu	Gln	Thr	Pro	Gly	Gly
1					5				10					15	

30

Ala	Val	Ser	Leu	Val	Cys	Lys	Gly	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
					20				25					30	

35

Gly	Met	Gly	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Tyr	Val
					35				40				45		

40

Ala	Ala	Ile	Arg	Lys	Asp	Gly	Ser	Thr	Asn	Tyr	Gly	Pro	Ala	Val	Lys
					50				55				60		

Gly	Arg	Ala	Thr	Ile	Ser	Arg	Asp	Asn	Gly	Gln	Ser	Thr	Val	Arg	Leu
					65				70				75		80

45

Gln	Leu	Ser	Asn	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Thr	Tyr	Tyr	Cys	Ala
					85				90				95		

50

Lys	Arg	Ser	His	Thr	Gly	Val	Asn	Ala	Ala	Lys	Ile	Asp	Ala	Trp	Gly
					100				105				110		

55

Arg	Gly	Thr	Glu	Val	Ile	Val	Ser
					115		120

&lt;210&gt; 78

&lt;211&gt; 8

&lt;212&gt; PRT

EP 2 740 796 B1

<213> Gallus gallus

<400> 78

5 Ser Gly Ala Ser His Asn Tyr Gly  
1 5

<210> 79

<211> 7

10 <212> PRT  
<213> Gallus gallus

<400> 79

15 Ser Asn Asp Lys Arg Pro Ser  
1 5

<210> 80

<211> 10

20 <212> PRT  
<213> Gallus gallus

<400> 80

25 Gly Gly Tyr Asn Ile Tyr Gly Pro Thr Phe  
1 5 10

<210> 81

<210> 01

30 <212> PRT  
<213> Gallus gallus

<400> 81

35

40

45

50

55

Ala Leu Thr Gln Pro Ala Ser Val Ser Ala Asn Pro Gly Glu Thr Val  
 1 5 10 15

5 Lys Ile Thr Cys Ser Gly Ala Ser His Asn Tyr Gly Trp Phe Gln Gln  
 20 25 30

10 Lys Ser Pro Gly Ser Ala Pro Val Thr Val Ile Tyr Ser Asn Asp Lys  
 35 40 45

15 Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ser Lys Ser Gly Ser  
 50 55 60

20 Thr Ala Thr Leu Thr Ile Thr Gly Val Gln Ala Asp Asp Glu Ala Val  
 65 70 75 80

25 Tyr Phe Cys Gly Gly Tyr Asn Ile Tyr Gly Pro Thr Phe Gly Ala Gly  
 85 90 95

30 Thr Thr Leu Thr Val  
 100

### Claims

- 30 1. An antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5.
2. The antibody or the fragment thereof according to claim 1, wherein the antibody or the fragment thereof has cytotoxic activity against a cancer cell expressing a CAPRIN-1 protein.
- 35 3. The antibody or the fragment thereof according to claim 1 or 2, wherein the antibody is a monoclonal antibody.
4. The antibody or the fragment thereof according to claim 1 or 2, wherein the antibody is a polyclonal antibody.
- 40 5. The antibody or the fragment thereof according to any one of claims 1 to 4, wherein the antibody is a human antibody, a humanized antibody, a chimeric antibody, a single-chain antibody, or a multispecific antibody.
6. The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 10, 11, and 12 and has immunological reactivity with the CAPRIN-1 protein.
7. The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 16, 17, and 18 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 20, 21, and 22 and has immunological reactivity with the CAPRIN-1 protein.
- 55 8. The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 6, 7, and 8 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 50, 51, and 52 and has immunological reactivity with the CAPRIN-1 protein.
9. The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain

variable region comprising complementarity determining regions of SEQ ID NOs: 55, 56, and 57 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 59, 60, and 61 and has immunological reactivity with the CAPRIN-1 protein.

5       **10.** The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 55, 56, and 57 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 59, 64, and 61 and has immunological reactivity with the CAPRIN-1 protein.

10      **11.** The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 66, 67, and 68 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 70, 71, and 72 and has immunological reactivity with the CAPRIN-1 protein.

15      **12.** The antibody or the fragment thereof according to any one of claims 1 to 3 or 5, which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 74, 75, and 76 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 78, 79, and 80 and has immunological reactivity with the CAPRIN-1 protein.

20      **13.** The antibody or the fragment thereof according to any one of claims 1 to 12, wherein the antibody or the fragment thereof is conjugated with an antitumor agent.

25      **14.** The antibody or the fragment thereof according to any preceding claim, for use in a method for treating and/or preventing cancer.

30      **15.** The antibody or the fragment thereof for use according to claim 14, wherein the cancer is breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.

35      **16.** A pharmaceutical composition comprising the antibody or the fragment thereof according to any one of claims 1 to 13 as an active ingredient.

40      **17.** The pharmaceutical composition according to claim 16, for use in a method for treating and/or preventing cancer.

45      **18.** The pharmaceutical composition for use according to claim 17, wherein the cancer is breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.

50      **19.** A pharmaceutical combination comprising a pharmaceutical composition according to claim 16 and a pharmaceutical composition comprising an antitumor agent.

55      **20.** The pharmaceutical combination according to claim 19, for use in a method for treating and/or preventing cancer.

60      **21.** The pharmaceutical combination for use according to claim 20, wherein the cancer is breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.

65      **22.** A DNA encoding the antibody or the fragment thereof according to any one of claims 1 to 12.

#### Patentansprüche

55      **1.** Antikörper oder Fragment davon mit immunologischer Reaktivität mit einem CAPRIN-1-Teilpolypeptid, das aus der durch Seq.-ID Nr. 5 dargestellten Aminosäuresequenz besteht.

2. Antikörper oder Fragment davon nach Anspruch 1, wobei der Antikörper oder das Fragment davon zytotoxische Aktivität gegen eine Krebszelle aufweist, die ein CAPRIN-1-Protein exprimiert.
3. Antikörper oder Fragment davon nach Anspruch 1 oder 2, wobei der Antikörper ein monoklonaler Antikörper ist.
4. Antikörper oder Fragment davon nach Anspruch 1 oder 2, wobei der Antikörper ein polyklonaler Antikörper ist.
5. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 4, wobei der Antikörper ein menschlicher Antikörper, ein humanisierter Antikörper, ein chimärer Antikörper, ein einkettiger Antikörper oder ein multispezifischer Antikörper ist.
10. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerkettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 6, 7 und 8 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 10, 11 und 12 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
15. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerkettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 16, 17 und 18 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 20, 21 und 22 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
20. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerkettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 6, 7 und 8 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 50, 51 und 52 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
25. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerkettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 55, 56 und 57 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 59, 60 und 61 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
30. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerkettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 55, 56 und 57 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 59, 64 und 61 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
35. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerkettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 66, 67 und 68 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 70, 71 und 72 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
40. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerkettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 74, 75 und 76 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 78, 79 und 80 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
45. Antikörper oder Fragment davon nach einem der Ansprüche 1 bis 3 oder 5, der/das eine variable Schwerkettenregion, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 74, 75 und 76 umfasst, und eine variable Leichtkettenregion umfasst, die komplementaritätsbestimmende Regionen der Seq.-ID Nr. 78, 79 und 80 umfasst, und immunologische Reaktivität mit dem CAPRIN-1-Protein aufweist.
50. Antikörper oder Fragment davon nach einem der vorangegangenen Ansprüche zur Verwendung in einem Verfahren zur Behandlung und/oder Prävention von Krebs.
55. Antikörper oder Fragment davon zur Verwendung nach Anspruch 14, wobei der Krebs Brustkrebs, Nierenkrebs, Pankreaskrebs, Kolorektalkrebs, Lungenkrebs, Hirntumor, Magenkrebs, Gebärmutterhalskrebs, Ovarialkrebs, Prostatakrebs, Harnblasenkrebs, Ösophaguskrebs, Leukämie, ein Lymphom, ein Fibrosarkom, ein Mastozytom oder ein Melanom ist.
60. Pharmazeutische Zusammensetzung, die einen Antikörper oder ein Fragment davon nach einem der Ansprüche 1

bis 13 als Wirkbestandteil umfasst.

17. Pharmazeutische Zusammensetzung nach Anspruch 16 zur Verwendung in einem Verfahren zur Behandlung und/oder Prävention von Krebs.

5 18. Pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 17, wobei der Krebs Brustkrebs, Nierenkrebs, Pankreaskrebs, Kolorektalkrebs, Lungenkrebs, Hirntumor, Magenkrebs, Gebärmutterhalskrebs, Ovarialkrebs, Prostatakrebs, Harnblasenkrebs, Ösophaguskrebs, Leukämie, ein Lymphom, ein Fibrosarkom, ein Mastozytom oder ein Melanom ist.

10 19. Pharmazeutische Kombination, die eine pharmazeutische Zusammensetzung nach Anspruch 16 und eine pharmazeutische Zusammensetzung umfasst, die ein Antitumormittel umfasst.

15 20. Pharmazeutische Kombination nach Anspruch 19 zur Verwendung in einem Verfahren zur Behandlung und/oder Prävention von Krebs.

20 21. Pharmazeutische Kombination zur Verwendung nach Anspruch 20, wobei der Krebs Brustkrebs, Nierenkrebs, Pankreaskrebs, Kolorektalkrebs, Lungenkrebs, Hirntumor, Magenkrebs, Gebärmutterhalskrebs, Ovarialkrebs, Prostatakrebs, Harnblasenkrebs, Ösophaguskrebs, Leukämie, ein Lymphom, ein Fibrosarkom, ein Mastozytom oder ein Melanom ist.

22. DNA, die für einen Antikörper oder ein Fragment davon nach einem der Ansprüche 1 bis 12 kodiert.

25 **Revendications**

1. Anticorps ou fragment de celui-ci qui possède une réactivité immunologique avec un polypeptide CAPRINE-1 partiel consistant en la séquence d'acides aminés montrée par SEQ ID NO: 5.
- 30 2. Anticorps ou fragment de celui-ci selon la revendication 1, où l'anticorps ou le fragment de celui-ci possède une activité cytotoxique contre une cellule cancéreuse exprimant une protéine CAPRINE-1.
3. Anticorps ou fragment de celui-ci selon la revendication 1 ou 2, où l'anticorps est un anticorps monoclonal.
- 35 4. Anticorps ou fragment de celui-ci selon la revendication 1 ou 2, où l'anticorps est un anticorps polyclonal.
5. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 4, où l'anticorps est un anticorps humain, un anticorps humanisé, un anticorps chimérique, un anticorps simple chaîne, ou un anticorps multispécifique.
- 40 6. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 6, 7 et 8 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 10, 11 et 12 et possède une réactivité immunologique avec la protéine CAPRINE-1.
- 45 7. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 16, 17 et 18 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 20, 21 et 22 et possède une réactivité immunologique avec la protéine CAPRINE-1.
- 50 8. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 6, 7 et 8 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 50, 51 et 52 et possède une réactivité immunologique avec la protéine CAPRINE-1.
- 55 9. Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 55, 56 et 57 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 59, 60 et 61 et possède une réactivité immunologique avec la protéine CAPRINE-1.

5           **10.** Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 55, 56 et 57 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 59, 64 et 61 et possède une réactivité immunologique avec la protéine CAPRINE-1.

10           **11.** Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 66, 67 et 68 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 70, 71 et 72 et possède une réactivité immunologique avec la protéine CAPRINE-1.

15           **12.** Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 3 ou 5, qui comprend une région variable de chaîne lourde comprenant les régions déterminant la complémentarité de SEQ ID NO: 74, 75 et 76 et une région variable de chaîne légère comprenant les régions déterminant la complémentarité de SEQ ID NO: 78, 79 et 80 et possède une réactivité immunologique avec la protéine CAPRINE-1.

20           **13.** Anticorps ou fragment de celui-ci selon l'une quelconque des revendications 1 à 12, où l'anticorps ou le fragment de celui-ci est conjugué avec un agent antitumoral.

25           **14.** Anticorps ou fragment de celui-ci selon une quelconque revendication précédente, destiné à être utilisé dans un procédé de traitement et/ou de prévention du cancer.

30           **15.** Anticorps ou fragment de celui-ci destiné à être utilisé selon la revendication 14, où le cancer est le cancer du sein, le cancer du rein, le cancer du pancréas, le cancer colorectal, le cancer du poumon, une tumeur cérébrale, le cancer de l'estomac, le cancer du col de l'utérus, le cancer de l'ovaire, le cancer de la prostate, le cancer de la vessie, le cancer de l'oesophage, une leucémie, un lymphome, un fibrosarcome, un mastocytome, ou un mélanome.

35           **16.** Composition pharmaceutique comprenant l'anticorps ou le fragment de celui-ci selon l'une quelconque des revendications 1 à 13 en tant qu'ingrédient actif.

40           **17.** Composition pharmaceutique selon la revendication 16, destinée à être utilisée dans un procédé de traitement et/ou de prévention du cancer.

45           **18.** Composition pharmaceutique destinée à être utilisée selon la revendication 17, où le cancer est le cancer du sein, le cancer du rein, le cancer du pancréas, le cancer colorectal, le cancer du poumon, une tumeur cérébrale, le cancer de l'estomac, le cancer du col de l'utérus, le cancer de l'ovaire, le cancer de la prostate, le cancer de la vessie, le cancer de l'oesophage, une leucémie, un lymphome, un fibrosarcome, un mastocytome, ou un mélanome.

50           **19.** Combinaison pharmaceutique comprenant une composition pharmaceutique selon la revendication 16 et une composition pharmaceutique comprenant un agent antitumoral.

55           **20.** Combinaison pharmaceutique selon la revendication 19, destinée à être utilisée dans un procédé de traitement et/ou de prévention du cancer.

60           **21.** Combinaison pharmaceutique destinée à être utilisée selon la revendication 20, où le cancer est le cancer du sein, le cancer du rein, le cancer du pancréas, le cancer colorectal, le cancer du poumon, une tumeur cérébrale, le cancer de l'estomac, le cancer du col de l'utérus, le cancer de l'ovaire, le cancer de la prostate, le cancer de la vessie, le cancer de l'oesophage, une leucémie, un lymphome, un fibrosarcome, un mastocytome, ou un mélanome.

65           **22.** ADN codant pour l'anticorps ou le fragment de celui-ci selon l'une quelconque des revendications 1 à 12.

50

55

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- US 5698396 A [0006]
- WO 2010016526 A [0006] [0123] [0124] [0125] [0126] [0129] [0133] [0136] [0151]
- WO 0243478 A [0054]
- WO 02092812 A [0054]
- JP 2007530068 A [0055]
- WO 9846777 A [0055]
- EP 239400 A [0061]
- WO 9602576 A [0061]
- WO 9951743 A [0061]
- WO 2011096519 A [0138] [0152] [0160]
- WO 2011096517 A [0160]
- WO 2011096528 A [0160]
- WO 2011096533 A [0160]
- WO 2011096534 A [0160]
- JP 2011171300 A [0165]

## Non-patent literature cited in the description

- BOON et al. *Ludwig Institute for Cancer Research*, 1991 [0003]
- TSUYOSHI AKIYOSHI. Japanese Journal of Cancer and Chemotherapy. Japanese Journal of Cancer and Chemotherapy Publishers Inc, 1997, vol. 24, 55-519 [0007]
- BRUGGEN P. et al. *Science*, 1991, vol. 254, 1643-1647 [0007]
- Proc. Natl. Acad. Sci. USA, 1995, vol. 92, 11810-11813 [0007]
- Int. J. Cancer, 1997, vol. 72, 965-971 [0007]
- Cancer Res., 1998, vol. 58, 1034-1041 [0007]
- Int. J. Cancer, 1998, vol. 29, 652-658 [0007]
- Int. J. Oncol., 1999, vol. 14, 703-708 [0007]
- Cancer Res., 1996, vol. 56, 4766-4772 [0007]
- Hum. Mol. Genet., 1997, vol. 6, 33-39 [0007]
- KARLIN ; ALTSCHUL. Proc. Natl. Acad. Sci. USA, 1993, vol. 90, 5873-5877 [0021]
- ALTSCHUL et al. *Nucleic Acids Res.*, 1997, vol. 25, 3389-3402 [0021]
- Seikagaku Jikken Koza (Biochemical Experimentation Course in English). Protein Chemistry IV, Chemical Modification and Peptide Synthesis. Tokyo Kagaku Dojin Co., Ltd, 1981, vol. 1 [0024]
- Current Protocols in Molecular Biology. SAMBROOK et al. Molecular Cloning. Cold Spring Harbor Laboratory Press, 1989 [0025]
- A compendium of Methods from Current Protocols in Molecular Biology. AUSUBEL et al. Short Protocols in Molecular Biology. John Wiley & Sons, 1995 [0025]
- A Compendium of Methods from Current Protocols in Molecular Biology. AUSUBEL et al. Short Protocols in Molecular Biology. John Wiley & Sons, 1995 [0026]
- Current Protocols in Molecular Biology. SAMBROOK et al. Molecular Cloning. 1989 [0027]
- J. Immunol., 1979, vol. 123, 1548-1550 [0043]
- Current Topics in Microbiology and Immunology, 1978, vol. 81, 1-7 [0043]
- KOHLER, G. ; MILSTEIN, C. *Eur. J. Immunol.*, 1976, vol. 6, 511-519 [0043]
- MARGULIES, D.H. et al. *Cell*, 1976, vol. 8, 405-415 [0043]
- SHULMAN, M. et al. *Nature*, 1978, vol. 276, 269-270 [0043]
- GROTH, S.F. et al. *J. Immunol. Methods*, 1980, vol. 35, 1-21 [0043]
- TROWBRIDGE, I.S. *J. Exp. Med.*, 1978, vol. 148, 313-323 [0043]
- GALFRE, G. et al. *Nature*, 1979, vol. 277, 131-133 [0043]
- KOHLER, G. ; MILSTEIN, C. *Methods Enzymol.*, 1981, vol. 73, 3-46 [0044]
- CARL, A.K. BORREBAECK ; JAMES, W. LARRICK. THERAPEUTIC MONOCLONAL ANTIBODIES. United Kingdom by MACMILLAN PUBLISHERS LTD, 1990 [0056]
- SATO K. et al. *Cancer Research*, 1993, vol. 53, 851-856 [0061] [0062]
- HASHIMOTO-GOTOH, T. et al. *Gene*, 1995, vol. 152, 271-275 [0067]
- ZOLLER, M.J. ; SMITH, M. *Methods Enzymol.*, 1983, vol. 100, 468-500 [0067]
- KRAMER, W. et al. *Nucleic Acids Res.*, 1984, vol. 12, 9441-9456 [0067]
- KRAMER, W. ; FRITZ, H.J. *Methods Enzymol.*, 1987, vol. 154, 350-367 [0067]
- KUNKEL, TA. *Proc. Natl. Acad. Sci. USA.*, 1985, vol. 82, 488-492 [0067]
- KUNKEL. *Methods Enzymol.*, 1988, vol. 85, 2763-2766 [0067]
- KABAT et al. Sequences of Proteins of Immunological Interest. Public Health Service, National Institute of Health, 1991 [0070]

- **SAMBROOK et al.** Molecular Cloning A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1989 [0071]
- **G.B. KIM et al.** *Protein Engineering Design and Selection*, 2007, vol. 20 (9), 425-432 [0074]
- **P.J. DELVES.** ANTIBODY PRODUCTION ESSENTIAL TECHNIQUES. WILEY, 1997 [0076]
- **P. SHEPHERD ; C. DEAN.** Monoclonal Antibodies. OXFORD UNIVERSITY PRESS, 2000 [0076]
- **J.W. GODING.** Monoclonal Antibodies: principles and practice. ACADEMIC PRESS, 1993 [0076]
- **NIWA R.** *Clinical Cancer Research*, 15 March 2005, vol. 11 (6), 2327-2336 [0094]

10305D



SZTNH-100070402

EP 2 740 796

**GYÓGYÁSZATI KÉSZÍTMÉNY RÁK KEZELÉSÉRE ÉS/VAGY  
MEGELŐZÉSÉRE**

**Szabadalmi igénypontok:**

1. Antitest vagy fragmense, amely immunológiai reaktivitással rendelkezik egy olyan részleges CAPRIN-1 polipeptid felé, amely a SEQ ID NO: 5 (azaz 5-ös azonosítási számú szekvencia) által bemutatott aminosav-szekvenciából áll.
2. Az 1. igénypont szerinti antitest vagy fragmense, ahol az antitest vagy fragmense citotoxikus aktivitással rendelkezik egy olyan rákos sejttel szemben, amely expresszál egy CAPRIN-1 fehérjét.
3. Az 1. vagy 2. igénypont szerinti antitest vagy fragmense, ahol az antitest monoklonális antitest.
4. Az 1. vagy 2. igénypont szerinti antitest vagy fragmense, ahol az antitest poliklonális antitest.
5. Az 1-4. igénypontok bármelyike szerinti antitest vagy fragmense, ahol az antitest humán antitest, humanizált antitest, kíméra antitest, egyláncú antitest vagy multispecifikus antitest.
6. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variabilis régiót, amely tartalmaz a SEQ ID NO: 6, 7 és 8 szerinti komplementaritás-meghatározó régiókat, és olyan könnyülánc variabilis régiót, amely tartalmaz a SEQ ID NO: 10, 11 és 12 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.

7. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variabilis régiót, amely tartalmaz a SEQ ID NO: 16, 17 és 18 szerinti komplementaritás-meghatározó régiókat, és olyan könnyülánc variabilis régiót, amely tartalmaz a SEQ ID NO: 20, 21 és 22 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.
8. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variabilis régiót, amely tartalmaz a SEQ ID NO: 6, 7 és 8 szerinti komplementaritás-meghatározó régiókat, és olyan könnyülánc variabilis régiót, amely tartalmaz a SEQ ID NO: 50, 51 és 52 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.
9. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variabilis régiót, amely tartalmaz a SEQ ID NO: 55, 56 és 57 szerinti komplementaritás-meghatározó régiókat, és olyan könnyülánc variabilis régiót, amely tartalmaz a SEQ ID NO: 59, 60 és 61 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.
10. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variabilis régiót, amely tartalmaz a SEQ ID NO: 55, 56 és 57 szerinti komplementaritás-meghatározó régiókat, és olyan könnyülánc variabilis régiót, amely tartalmaz a SEQ ID NO: 59, 64 és 61 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.
11. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variabilis régiót, amely tartalmaz a SEQ ID NO: 66, 67 és 68 szerinti komplementaritás-meghatározó régiókat, és olyan könnyülánc variabilis régiót, amely tartalmaz a SEQ ID NO: 70, 71 és 72 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.

12. Az 1-3. vagy 5. igénypontok bármelyike szerinti antitest vagy fragmense, amely tartalmaz olyan nehézlánc variabilis régiót, amely tartalmaz a SEQ ID NO: 74, 75 és 76 szerinti komplementaritás-meghatározó régiókat, és olyan könnyülánc variabilis régiót, amely tartalmaz a SEQ ID NO: 78, 79 és 80 szerinti komplementaritás-meghatározó régiókat, és immunológiai reaktivitással rendelkezik a CAPRIN-1 fehérje felé.
13. Az 1-12. igénypontok bármelyike szerinti antitest vagy fragmense, ahol az antitest vagy fragmense tumoreellenes ágenssel van konjugálva.
14. Az előző igénypontok bármelyike szerinti antitest vagy fragmense rák kezelésére és/vagy megelőzésére szolgáló eljárásban történő alkalmazásra.
15. Az antitest vagy fragmense alkalmazásra a 14. igénypont szerint, ahol a rák mellrák, veserák, hasnyálmirigyrák, kolorektális rák, tüdőrák, agytumor, gyomorrák, méhnyakrák, petefészekrák, prosztatarák, húgyhólyagrák, nyelőcsőrák, leukémia, limfóma, fibroszarkómá, masztocitóma vagy melanóma.
16. Gyógyászati készítmény, amely hatóanyagként tartalmazza az 1-13. igénypontok bármelyike szerinti antitestet vagy fragmensét.
17. A 16. igénypont szerinti gyógyászati készítmény rák kezelésére és/vagy megelőzésére szolgáló eljárásban történő alkalmazásra.
18. A gyógyászati készítmény alkalmazásra a 17. igénypont szerint, ahol a rák mellrák, veserák, hasnyálmirigyrák, kolorektális rák, tüdőrák, agytumor, gyomorrák, méhnyakrák, petefészekrák, prosztatarák, húgyhólyagrák, nyelőcsőrák, leukémia, limfóma, fibroszarkómá, masztocitóma vagy melanóma.

19. Gyógyászati kombináció, amely tartalmaz a 16. igénypont szerinti gyógyászati készítményt, valamint tumorellenés ágenst tartalmazó gyógyászati készítményt.
20. A 19. igénypont szerinti gyógyászati kombináció rák kezelésére és/vagy megelőzésére szolgáló eljárásban történő alkalmazásra.
21. A gyógyászati kombináció alkalmazásra a 20. igénypont szerint, ahol a rák mellrák, veserák, hasnyálmirigyrák, kolorektális rák, tüdőrák, agytumor, gyomorrák, méhnyakrák, petefészekrák, prosztatarák, húgyhólyagrák, nyelőcsőrák, leukémia, límfóma, fibroszarkóma, masztocitóma vagy melanóma.
22. DNS, amely kódolja az 1-12. igénypontok bármelyike szerinti antitestet vagy fragmensét.